Drug, bio-affecting and body treating compositions inventions 11/07

20070274919 - Method for measuring in vivo mutation frequency at an endogenous gene locus: The present invention relates a method for the enumeration of in vivo gene mutation. The method utilizes differential staining of GPI-anchor deficient erythrocyte populations to distinguish between wild-type and pig-a gene mutants. Quantitative analyses can be conducted on erythrocytes and/or reticulocytes, and is based upon fluorescent emission and light scatter... Agent: Nixon Peabody LLP - Patent Group

20070274924 - Spinosyn fumigants: Methods of controlling arthropod pests by dispersing spinosyn compositions in the form of aerosols, fogs, smokes, or vapors are disclosed.... Agent: Dow Agrosciences LLC

20070274925 - Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists: Compositions and methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders are provided. The compositions provided herein are nebulizable compositions comprising quaternary ammonium muscarinic receptor antagonists. The compositions are suitable for direct administration to a patient in need thereof via a nebulizer. Also provided are... Agent: Lucas & Mercanti, LLP

20070274927 - Adherent polyol troche: A slow-dissolving troche with polyol molecules is disclosed. It may be an adherent troche, preferably adhered to teeth or gums or cheek with acacia gum, or a lollipop or child's pacifier. Consumers are instructed to use the troches at the end of each day and after each meal, at least... Agent: Graybeal, Jackson, Haley LLP

20070274939 - Color cosmetic compositions: A color cosmetic composition comprising at least one silicone film forming polymer, at least one pigment, and at least one dispersant that aids in dispersion of the pigment and silicone film forming polymer in the composition.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070274944 - Antimicrobial composition of 3-iodo-2-propynylbutyl carbamate and 1,3-butylene glycol as solvent: An antimicrobial composition of 3-iodo-2-propynylbutyl carbamate (IPBC) and 1,3-butylene glycol (BG) as solvent, in a defined weight ratio, preferably 9-11% IPBC and 89-91% BG, and personal care formulations including the composition in an amount of about 0.1-0.2% therein, at a pH of 4-9, is described.... Agent: International Specialty Products Attn: William J. Davis, Esq.

20070274945 - High molecular weight chelation structure: A chelation structure and method of forming and using the chelation structure. The chelation structure has a backbone that includes a linear sequence of monomeric backbone units, at least one polymer side chain, and at least one chelator side chain. The side chains are each covalently coupled to the backbone... Agent: Schmeiser, Olsen & Watts

20070274967 - Compositions and methods of treating burn victims using stem cells: The present disclosure relates to a method for treating severe burns using a preparation of tissue-derived material, which may comprise stem cells. The method may include systemic administration of stem cells. The method may also include administration of topical preparations of stem cells or tissue extract.... Agent: Calvin Cao

20070274968 - Substrate for cell culture: An object of the present invention is to provide a means capable of transferring a cell sheet, a cell pattern or the like to a desired material at a high speed. The present invention provides a substrate for cell culture comprising a base and a cell adhesive region formed on... Agent: Sughrue Mion, PLLC

20070274907 - Magnetically targetable mitomycin c compositions and methods of their use: The present embodiments are directed to compositions and methods of delivering the compositions that comprise mitomycin C and superior magnetically targetable carrier particles. As the compositions are magnetically targetable, their use allows the localization of mitomycin C to particular locations within a patient. This allows for an increase in the... Agent: The Mccallum Law Firm, P. C.

20070274908 - Methods and compositions related to adenoassociated virus-phage particles: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic... Agent: Fulbright & Jaworski L.L.P.

20070274909 - Radiation therapy and medical imaging using uv emitting nanoparticles: The invention relates to UV emitting nanoparticles for radiation therapy purposes. If the nanoparticles are brought indirectly or directly to the diseased tissue, excitation with high energy radiation leads to VUV or UV-C emission. This UV radiation is absorbed by the surrounding organic matrix, resulting in decomposition of the material.... Agent: Philips Intellectual Property & Standards

20070274910 - A1 adenosine receptor antagonists: This invention relates to compounds of formula (I): wherein R1 is a branched or straight chain C1-C6 alkyl; R2 is of the formula (II), wherein n is an integer ranging from 1 to 8; R5 is H or (CH2)pCH3, and R6 is H or (CH2)mOH, wherein p is an integer... Agent: Alston & Bird LLP

20070274911 - Production of 2-18f-2-deoxy-d-glucose via solid-phase synthesis: The invention relates to a compound of formula (1): wherein P1,P2,P3, and P4 are each independently hydrogen or a protecting group; and n is an integer of from 2 to 20 and to the use of such compounds for the synthesis of 18F—FDG.... Agent: Ge Healthcare, Inc.

20070274912 - Histone modifications as binary switches controlling gene expression: The present invention relates to a method of modulating a chromatin binding protein or complex which binds to a functional group on an amino acid of a histone. This method involves phosphorylating or dephosphorylating a serine or threonine on the histone proximate to the amino acid under conditions effective to... Agent: Nixon Peabody LLP - Patent Group

20070274913 - Preventives/remedies for stress urinary incontinence and method of screening the same: An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that stimulates an androgen binding site, and a method of screening for a drug... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070274921 - Diagnostics and therapeutics for ocular disorders: The invention relates to methods for treating, preventing and diagnosing drusen-associated disorders.... Agent: Townsend And Townsend And Crew, LLP

20070274918 - Lingo-1 structure: This disclosure relates to LINGO-1 polypeptides, LINGO-1 polypeptide/ligand complexes, crystals of LINGO-1 polypeptides, crystals of LINGO-1 polypeptide/ligand complexes, and related methods and software systems.... Agent: Fish & Richardson P.C.

20070274916 - Method for identifying compounds that affect expression of tryptophan hydroxylase isoform 2: A method for identifying analytes which directly or indirectly affect tryptophan hydroxylase isoform 2 (TPH2) expression is described. The method enables glucocorticoid receptor modulators and &bgr;-hydroxysteroid dehydrogenase type 1 (&bgr,-HSD1) inhibitors to be screened for central nervous system penetrance and activity by determining their ability to regulate expression of TPH2.... Agent: Merck And Co., Inc

20070274920 - Method for inducing a psychotic state in an animal and a high throughput assay method for identifying a candidate agent having anti-psychotic properties: A high throughput neurophysiological assay for identifying anti-psychotic compounds is disclosed. In particular, a high throughput neurophysiological assay using information obtained from injecting a neural activity blocker, such as tetrodotoxin (TTX), into one hippocampus persistently coactivated pyramidal cells in the uninjected hippocampus that initially discharged independently. In accord with the... Agent: Dilworth & Barrese, LLP

20070274915 - Modulation of anergy and methods for isolating anergy-modulating compounds: The present invention provides methods for identifying compounds capable of modulating anergy by inhibiting the production or activity of anergy associated E3 ubiquitin ligases or by altering the interaction between a ligase and its substrate.... Agent: Fish & Richardson PC

20070274914 - Mptens as modifiers of the pten/igf pathway and methods of use: Human MPTEN genes are identified as modulators of the PTEN/IGF pathway, and thus are therapeutic targets for disorders associated with defective PTEN/IGF function. Methods for identifying modulators of PTEN/IGF, comprising screening for agents that modulate the activity of MPTEN are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070274917 - Pharmacologic method of lowering cholesterol production: The present invention provides a screening method for identifying test agents that modulate cell membrane cholesterol activity. The modulating activity of the test agents may be measured using lytic compounds, which cause cell lysis or increases in cell permeability in response to cell membrane cholesterol levels. The invention further provides... Agent: Foley & Lardner LLP

20070274923 - Non-invasive real-time in vivo bioluminescence imaging of local ca2+ dynamics in living organisms: The invention relates to a method for optical detection of the dynamics of Ca2+ in a biological system, said method comprising monitoring the photons emitted by a recombinant Ca2+-sensitive polypeptide, which comprises or consists of a chemiluminescent protein linked to a fluorescent protein, present in said biological system. In a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070274922 - Water soluble boronic acid fluorescent reporter compounds and methods of use thereof: Described herein are boronic acid fluorescent compounds and methods of use thereof.... Agent: Gardner Groff Greenwald & Villanueva. PC

20070274926 - Method of inhibiting the transmission of viruses: A method of imparting a rapid and a persistent antiviral activity against viral-mediated diseases is disclosed. The method includes applying an antimicrobial compositions containing (a) a disinfecting alcohol, (b) an organic acid, and (c) water, and having a pH of about 5 or less, to at least one of the... Agent: Marshall, Gerstein & Borun LLP (dial)

20070274928 - Novel cyclic oxygenated compounds having cooling, fragrance, and flavor properties, and uses thereof: Compositions that include compounds capable of producing a cooling sensory effect such as certain hydroxy-ketones and hydroxy-aldehyde compounds, their cyclic semi-ketals and semiacetals, and other derivatives thereof. The compounds impart a refreshing and cooling sensation of long duration and high potency, and thus are useful in a variety of formulations,... Agent: Fish & Richardson P.C.

20070274929 - Oral composition comprising chlorhexidine and maltitol or erythritol or a mixture thereof: An oral hygiene composition comprising chlorhexidine is described which has reduced bitterness.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070274930 - Particulate flavoring composition: The present invention relates to particulate compositions comprising controlled release particles wherein discrete elements of flavouring-containing fat are dispersed in a gelatine matrix, said particles containing: 0.1 -40 wt %, preferably 5-30 wt % of flavouring; 10 -70 wt %, preferably 20 -50 wt % of gelatine; and 0.1-1.75 wt... Agent: Abelman, Frayne & Schwab

20070274933 - Amino- and hydroxysubstituted triphenyl-s-triazines as stabilizers: e

20070274931 - Long lasting waterproof sunscreen comprising metal oxide and peptide conditioner: The disclosure provides a sunscreen formulation comprising a peptide-based metal oxide sunscreen agent, such as titanium dioxide nanoparticles, and a fluid vehicle.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070274932 - Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers: The present invention relates to water in oil emulsion compositions suitable for use as sunscreen comprising: from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of a solvent for the emulsifying crosslinked siloxane elastomer; from about 0.01% to about 5% of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070274934 - Bis-urea compounds and compositions and method of cosmetic treatment: Disclosed herein is a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, a fatty phase and at least one compound chosen from compounds of formula (I), salts thereof, and isomers thereof, used to texture the fatty phase. Also disclosed herein is a method for texturing a cosmetic and/or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070274935 - Method for treatment of onychomycosis: Onychomycosis present in a nail is treated by debridement such as grinding a portion of the nail, which includes an infected portion and thereafter applying a composition containing alkyl cyanoacrylate to the debrided surface which cures to a hard layer. The hard layer can be successively ground and coated with... Agent: Ralph D Chabot

20070274938 - Changing skin-color perception using quantum and optical principles in cosmetic preparations: The present invention teaches how to change the skin color perception, mainly the facial color from red, blue or yellow to white appearance, using quantum and optical principles. By selecting the right size and material of particles compounded in cosmetic preparations and applying the preparations to the skin, the scattering... Agent: Lackenbach Siegel, LLP

20070274936 - Oligonucleotide and the use thereof for modulating an isoform c beta-1 protein-kinase in the form of a skin depigmentation agent: This invention relates to oligonucleotide sequences and their derivatives. These oligonucleotide sequences are capable of hybridising with the genes or with products of the genes coding for the PKC-beta 1. This invention also relates to the use of these oligonucleotide sequences as a depigmenting or bleaching agent for the skin... Agent: Blakely, Sokoloff, Taylor & Zafman

20070274937 - Use of a cruciferous protein hydrolysate as a depigmentation agent or for a cosmetic and/or pharmaceutical composition: A composition and method for whitening and/or depigmenting skin with a protein hydrolysate from plants belonging to the crucifer family.... Agent: Young & Thompson

20070274940 - Method of enhancing the control of viruses on skin: A method of imparting a rapid antiviral effectiveness, and a persistent antiviral effectiveness, to an animate surface is disclosed. The method includes first treating the animate surface with a preconditioning composition, followed by treating the animate surface with an antiviral composition.... Agent: Marshall, Gerstein & Borun LLP (dial)

20070274941 - Two-coat cosmetic product comprising at least one silicone polymer: The present disclosure relates to a cosmetic product comprising at least one first and at least one second compositions, wherein the at least one first composition comprises a silicone polymer of formula (I) and the at least one second composition comprises a cosmetically acceptable medium. The present disclosure also relates... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070274942 - Aqueous composition comprising a polyionic dendritic polymer and an ionic surface-active agent: The invention relates to a composition comprising a single-phase aqueous phase consisting of a system containing: water; a water-dispersible or water-soluble polyionic dendritic polymer (a); at least one ionic surface active agent (b); and, optionally, a polycationic or polyanionic polymer (c) which is different from the dendritic polymer. The inventive... Agent: Jean-louis Seugnet Rhodia Inc.

20070274943 - Emulsified composition for hair: An emulsified composition for hair, which contains a nonionic surfactant that is a solid at normal temperature and has a Krafft point of at least 40° C., an oil component, and water, and which has an average emulsified particle size of 0.5 μm or less, provides long-lasting luster. Further, an... Agent: Snider & Associates

20070274947 - Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer: The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R1 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer.... Agent: Ivor R. Elrifi, Ph.d. Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, PC

20070274949 - Cd25 dna vaccines for treating and preventing t-cell mediated diseases: Compositions comprising nucleic acids encoding the α chain of IL-2 receptor (IL-2Ra, CD25), homologs and fragment thereof, are effective in the treatment and prevention of T cell mediated pathologies. Methods are provided for enhancing anti-ergotypic T cell activity in a subject in need thereof, and for treating or preventing T... Agent: Heslin Rothenberg Farley & Mesiti PC

20070274948 - Methods of therapy for chronic lymphocytic leukemia: Methods for treating a human with chronic lymphocytic leukemia using a combination of an interleukin-2 and an anti-CD52 antibody are provided. These therapeutic agents are administered as two separate pharmaceutical compositions, one containing an IL-2, the other containing an anti-CD2 antibody, according to a dosing regiment. Administering of these two... Agent: Davis Wright Tremaine 2600 Century Square

20070274946 - Tolerance to graft prior to thymic reactivation: The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue, and/or cells, by disrupting sex steroid signaling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070274951 - Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of at least one HCV protease inhibitor and at least one HCV polymerase inhibitor but not HCV-796; for concurrent or consecutive administration in treating or ameliorating one or more symptoms of HCV, or disorders associated with HCV in... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070274950 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070274954 - Cloning b and t lymphocytes: This invention includes methods for producing non-human mammals expressing monoclonal or oligoclonal B or T lymphocytes, as well as embryonic and hematopoietic stem cells that differentiate into monoclonal or oligoclonal B or T cells, using cloning by nuclear transfer with a B or T cell of interest as the nuclear... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070274952 - Compositions and methods for modifying the content of polyunsaturated fatty acids in biological cells: The present invention features compositions (e.g., nucleic acids encoding fat-1, optionally and operably linked to a constitutively active or tissue-specific promoter or other regulatory sequence and pharmaceutically acceptable formulations including that nucleic acid or biologically active variants thereof) and methods that can be used to effectively modify the content of... Agent: Ewards Angell Palmer & Dodge LLP

20070274953 - Photochemical internalization for delivery of molecules into the cytosol: The present invention provides a method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the same time or after the... Agent: Cantor Colburn, LLP

20070274969 - Immortalization of mammalian cells: Genomic instability in T-antigen expressing cells can be overcome by modifying the gene expressing T-antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T-antigen gene, preferably together with the catalytic sub-unit of the telomerase construct.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070274972 - Maize antifungal rnase ne homolog gene sequence encoding an antimicrobial protein useful for enhancing plant resistance to pathogens: Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include novel amino acid sequences, and variants and fragments thereof, for antipathogenic polypeptides that were isolated from maize. Nucleic acid molecules comprising nucleotide sequences that encode the antipathogenic polypeptides of the embodiments are... Agent: Pioneer Hi-bred International, Inc.

20070274971 - Method of proliferating precursor cells: There is provided a method of proliferating precursor cells by modulating the expression of the protein FRS3 within the precursor cells. The method is useful for the production of large populations of precursor cells, which are useful for in vitro research techniques, including drug screening, and for in vivo therapeutic... Agent: Clark & Elbing LLP

20070274970 - Stem cells: The present invention relates to an isolated stem cell population wherein said stem cells are CD34+, capable of self regeneration, capable of differentiation into ectodermal, mesodermal and endodermal cells and capable of adhering to tissue-culture grade plastic as well as to methods of isolation of said cells, methods of culturing... Agent: Knobbe Martens Olson & Bear LLP

20070274955 - Novel galactooligosaccharide composition and the preparation thereof: Novel strains of Bifidobacterium hifidum capable of producing a novel galactosidase enzyme activity that converts lactose to a novel mixture of galactooligosaccharides. The mixture of oligosaccharidcs may be incorporated into numerous food products or animal feeds for improving gut health by promoting the growth of bifidobacteria in the gut, and... Agent: Christie, Parker & Hale, LLP

20070274975 - Method for controlling harmful organisms in bt maize crops: Method for controlling harmful organisms in genetically modified maize plants containing a gene derived from Bacillus thuringiensis, said gene encoding and expressing protein with an insecticidal action, wherein an insecticidally active quantity of one or more compounds from the groups (a) to (f) specified in detail in the description is... Agent: Buchanan, Ingersoll & Rooney PC

20070274973 - Method of controlling fungal pathogens, and agents useful for same: A method of preventing or treating infection by a range of fungal pathogens in an animal or plant or stored plant product comprising administering an effective amount of a sugar acid, in particular mannonic acid, gluconic acid or galacturonic. The sugar acid can be delivered by a biocontrol that can... Agent: Fish & Richardson PC

20070274956 - Plant germination inhibitor and method of use thereof: A novel plant germination inhibitor that without any hazardous effects on cultivated crop and without the danger of environmental pollution, can exert high efficacy with an extremely small dosage. There is provided a plant germination inhibitor comprising as an active ingredient a pigment produced in woody parts by fungi of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070274957 - Antisense antiviral compound and method for treating arenavirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Arenaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Arenavirus infection in a mammal. The antisense antiviral compounds are... Agent: Perkins Coie LLP

20070274964 - Cell population of nurr1-positive neuron stem cell and pharmaceutical composition thereof: The present invention relates to a population of Nurr1-positive neuron stem cells, a pharmaceutical composition including the population of Nurr1-positive neuron stem cells, and methods for isolation, culture and preservation of the Nurr1-positive neuron stem cells. More specifically, the present invention provides a method of isolation of Nurr1-positive neuron stem... Agent: Edwards Angell Palmer & Dodge LLP

20070274961 - Composition and methods for cell culturing and tissue culture platforms: This present invention describes a method of coating a polymer surface with diamond-like carbon (DLC) to render it useful as a carrier for cells derived from neural crest origin, preferable neuronal cells that form dendrites. The biopolymer to be coated with the DLC will include biodegradable polymers and other implantable... Agent: Jacobson Holman PLLC

20070274959 - In vitro method for the diagnosis of cardiovascular functionality of bone marrow-precursor cells (bmp) and/or circulation precursor cells derived from blood (bdp): The present invention relates to an in vitro method for the analysis of a sample from a mammal in connection with cardiovascular diseases, wherein the method comprises the following steps: a) isolating of bone marrow-precursor cells (BMPs) and/or blood-derived circulating precursor cells (BDPs) by means of cell specific surface markers,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070274965 - Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates: The present invention relates to a method of isolating hematopoietic stem cells from adipose tissue. The method yields a notably high number of CD34+, ALDHbr and/or ABCG2-expressing cells, comprising hematopoietic stem cells, permitting the use of the cells with no or minimal expansion.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070274962 - Methods and composition for transplantation of dopaminergic neurons for parkinson's disease: This invention discloses methods to attach and grow a monolayer of cultured human retinal pigment epithelial cells (RPE) for use in implantation into the brain as a treatment for Parkinson's disease. The invention will enable the delivery of the transplanted RPE cells in microcarriers composed of intergratable or degradable substrates,... Agent: Jacobson Holman PLLC

20070274963 - Methods for culturing keratinocytes from human embryonic stem cells: The invention relates to methods for isolating and culturing human keratinocytes from embryonic stem cells. The methods are useful for producing substantially pure cultures of keratinocytes.... Agent: Wolf Greenfield & Sacks, P.C.

20070274960 - Methods of preparing and using novel stem cell compositions and kits comprising the same: The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of... Agent: Seed Intellectual Property Law Group PLLC

20070274966 - Neural regeneration with transplanted ac133 positive cells: We focused attention on AC133 positive cells as a cell source. AC133 positive cells were transplanted to an injured sciatic nerve model and an injured spinal cord model and were found to have very intensive neural regeneration ability. Such AC133 positive cells are easily available from the peripheral blood with... Agent: Kratz, Quintos & Hanson, LLP

20070274958 - Postnatal stem cells and uses thereof: The invention generally relates to postnatal dental stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal dental pulp stem cells, use of the cells to generate dentin, and differentiation of the cells. In another aspect, the invention relates to human postnatal deciduous... Agent: Schwegman, Lundberg & Woessner/nih

20070274974 - Compositions and methods for restoring immune responsiveness in patients with immunological defects: The present invention relates generally to methods for stimulating, activating, and maintaining or increasing the polyclonality of expressed TCRs in a population of T cells. In the various embodiments, cells are stimulated with a surface, wherein the surface has attached thereto one or more agents that ligate a cell surface... Agent: Seed Intellectual Property Law Group PLLC

20070274976 - Ethanol dependence of alpha1 antitrypsin c-terminal lys truncation by basic carboxypeptidases: The present invention provides methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same.... Agent: Baxter Healthcare Corporation

20070274978 - Method of killing spores: A method for killing or inactivating spores, by contacting the spores with a haloperoxidase, a source of hydrogen peroxide and a source of iodide ions. The spores may additionally be contaced with a haloperoxidase enhancing agent.... Agent: Novozymes North America, Inc.

20070274977 - Methods for lowering elevated uric acid levels using intravenous injections of peg-uricase: A method for lowering elevated uric acid levels in patients is disclosed and consists of administering to the patients an intravenous injection of PEG-uricase having a dosage from about 4 to about 12 mg.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20070274979 - Compositions and methods for promoting neuronal outgrowth: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.... Agent: Pepper Hamilton LLP

20070274980 - Compositions of less immunogenic and long-circulating protein-lipid complexes: Provided are lipidic particles comprising phopatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and/or longer circulating time. These compositions can be used for therapeutic administration... Agent: Hodgson Russ LLP The Guaranty Building

20070274982 - Anti-epcam immunoglobulins: The invention relates inter alia to a method of treating tumorous disease in a human patient by administering to the patient a human immunoglobulin specifically binding to the human EpCAM antigen, the immunoglobulin exhibiting a serum half-life of at least 15 days, the method comprising the step of administering the... Agent: Fulbright & Jaworski L.L.P.

20070274981 - Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4... Agent: Kenyon & Kenyon LLP

20070274983 - Nutritional composition comprising immunoglobulins and oligosaccharides: The present invention provides a method and composition for the treatment and/or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and immunoglobulin from the milk or colostrum of hyperimmunized cows.... Agent: Foley And Lardner LLP Suite 500

20070274984 - Methods for treating autoimmune diseases using a taci-ig fusion molecule: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or... Agent: Howrey LLP

20070274985 - Antibody: The present invention refers to synthetic antibody molecules which comprise domains from naturally occuring antibodies, e.g. domains derivable from IgG, preferably of human origin, in a novel arrangement. Single chain molecules are provided which are suitable for expression in micro-organisms in their active conformation, which single chain molecules generally comprise... Agent: William Collard Collard & Roe, P.C.

20070274986 - Compositions comprising anti-ccr5 antibody: This invention provides a composition which comprises a monoclonal antibody or a fragment of such antibody, wherein the monoclonal antibody or fragment of such antibody binds to the same epitope as antibody PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) and a carrier. This invention... Agent: John P. White Cooper & Dunham LLP

20070274987 - Expression of the cysteine protease legumain in vascular and inflammatory diseases: The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists... Agent: Fitzpatrick Cella (wyeth)

20070274988 - Kiaa0779, splice variants thereof, and methods of their use: The invention provides novel polynucleotides, related polypeptides related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic, and therapeutic applications. The compositions and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070274989 - Methods and compositions for the prevention and treatment of sepsis: The present invention includes compositions comprising one or more complement inhibitors and one or more CD14 pathway inhibitors for the prevention or treatment of sepsis. The complement inhibitors may be antibodies that bind to and inhibit complement proteins such as C5a and the CD14 pathway inhibitors may be antibodies that... Agent: Cheryl A Liljestrand Tanox Inc

20070274990 - Novel therapeutic targets in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel... Agent: Novartis Vaccines And Diagnostics Inc.

20070274991 - Treatment of tumors expressing mutant egf receptors: The invention discloses methods of treatment of tumors that express oncogenic forms of the epidermal growth factor receptor (EGFR), such as EGFRvIII. The methods include testing of cancer patients for expression of EGFRvIII in their tumors, followed by treatment with a protein that contains antibody variable regions that recognize specific... Agent: Clark & Elbing LLP

20070274993 - Immunocompetent cell activation inhibitor and use thereof: The invention relates to an immunocompetent cell activation inhibitor comprising an antibody against OPN or peptide fragment thereof; a therapeutic agent for diseases attributed to immunocompetent cell activation comprising this inhibitor as an active ingredient; and a method of treatment with the use of the therapeutic agent. The invention provides... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070274992 - Secreted protein family: This invention relates to a new family of secreted proteins, termed the SECFAM3 family, its family members including the novel human proteins INSP123, INSP124, and INSP125, herein identified as secreted proteins containing a von Willebrand Factor type C (vWFC) domain, and to the use to these proteins and nucleic acid... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070274994 - Virulence-associated adhesins: Virulence-associated antigens involved in adhesin have been identified in several organisms: Haemophilus influenzae biogroup aegyptius; Escherichia coli K1; EHEC E.coli; Actinobacillus actinomycetencomitans; Haemophilus somnus; Haemophilus ducreyi; EPEC E.coli; EA EC E.coli; uropathogenic E.coli; Shigella flexneri; Brucella melitensis; Brucella suis; Ralstonia solanacearum; Sinorhizobium meliloti; Bradorhizobium japonicum; and Burkholderia fungorum. Although the... Agent: Novartis Vaccines And Diagnostics Inc.

20070274995 - Cardiotrophin-1 compositions and methods for the treatment of tumor: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of... Agent: Genentech, Inc.

20070274996 - Antibodies that bind interleukin-4 receptor: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4... Agent: Immunex Corporation Law Department

20070274997 - Compositions and methods for herpes simplex prophylaxis and treatment: The present invention concerns compositions and methods involving polypeptides, such as single chain antibodies, that target microbial antigens. Embodiments of the invention include compositions and methods related to a prophylactic and therapeutic treatments for microbes that can be neutralized prior to infection of a cell. In particular embodiments, microbes against... Agent: Fulbright & Jaworski L.L.P.

20070274998 - Novel bispecific molecules for use in therapy and diagnosis: Provided are bispecific molecules that are characterized by having at least a first binding domain which binds T-cell immune response cDNA 7 (TIRC7) and a second binding domain which binds T cell receptor (TCR), in particular TCR beta or gamma chain. Furthermore, compositions comprising said bispecific molecules and their use... Agent: John P White Cooper & Dunham

20070274999 - Method of treating disorders using platelet glycoprotein ib alpha fusion polypeptides: The present invention provides compositions and methods for treating or preventing thrombotic thrombocytopenic purpura, infective endocarditis, metastatic cancer, and sickle cell anemia disease.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275001 - Rational design and engineering of proteins and peptides for immunomodulation: The present invention discloses an immunomodulatory protein or peptide mimetic and method for treatment of immunosuppressive diseases and conditions by administering an effective dose of the immunoactive form of the mimetic sufficient to activate phagocytic cells and triggering phagocytosis, thereby activating the immune system.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275000 - Tick engorgement factor proteins: The invention provides for novel polynucleotides and associated peptides providing tick Engorgement Factor activity and methods for using same for vaccines, thereby decreasing transmission of tick-borne disease and tick-borne pathogens.... Agent: Craig K. Sherburne

20070275003 - Human papillomavirus polypeptides and immunogenic compositions: The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides... Agent: Wyeth C/o Darby & Darby, P.C.

20070275002 - Use of proteins and peptides encoded by the genome of a novel sars-associated coronavirus strain: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275004 - Group b streptococcus antigens: The present invention relates to polypeptides, epitopes and antibodies directed to these epitopes, more particularly to the Sip polypeptide of Group B streptococcus (GBS), also called Streptococcus Agalactiae which may be used to prevent, diagnose and/or treat streptococcal infection.... Agent: Seed Intellectual Property Law Group PLLC

20070275006 - Iridoid glycoside composition: The present invention also relates to the method of producing the iridoid glycoside adjuvant and the products utilizing such adjuvants for induction of cellular immunity. The adjuvants may be used alone or with specific antigens. The two antigens used in the study represents HBsAg, a recombinant antigen expressed in Pichia... Agent: Fenwick & West LLP

20070275005 - Use of lipopeptides for activating t lymphocytes through the skin: The present invention relates to the use of a method of treating or preventing a disease selected from the group of skin and diseases of the mucosa, comprising administering topically to a mammal in need of such a treatment a topical medicinal product comprising a lipopeptide or a mixture thereof,... Agent: Foley And Lardner LLP Suite 500

20070275007 - Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer: Carbohydrate antigen-nanoparticle conjugates are disclosed. Methods of making carbohydrate antigen-nanoparticle conjugates are also disclosed. The carbohydrate antigen-nanoparticle conjugates can be used to inhibit metastasis of tumor cells in mammals.... Agent: Woodcock Washburn LLP

20070275008 - Synergistic diabetic phyto-nutraceutical composition: Phytoceutical composition for the prevention and treatment of hepatic disorders. A specific combination of extracts of plants is taught, as well as the principles for the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel

20070275009 - Dry fertilizer with growth hormone-containing formulation and methods of use and making: A growth hormone formulation includes an enzyme inactivating component and a preservative. The formulation can be incorporated into a dry fertilizer for application using the fertilizer itself or a component of the fertilizer such as one or more of the fillers commonly used in fertilizers.... Agent: Clark & Brody

20070275010 - Mva vaccines: Recombinant modified vaccinia Ankara vectors are provided having a null mutation in a gene necessary for replication of the recombinant modified vaccinia Ankara virus and at least one heterologous antigen. The disclosed vectors optionally encode at least one pro-apoptotic factor, at least one anti-apoptotic factor, at least one immunomodulator, and... Agent: Thomas, Kayden, Horstemeyer & Risley

20070275011 - Inducible bacterial expression system utilising sspa promoter from salmonella: The invention provides a new stringent starvation protein Salmonella sspA promoter and expression system suitable for expression of heterologous nucleic acids and proteins. The invention also relates to the use of an expression construct comprising either a Salmonella or an E. coli sspA promoter, or a bacterium into which the... Agent: Hoffmann & Baron, LLP

20070275012 - Pharmaceutical compositions for therapeutic use: The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the... Agent: Hoffmann & Baron, LLP

20070275013 - Vaccine and method of use: A therapeutic vaccine is prepared by a method which includes the steps of extracting, with a lipid-extracting solvent, a biological fluid obtained from a person or animal infected with a lipid-containing infectious organism, the biological fluid containing the lipid-containing infectious organism, and the extraction producing an aqueous phase and a... Agent: Thomas Moga Butzel Long

20070275014 - Influenza antigens, vaccine compositions, and related methods: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.... Agent: Choate, Hall & Stewart LLP

20070275015 - West nile virus vaccine: The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection.... Agent: Clark & Elbing LLP

20070275016 - Kennel cough vaccine: Improved, low cost vaccines for administration to living subjects such as mammals and birds are provided, which include killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior... Agent: Hovey Williams LLP

20070275017 - Identification of antigenically important neisseria antigens by screening insertional mutant libraries with antiserum: A method for identifying a polypeptide of a microorganism which polypeptide is associated with an immune response in an animal which has been subjected to the microorganism, the method comprising the steps of (1) providing a plurality of different mutants of the microorganism; (2) contacting the plurality of mutant microorganisms... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275018 - Use of the gene ncsag4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis: The invention relates to gene NcSAG4, the RNA messenger of said gene, the oligonucleotides designed based on the nucleotide sequence thereof or any of the fragments of same, and to protein NcSAG4 encoded thereby, or any of the recombinant forms of same, expression vectors, and host cells containing same, for... Agent: Knobbe Martens Olson & Bear LLP

20070275019 - Vaccines directed to cancer-associated carbohydrate antigens: A vaccine and method to prevent or to retard the growth and replication of cancer cells that express a carbohydrate wherein the vaccine comprises: (a) a pharmaceutically effective amount of a carbohydrate antigen found on said cancer cells, or a mimetic thereof; and (b) a pharmaceutically acceptable carrier. The carbohydrate... Agent: Bell, Boyd & Lloyd, LLP

20070275022 - Cosmetic hair preparation: One or more esters selected among an ester of a C2-10 fatty acid with a polyhydric alcohol, an ester of a monobasic hydroxy acid with a mono- or polyhydric alcohol, and an ester of a polybasic acid with a mono- or polyhydric alcohol are incorporated into a cosmetic hair preparation... Agent: Birch Stewart Kolasch & Birch

20070275020 - Method for hair treatment with shape memory polymers: A method for producing a retrievable hairstyling using shape memory polymers is described. Here a composition is applied to the hair, said composition containing a shape memory polymer P or a macromer M that can be cross-linked to a shape memory polymer, the hair is arranged into a given (permanent)... Agent: Seed Intellectual Property Law Group PLLC

20070275021 - New cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same: The present invention involves new cosmetic, personal care, cleaning agent, biocidal agent, functional food, and nutritional supplement compositions. These new compositions incorporate bioactive glass into cosmetics, personal care items, cleaning agents, biocidal agents, functional foods, and nutritional supplements. The present invention also involves methods of making and methods of using... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20070275023 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070275024 - Starch films and uses thereof: The invention provides novel starch films and processes for production thereof based on starch from C-type starch granules (e.g. from legumes) and polyols (e.g. glycerol). In other aspects the invention provides wound dressings and systems for controlling microorganisms using starch films.... Agent: Michael Best & Friedrich LLP

20070275025 - Combustible mosquito coil or stick: A combustible coil or stick for controlling mosquitoes is disclosed containing an insecticidally effective amount of bifenthrin.... Agent: Merchant & Gould PC

20070275030 - Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations: The invention relates to cross-link-resistant injectable hydrogel formulations and methods of partially or practically wholly inhibiting injectable hydrogel formulations from cross-linking, for example, during irradiation, using anti-cross-linking agents, which facilitates injectability of the hydrogel formulation. The invention also relates to methods of making the cross-link-resistant, for example, irradiation cross-link resistant,... Agent: Proskauer Rose LLP

20070275031 - Implantable polymeric device for sustained release of buprenorphine with minimal initial burst: The present invention provides compositions, methods, and kits for treatment of pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time, and exhibits minimal initial burst upon subcutaneous implantation. Buprenorphine is released through pores that open to... Agent: Morrison & Foerster LLP

20070275028 - Injectable fibrin composition for bone augmentation: The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone.... Agent: Baxter Healthcare Corporation

20070275027 - Microparticle containing matrices for drug delivery: Polymeric matrices including microparticles that provide sustained release of a hydrophilic bioactive agent are described. The matrices can be in the form of a coating on the surface of an implantable medical article or an in situ formed matrix. The microparticles of the matrix include a first polymer and a... Agent: Kagan Binder, PLLC

20070275029 - Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders: The present invention is directed to combination therapies and drug delivery devices comprising antisense oligonucleotides directed to a raf gene. In certain embodiments, the combination therapies and drug delivery devices of the present invention are used to treat cancers and ocular diseases.... Agent: Seed Intellectual Property Law Group PLLC

20070275026 - Therapeutic use of a growth factor, nsg33: The present invention relates to the field of therapeutic use of proteins, genes and cells. More specifically the invention relates to therapy based on the biological function of a secreted therapeutic protein. NsG33, in particular for the treatment of disorders of the nervous system. NsG33 is a nerve survival and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275033 - Biodegradable polyurethane and polyurethane ureas: This invention relates to biocompatible, biodegradable thermoplastic polyurethane or polyurethane/ureas comprising isocyanate, polyol and a conventional chain extender and/or a chain extender having a hydrolysable linking group and their use in tissue engineering and repair applications, particularly as stents and stent coating.... Agent: Needle & Rosenberg, P.C.

20070275034 - Swellable fiber- and microfiber-forming polyether-esters and applications thereof: Biomedical and tissue engineering devices, such as surgical sutures and microporous scaffolds, respectively, which undergo swelling and increase in dimensions when placed in aqueous environments such as living tissues, are produced by the melt-spinning or electrostatic spinning into strong monofilament and multifilament yarns or microfibrous fabrics, respectively. Such devices are... Agent: Leigh P. Gregory

20070275032 - Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro: A mixture of one or several substances from group A) lubricin, proteoglycan 4 (PRG4) and phosphollipid (SAPL); with one or several substances from group B) hyaluronic acid, glycosaminoglycan and derivatives of said substances; dissolved in a solvent, used for the production of an agent for treating defective or degenerated cartilage... Agent: Jones Day

20070275035 - Minimally invasive medical implant devices for controlled drug delivery: Implantable medical devices and methods of use are provided for controlled drug delivery. The devices may include an elongated body dimensioned to facilitate minimally invasive and complete implantation into a patient, wherein the elongated body portion comprises a first, closed end portion, a second closed end portion and an intermediate... Agent: Sutherland Asbill & Brennan LLP

20070275036 - Avian follistatin product: Described herein are avian follistatin products, and methods for producing such products, in which such products are effective for a variety of conditions, including increasing muscle mass. Avian follistatin products described herein are packaged as dietary supplements or nutritional supplements are useful in muscle regeneration.... Agent: Wilson Sonsini Goodrich & Rosati

20070275038 - Food and feed compositions including resistant starch: The invention described in this application relates to a method of increasing the amount of weight gained by the mammal during a feeding period, to a method of increasing the amount of milk replacer consumed by the mammal during a feeding period, to a method of decreasing the amount of... Agent: Marshall, Gerstein & Borun LLP

20070275037 - Recombinant vitellogenin enriched feed: The invention provides an expression vector for expression of recombinant vitellogenin in an eukaryotic host. An eukaryotic host, including yeast comprising the expression vector according to the invention may be used as a feed or feed additive for both oviparous and non-oviparous animals, including domesticated animals. A transgenic yeast according... Agent: Townsend And Townsend And Crew, LLP

20070275039 - Compressed articles with microencapsulation: Microencapsulated materials are added to compressed products. Microencapsulation permits a wide range of products to be incorporated into these compressed products while maintaining the dry, compressed nature of the products. In one aspect, methods are provided that comprise forming the article, that comprises paper or fabric, in a size of... Agent: Glen M. Diehl Diehl Servilla LLC

20070275040 - Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the... Agent: Perkins Coie LLP

20070275041 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070275042 - Curable hydrophilic compositions: A curable composition is described, including a gel material derived from the curable composition, and medical articles including such material, wherein the transparent gel material includes a polymerized monofunctional poly(alkylene oxide) macromonomer component and a surface modified nanoparticle component.... Agent: 3m Innovative Properties Company

20070275043 - Wound dressings: A wound dressing comprises a wound contacting material incorporating a therapeutically effective amount of a particulate, water insoluble, inorganic silver salt containing at least 50% by weight (based on the weight of the salt) of silver for delivering silver to a wound. The preferred water-soluble, inorganic silver salt is sodium... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070275044 - Novel drug delivery technology: The invention relates to a novel drug delivery technology. More particularly the invention relates to a method of delivering at least one therapeutic compound or a formulation comprising the at least one therapeutic compound to a patient; to a throwaway or reusable device for delivering at least one therapeutic compound... Agent: Dickinson Wright, PLLC

20070275045 - Composition for the treatment of warts and molluscum contagiosum: The present invention provides compositions comprising mixtures of papain and bromelain, combined with a pharmaceutically acceptable carrier, for treating viral-induced skin lesions. The present invention further provides methods of treating viral-induced skin lesions by administering to a subject in need thereof a therapeutically effective amount of papain and bromelain.... Agent: Edwards Angell Palmer & Dodge LLP

20070275048 - Liposome composition for delivery of a therapeutic agent to eyes: The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070275049 - Anti-tumor molecular vacine and method of making thereof: The present invention provides a vaccine which is capable of inhibiting the growth and formation of tumors which can express an endogenous tumor specific protein. Also disclosed are methods of administering the vaccine to a subject bearing a tumor whose formation and growth is inhibited by the vaccine.... Agent: Ben Wang

20070275050 - Method for treating blood coagulation disorders: Provided is a method for treatment of blood coagulation disorders. The method comprises administering to an individual compositions comprising lipidic particles comprising phopatidylcholine, phosphatidylinositol and cholesterol. One or more peptides, polypeptides or proteins involved in the blood coagulation cascade are associated with the lipidic particles.... Agent: Hodgson Russ LLP The Guaranty Building

20070275046 - Noval surfactants and applications thereof: The invention relates to novel surfactant compounds and the use thereof for preparing metastable supramolecular systems or nanoparticles. Said nanoparticles may be used as vectors for active ingredients, in particular therapeutic active ingredients.... Agent: Merchant & Gould PC

20070275047 - Oligonucleotides related to lipid membrane attachments: Oligonucleotide structures are provided that are capable of forming more stable bonds to a lipid membrane and thereby generate an improved control of the process whereby oligonucleotide linkers are introduced to lipid membranes. Methods of forming lipid membrane oligonucleotide attachments are provided including lipid vesicles. The oligonucleotides typically comprise at... Agent: Dinsmore & Shohl, LLP

20070275053 - Anti-stick formula delivered by spray process to facilitate swallowing of solid object, such as pill, tablet capsule or caplet.: An oral delivery method and composition that will facilitate the swallowing of any object such as a pill, tablet, capsule or caplet in a fast, easy, untroubled manner so as to markedly decrease the risk of the pill, caplet, capsule or tablet lodging or sticking in the mouth or the... Agent: Luise Anneliese Lenk

20070275052 - Pharmaceutical compositions containing sterol inhibitors: Pharmaceutical compositions containing ezetimibe or its pharmaceutically acceptable salt that is substantially free of microcrystalline cellulose or crystalline cellulose are disclosed. Also disclosed are pharmaceutical compositions containing micronized particles of ezetimibe.... Agent: M. Carmen & Associates, PLLC

20070275051 - Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same: Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070275055 - Compositions capable of facilitating penetration across a biological barrier: This invention relates to novel pharmaceutical compositions mixing one or more effectors (anionic impermeable molecules) with a counter ion to the effector (a liquid forming cation). The invention also relates to methods of treating or preventing diseases by administering pharmaceutical compositions to affected subjects.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275054 - Novel composition and use: A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070275056 - Method for treating minor aphthous ulcers: A method for treating recurrent minor aphthous ulcers is provided in which a sufferer is treated with a combination therapy of Vitamin B6 and B12 compounds. The treatment is done orally and the treatment minimizes the duration and pain of the sore, as well as increasing the period of time... Agent: Weiss & Moy PC

20070275057 - Formulation and process for the preparation of modafinil: The present invention provides pharmaceutical tablets comprising modafinil particles, processes for preparing such pharmaceutical tablets, and methods of treating a disease or disorder using the pharmaceutical tablet of the invention. In particular, the pharmaceutical tablet of the invention comprises modafinil particles and one or more pharmaceutically acceptable excipients, wherein the... Agent: Sutherland Asbill & Brennan LLP

20070275059 - Flashmelt oral dosage formulation: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as... Agent: Louis J. Wille Bristol-myers Squibb Company

20070275058 - Tablet quickly disintegrating in oral cavity: The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness compared to rapid disintegrating tablets of the prior art. The above objective is solved by a composition in which the inorganic excipient and the disintegrating agent... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070275061 - Pharmaceutical compositions and formulations of metformin extended release tablets: The present invention relates to a metformin extended release tablet, particularly to a metformin extended release tablet comprising metformin, which is effective in treating non-insulin dependent diabetes mellitus, as active ingredient, and a matrix in which hydrophilic polymers and hydrophobic materials are mixed at a specific proportion. The hydrophilic polymers... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070275062 - Controlled release oxycodone compositions: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation... Agent: Jones Day

20070275065 - Controlled release oxycodone compositions: A method for substantially reducing the range in daily dosages required to control pain in approximately. 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation... Agent: Jones Day

20070275060 - Extended release solid pharmaceutical composition containing carbidopa and levodopa: The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally further comprises an immediate or rapid release composition of carbidopa and/or levodopa. The extended release composition in the tablet excludes a... Agent: Innovar, LLC

20070275064 - Solid tablets composition rapidly dissolvable in water or watery liquids and used for body, skin, hair and oral hygiene and desinfection: Compositions of solid tablets of quick dissolution in water or aqueous liquids for body or mouth cleansing, skin and hair treatment, and disinfection, wherein said tablet composition comprises from 75% to 92% of at least one disintegrating agent, from 0.5% to 9% of at least one surfactant and from 0.5%... Agent: Fitch Even Tabin And Flannery

20070275063 - Sustained release pharmaceutical compositions and methods of treatment using the same: A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof, of an effective non-toxic amount of an insulin sensitiser so as to provide a plasma concentration of the insulin sensitiser... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070275066 - Sustained release drug delivery system composed of water insoluble polymer: The present invention relates to a sustained release drug delivery system composed of a water insoluble polymer, and more particularly, to a sustained release drug delivery system comprising: a crystalline core material; an active ingredient layer which is formed on an outer surface of the crystalline core material and comprises... Agent: The Webb Law Firm, P.C.

20070275067 - Compression coated tablet comprising sumatriptan: The present invention provides a pharmaceutical composition for oral administration, comprising a core of active ingredient and an outer non-active layer formed on the core by application of pressure.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070275068 - Controlled release delivery system for bio-active agents: The invention provides a controlled release delivery system comprising a bio-active compound and a matrix carrier, wherein said matrix carrier is an amorphous microporous non-fibrous silicon or titanium oxide being loaded with said bio-active compound and wherein the micropores of said matrix carrier have a mean size in the range... Agent: Clark & Elbing LLP

20070275070 - Barrier film-forming germicidal composition for controlling mastitis: A long-lasting persistent, uniform film-forming skin protecting germicidal composition provides a long-lasting persistent barrier film when applied to skin. The compositions have particular utility as barrier teat dips for protecting cows against mastitis. A barrier film-forming agent is selected from the modified or hydrolyzed polysaccharides, particularly a hydrolyzed or modified... Agent: Lathrop & Gage Lc

20070275069 - Hydrophobic biomolecular structure: The present invention relates to a new hydrophobe biomolecular structure, which is compacted due to the passing of the structure over its point of collapse, a method for the preparation of the structure and use of the new structure for the manufacture of a medicament.... Agent: Young & Thompson

20070275072 - Butyl lactate emulsions for the precipitation of water-insoluble drug nanoparticles: Emulsions for use in precipitating water-insoluble drug nanoparticles. The continuous phase of the emulsions include water and an external surfactant. The discontinuous phase of the emulsions include butyl lactate, a co-solvent, an internal surfactant and a water-insoluble drug that is solubilized in the discontinuous phase. The emulsions allow for the... Agent: Rankin, Hill, Porter & Clark, LLP

20070275073 - Clay-based hemostatic agents and devices for the delivery thereof: A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate.... Agent: Michaud-duffy Group LLP

20070275076 - Method for the production of porous particles: The present invention provides a method for the production of porous particles that involves extracting an organic solvent from a water-in-oil-in-water emulsion. In accordance with the method of the invention, a first aqueous solution including a porosity-promoting agent is emulsified into an organic solution including a therapeutic constituent and, optionally,... Agent: Rankin, Hill, Porter & Clark, LLP

20070275077 - Wound compress: A wound compress may include a sealed, fluid permeable, fenestrated pouch, and a quantity of particles inside the pouch, each particles having a smallest linear dimension larger than the largest linear dimension of the pouch fenestrations. A wound compress kit may include a wound compress and an overwrap. A method... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070275074 - Controlled agglomeration: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low... Agent: Edwards Angell Palmer & Dodge LLP

20070275075 - Ezetimibe compositions: Provided are ezetimibe compositions with improved solubility and increased bioavailability, methods of their preparation, and method of treatment using the same. An ezetimibe composition may be prepared, for example, by co-milling ezetimibe with at least one hydrophilic excipient.... Agent: Kenyon & Kenyon LLP

20070275071 - Use of microparticles for antigen delivery: The invention relates to microparticles that may be used for antigen delivery and vaccine immunization strategies. The invention in particular relates to microparticles that are useful in the prophylaxis and treatment of human immunodeficiency virus (HIV) infections.... Agent: Clark & Elbing LLP

20070275079 - Antigen-containing microspheres for the treatment of allergies: Microspheres containing antigens for allergy therapy, the microspheres having a binding constant of 1×104 M−1 toward a specific carbohydrate residue of intestinal and/or nasal epithelial cells.... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070275078 - Microcapsules for the administration of active ingredients: The present invention relates to microcapsules for the administration of active ingredients, consisting of a core comprising one or more active ingredients, a surfactant and at least one wax or at least one fat, or a mixture of at least one wax and at least one fat, and of a... Agent: Merchant & Gould PC

20070275081 - Aqueous dispersion and its use: The invention relates to a dispersion comprising particles of at least one active substance dispersed in an aqueous solution of a modified starch, wherein said aqueous solution has a pH value in the range 5 to 10, as well as its use. The invention further relates to a process of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070275080 - Polymer-based microstructures: The present invention relates to the fields of controlled release of drugs, proteins, nucleic acids, and other pharmaceuticals. It also relates to delivery systems for these agents and other compounds. The invention also relates to stable encapsulation of cells and molecules. The invention provides a population of microstructures comprising a... Agent: Darby & Darby P.C.

20070275082 - Preparation method for sustained release microspheres using a dual-feed nozzle: Disclosed is a method of preparing sustained release microspheres by spray-drying liquids with different compositions for preparation the sustained release microspheres through an ultrasonic dual-feed nozzle. Unlike conventional methods of preparing sustained release microspheres by spray-drying a single liquid containing a biodegradable polymer, a drug, an additive and a solvent... Agent: Medlen & Carroll, LLP

20070275083 - Detection, isolation and uses of renalase (monoamine oxidase c): The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070275085 - Compositions and methods for the cure of hiv / aids: A pharmaceutical composition for the treatment of patients with human immunodeficiency virus infection is disclosed. The composition comprises effective amounts of: components obtained from Neem (Azadirachta Indica); and a protein supplement. This composition can be produced by: contacting powdered Neem with water to allow said water to extract components from... Agent: Rajesh Radhakrishnan

20070275084 - Compositions and methods for the treatment of skin damage: The present invention provides methods and compositions for use in cosmetic and dermatological formulations. In various embodiments of the present invention, compositions comprising beta-alanyl-L-histidine (carnosine) or derivatives or analogs thereof and basic milk factor (BMF) for prophylaxis and treatment of aged or photodamaged, or damaged, as in wounded or disrupted,... Agent: Christie, Parker & Hale, LLP

20070275086 - Use of increased molecular-weight hirudin as an anticoagulant in extracorporeal kidney replace therapy: The invention relates to the use of increased-molecular-weight hirudin for the manufacture of an anticoagulant for extracorporeal renal replacement therapy which does not induce an autoimmune disease and which does not cross react with autoimmune antibodies. In particular, the use according to the invention does not induce type II thrombocytopenia... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070275087 - Natural composition based on chilean monofloral honey extract from native vegetable species for bacterial infection control in vegetables at all: Natural composition for controlling bacterial infections in potatoes, lettuce, vegetables, cores and flowers in general comprising extracts from monofloral honey flavonoids and/or phenols that act independently as controller of various bacterial infections.... Agent: Millen, White, Zelano & Branigan, P.C.

20070275088 - Conversion of sea-shells and other calcite-based and aragonite-based materials with dense structures into synthetic materials for implants and other structures and devices: Bulk materials for implants and scaffolds made from hydrothermal conversion of bulk calcium carbonate materials with desired initial structures in order to utilize the mechanical and structural properties of the initial structures. Dense sea-shells, light-weighted sea urchin spines and strong marine bones such as cuttlebones are examples of bulk calcium... Agent: Fish & Richardson, PC

20070275089 - Argon-based inhalable gaseous medicinal product for the treatment of neurointoxications: The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the... Agent: Air Liquide Intellectual Property

20070275091 - Compositions and methods for improved mucus function: The invention relates to compositions and methods for enhancing mucus functions such as but not limited to improved respiratory tract mucus clearance. The compositions of the invention are mucothickening compositions. They can be used to improve mucus clearance in a subject in need thereof, such as in the treatment of... Agent: Bereskin And Parr

20070275090 - Ionic uv-a sunscreens and compositions containing them: The present invention relates to novel 1,4-dihydropyridine derivatives, to novel cosmetic or dermatological sunscreen compositions containing these derivatives and the use of these derivatives for photoprotecting human skin and/or hair against UV radiation, in particular solar radiation.... Agent: Stephen M. Haracz Bryan Cave

20070275092 - Therapeutic composition supporting the immune system: Disclosed is a therapeutic nutritional compound for treating and supporting the immune response in a mammal, particularly a human baby or child, and the treatment method. Additionally, the therapeutic nutritional compound can be used in conjunction with a vaccine or immunization regimen to reduce the potential undesirable effects caused by... Agent: Rogers Towers, P.A.

20070275094 - Isothiazolinone biocides enhanced by zinc ions: The present invention relates to an antimicrobial composition comprising an isothiazolinone, such as 1,2-benzisothiazolin-3-one, and a zinc compound selected from zinc salts, zinc oxides, zinc hydroxides or combinations thereof. Useful zinc salts include for example, oxides, sulfates, chlorides, and combinations thereof. In use, the zinc from the zinc compound enhances... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20070275093 - Methods for treating non-microbial inflammatory skin conditioners: The present invention relates generally to the field of skin care products and more particularly to topical skin applications containing azole derivatives for treatment and prevention of transepidermal water loss. The present invention may be embodied in creams, lotions, oils, sprays and other typical dosage forms for direct application to... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070275095 - Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin: Treatments are disclosed for inflammatory, autoimmune, or other disorders characterized by excessive activity of calprotectin, a protein that normally defends against microbial infections by sequestering available zinc, at a site of infection. Excessive calprotectin activity, which can cause zinc deficiencies in localized tissues, can create or aggravate various disorders. However,... Agent: Patrick D. Kelly

20070275096 - Composition and methodology for the treatment of hearing impairment symptoms: One possible embodiment of the invention could include a homeopathic composition suitable for the treatment of the symptoms of hearing impairment comprises: 3-Isothiocyanato-1-Propene in 6 times potency, Arnica Montana in 6 times potency, Arnica Montana in 30 times potency, Calcium Sulphide in 6 times potency, Hypericum Perforatum in 6 times... Agent: John D. Long, Patent Counsel Long & Chybik

20070275097 - Cosmetic and/or dermatological preparation and use thereof in the regulation of skin capillary blood flow: This invention relates to the field of cosmetology and/or dermatology and concerns a use of preparations that influence indices of blood microcirculation in the skin. Aim of this invention is the use of perfluoride emulsions for essential increase of the skin blood flow and for improving conditions of the blood... Agent: Knobbe Martens Olson & Bear LLP

20070275098 - Formulation and methodology for the treatment for eye impairment symptoms: One possible embodiment of the invention could comprise a homeopathic composition suitable for the treatment of the symptoms of eye impairment conditions which comprises Cineraria Maritima in five times potency; Calcium Fluoride in thirteen times potency; Conium Maculatum in six times potency; Euphrasia Stricta in six times potency; Gelsemium Sempervirens... Agent: John D. Long, Patent Counsel Long & Chybik

20070275099 - Mst1 modulation of apoptosis in cardiac tissue and modulators of mst1 for treatment and prevention of cardiac disease: The present invention relates to methods and agents for treatment, amelioration and prevention of cardiac disease, including cardiac myopathy, chronic heart failure and for management and reduction of cardiac myocyte death which may occur in response to ischemia/reperfusion or following myocardial infarction or other injury to the heart. The invention... Agent: Klauber & Jackson

20070275100 - Use of gaseous nitric oxide as an anti-cancer agent: The invention relates to a method for treating, controlling, or preventing cancerous cell phenotypes and growths in an animal involving the administration of gaseous nitric oxide to one or administration sites in a body. The invention generally is capable of treating cancers found in or on the adrenal gland, bladder,... Agent: Sidley Austin Brown & Wood LLP (laip Group)

20070275101 - Removable antimicrobial coating compositions and methods of use: This invention relates to a method for controlling microorganisms comprising coating a surface with a removable, antimicrobial film-forming composition.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070275102 - Method of affecting sleep and sleep-related behaviors: A method of affecting sleep and sleep-related behaviors of a mammal having a diurnal rhythm, by reducing the basal activity of the hypothalamus-pituitary-adrenal axis by administering an effective amount of a sensory regimen is disclosed. Such reduction may be accomplished by reducing at least one of the following: a. the... Agent: Philip S. Johnson Johnson & Johnson

20070275103 - Herbal mixture extract of notoginseng radix, rehmanniae radix preparata and acanthopanacis cortex and composition comprising the same for prevention and treatment of arthritis: The present invention relates to a herbal mixture extract of Notoginseng radix, Rehmanniae radix preparata and Acanthopanacis cortex, and a composition for the prevention and the treatment of arthritis comprising the same as an effective ingredient. The herbal mixture extract of the present invention can be effectively used for the... Agent: Joseph Hyosuk Kim, Ph.d. Jhk Law

20070275104 - Food compositions and methods of treating periodontal disease: The invention provides a method of alleviating a sign or symptom of periodontal disease in a subject, by administering to the subject a composition containing a natural compound which inhibits matrix metalloproteinase activity and interleukin-1 activity.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070275105 - Bruise amelioration composition and method of use: A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 85% by weight of glycerin and at least 2% by weight of primrose... Agent: Ladas & Parry LLP

20070275106 - Hydroxylated polymethoxyflavone compositions: Provided herein are compositions enriched in polyhydroxylated polymethoxyflavones useful as dietary supplements, food additives, pharmaceutical compositions, nutraceutical compositions and cosmetic compositions.... Agent: Jones Day

20070275107 - Method for the removal of aloin, emodin and/or isoemodin from aloe vera by treatment with an oxidase: The invention relates to a method for the removal of aloin, emodin and/or isoemodin from aloe vera gel and a method for the production of aloe vera gel with less than 5 ppm of aloin, emodin and/or isoemodin by treatment with an oxidase, whereby a manual slicing of the aloe... Agent: Nixon & Vanderhye, PC

20070275108 - Life span managment: Natural products can confer protective effects, effects identical to or similar to protective effects of a “protective” genetic variant. Through the administration (e.g. consumption, ingestion, topical application, etc) of natural products, it is possible in some cases to counter one or more effects of a detrimental gene and mimic one... Agent: Fish & Richardson PC

20070275109 - Eggplant extract for medical treatments: An extract is made by cooking the fruit of an eggplant for about 15 to 30 minutes at about 120 to about 250° C., extracting the juice from the cooked fruit, and adding an oxidant to the juice that reacts with a component in it and changes its color from... Agent: Richard D. Fuerle

20070275110 - Botulinum toxin treatment of spastic bladder: The invention relates to the use of a liquid or semi-solid formulation of botulinum toxin for the preparation of a medicament intended to treat a disorder characterised by bladder spasms (e.g. urinary incontinence due to unstable bladder or unstable detrusor sphincter, voiding complications due to detrusor overactivity or unstable detrusor... Agent: Jacobson Holman PLLC

20070269386 - New product and use and manufacture thereof: A pharmaceutical oral formulation for delivering nicotine in any form to a subject by transmucosal uptake in the oral cavity comprising nicotine in any form, wherein said oral formulation is buffered with at least trometamol. Also contemplated is a method for the oral delivery of nicotine in any form, a... Agent: Rosemary M. Miano Legal Division

20070269397 - Aqueous hair cleansing agent: p

20070269398 - Aqueous hair cleansing agent:

20070269396 - Polyetheramide compositions: Ethanol soluble or dispersible polyetheramide polymers that have a percent elongation to break of less than 100%. The polymers are formed from a reaction mixture comprising at least one or more poly(alkyleneoxy) diamines and one or more diacids. The reaction mixture can optionally include one or more aliphatic diamines in... Agent: National Starch And Chemical Company

20070269399 - Hydrogen peroxide containing composition: A hydrogen peroxide containing composition, which sufficiently decreases the stimulation to the scalp, skin, and the like when used as a hair dye. The hydrogen peroxide containing composition includes allantoin, guaiazulene and aloe extract as the second agent for mixing with a first agent containing an oxidation dye. These ingredients... Agent: Law Office Of Delio & Peterson, LLC.

20070269402 - Aerosol total release container and method of use for odor elimination: An odor eliminating device comprises a total release aerosol container that contains an odor elimination compound in the container. The container is placed in an enclosed space that has an odor problem. The container is triggered to release tie odor elimination compound into the enclosed space to cure the odor... Agent: Clark & Brody

20070269404 - Controlling sugar feeding insects: Methods for controlling sugar feeding insects by a chemical compositions which includes mixing an extract of flowers and of fruit, or their components in water with predetermined amount of sugar mixture and oral toxin. The methods also concern applying an effective amount of the insect bait to an area to... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20070269368 - Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume... Agent: Wood, Herron & Evans, LLP

20070269369 - Modified fc molecules: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at... Agent: Amgen Inc.

20070269371 - Antibodies with altered effector functions: The invention provides antibodies with altered effector functions, and methods of using these antibodies in the treatment of various diseases. The invention further provides compositions, kits and articles of manufacture for practicing methods of the invention.... Agent: Genentech, Inc.

20070269370 - Compositions and methods for treating b-cell malignancies: The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070269372 - Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes.... Agent: Morgan & Finnegan, L.L.P.

20070269373 - Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume... Agent: Wood, Herron & Evans, LLP

20070269374 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ-opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ-opioid receptor-mediated diseases, disorders, and/or... Agent: Woodcock Washburn LLP

20070269375 - Stable radiopharmaceutical compositions and methods for preparation: Stabilized radiopharmaceutical formulations are disclosed. Methods of making and using stabilized radiopharmaceutical formulations are also disclosed. The invention relates to stabilizers that improve the radiostability of radiotherapeutic and radiodiagnostic compounds, and formulations containing them. In particular, it relates to stabilizers useful in the preparation and stabilization of targeted radiodiagnostic and... Agent: Kramer Levin Naftalis & Frankel LLP

20070269376 - Method for determining dosage for an oral killed vaccine: There is disclosed a method for determining an administration regimen for an oral killed vaccine for use in immunising individuals in a population against an infection or disease. The method comprise administering the oral killed vaccine to one or more individuals in a population and identifying an indicative dosaging level... Agent: Fulbright & Jaworski L.l.p

20070269377 - Method of producing partial peptide of enolase protein from plasmodium falciparum: e

20070269378 - Nadks as modifiers of branching morphogenesis and methods of use: Human NADK genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morpho-genesis, comprising screening for agents that modulate the activity of NADK are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070269379 - Penetration enhancer combinations for transdermal delivery: A high throughput screening and isolation system identifies rare enhancer mixtures from a candidate pool of penetration enhancer combinations. The combinations are screened for high penetration but low irritation potential using a unique data mining method to find new potent and safe chemical penetration enhancer combinations. The members of a... Agent: Rober Berliner Berliner & Associated

20070269380 - Methotrexate-modified nanoparticles and related methods: Methotrexate-modified nanoparticles that target tumors, compositions that include the nanoparticles, methods of imaging tissues using the nanoparticles, and methods for treating tissues using the nanoparticles.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070269383 - Dielectric element and method for generating a magnetic resonance image therewith: A dielectric element is formed of a dielectric material exhibiting a magnetic resonance relaxation time, with a relaxation agent incorporated in the dielectric material that reduces the relaxation time of the dielectric material. The dielectric element is adapted for placement on a subject while magnetic resonance data are acquired from... Agent: Schiff Hardin, LLP Patent Department

20070269382 - Nanoparticles and their use for multifunctional bioimaging: The present invention relates to fluorescent, radio-opaque and magnetic quantum nanoparticles, useful as multifunctional contrast agents or probes for in vivo bioimaging, and methods of their use. The invention provides for multifaceted bioimaging (e.g., intra-arterial pre-operative brain mapping and broad based in vivo diagnostic imaging), including imaging of various cell... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070269384 - Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of alzheimer's disease: The invention relates to the use of metal complexes that contain at least one perfluorinated alkyl radical and at least one chelating agent radical and at least one metal ion equivalent of the atomic numbers 21-29, 31-33, 37-39, 42-44, 49 or 57-83, as well as salts thereof for the production... Agent: Millen, White, Zelano & Branigan, P.C.

20070269381 - Ultrasound contrast agent dosage formulation: Clinical studies have been conducted and specific dosage formulations developed using polymeric microparticles having incorporated therein perfluorocarbon gases that provide significantly enhanced images of long duration. The dosage formulation includes microparticles formed of a biocompatible polymer, preferably including a lipid incorporated therein, and containing a perfluorocarbon that is a gas... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070269385 - Devices, methods, and systems for delivering therapeutic agents for the treatment of sinusitis, rhinitis, and other disorders: Methods and kits for delivering pharmaceutical agents to the sinuses, sinus ostia, Eustachian tube, and pharynx are presented. A needle tip is translated through the mucosal tissue layer to a sub-epithelial or peri-luminal orientation and pharmaceutical agents are delivered into the sub-epithelial or peri-luminal tissue. Drugs distribute from the site... Agent: Townsend And Townsend And Crew, LLP

20070269387 - Moisture-retaining agent comprising alpha-glycosyl glycyrrhizing as an effective ingredient and use thereof: The present invention has objects to provide a humectant applicable to preparations for external dermal agents, which has a moisturizing activity without causing unfavorable sticky feeling, and to provide an external dermal agent incorporated with the humectant. These objects are solved by providing a humectant containing α-glycosyl glycyrrhizin as an-effective... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070269388 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070269389 - Base composition for preparing multi-functional formulations for care and protection of the skin and hair: The present invention relates to a cosmetic composition comprising a filmogenic system constituted by at least dimethicone, trimethylsiloxysilicate, stearyl dimethicone, cyclopentasiloxane and dimethiconol, and an emulsifying system constituted by at least PEG-8 dimethicone. This composition imparts to the skin a high resistance to water and to sweat, as well as... Agent: Alston & Bird LLP

20070269391 - Glyceryl and glycol acid compounds: A composition comprising a glyceryl salicylate compound and/or a glycol salicylate compound. The compositions can be used to reduce the amount of moisture evaporated from skin, protect the skin from UV light, and treat aged or damaged skin.... Agent: Fulbright & Jaworski L.L.P.

20070269390 - Oil-in-water emulsion: Oil-in-water emulsion containing (1) an emulsifying system containing at least one silicone surfactant of molecular weight greater than or equal to 10,000, at least one non-ionic cosurfactant, and at least one anionic cosurfactant, and (2) at least one monohydric alcohol containing from 2 to 6 carbon atoms, where the oils... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070269392 - Personal care compositions: This invention relates to personal care compositions containing polytrimethylene ether glycol in a variety of physical forms including solutions, gels, oil-in-water emulsions, water-in-oil emulsions, suspensions and solids. In a particularly preferred embodiment, the polytrimethylene ether glycol is derived predominantly from monomers obtained from renewable resources, making the personal care products... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070269393 - Topical anesthetic formulation: The topical medicament gel formulation of the present invention includes an anesthetic, an anti-microbial, an oxidant, a nutrient, a diuretic, an opioid, an anti-emetic, an anti-seizure drug, and a non-steroidal anti-inflammatory drug (NSAID), USP in a molecular, as opposed to a salt form, as the active ingredient. Additional constituents illustratively... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070269394 - Peptide-based body surface coloring reagents: Peptides have been identified that bind with high affinity to body surfaces, such as, hair, skin, nails, teeth, gums, and oral cavity surfaces. Diblock and triblock peptide-based body surface coloring reagents formed by coupling a body surface binding peptide to a pigment binding peptide, either directly or through a spacer,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070269395 - Inhibition of hairless protein mrna: Methods for inhibition of hairless protein mRNA using RNA interference is described, in particular methods for hair removal. Also described are nucleic acid constructs for RNAi-mediated inhibition of hairless protein mRNA and compositions including such constructs.... Agent: Baker Botts L.L.P.

20070269400 - Moisture-regulating cosmetic: The invention relates to a cosmetic composition with a moisture-regulating effect based on plant active ingredients with a long-lasting moisturizing effect of up to 24 hours. The cosmetic comprises in each case a watery plant milk of the fruit of Elaeis guinensis, of the leaves of Phoenix canariensis, of the... Agent: Millen, White, Zelano & Branigan, P.C.

20070269401 - Device for distributing and/or controlling the discharge of unitary products, fitted onto a container, and for the in-situ treatment of its internal atmosphere: The present invention relates to a device for distribution and/or controlling the discharge of unitary products, and for simultaneous in-situ treatment of the atmosphere of a container onto which it is fitted. The device comprises a lower surface provided with an entry opening, an upper surface provided with at least... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing 32nd Floor

20070269403 - Composition and method for treatment of hepatic encephalopathy: The inventions provide an improved treatment for hepatic encephalopathy characterized by hyperammonemia and/or constipation, comprising the oral administration of polyethylene glycol (PEG) in amounts sufficient to reduce plasma levels of ammonia and/or to alleviate constipation. Preferably, the PEG is administered in combination with lactulose, which provides a palatable composition for... Agent: Hoffman, Wasson & Gitler, P.C. Suite 522

20070269405 - Androgen receptor modulators: Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20070269408 - Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant: The present invention relates to the IL-12p40 subunit mutant gene which can produce IL-12 (interleukin 12) of human and mouse origin with high activity, the expression vector including above mutant gene and the use of them to DNA vaccine adjuvant. Particularly, it relates to IL-12p40 mutant gene which inhibits the... Agent: Joseph Hyosuk Kim, Ph.d. Jhk Law

20070269406 - Transcatheter tumor immunoembolization: Methods of inducing a cancer-specific immune response are disclosed through administration of an immune stimulant in the context of tumor cell death induction. Currently used clinical methods of inducing localized tumor cell death are modified to optimize immune response induction. One embodiment of the invention discloses pharmaceutical compositions and kits... Agent: Baumgartner Patent Law

20070269407 - Use of interleukin-19 to treat cervical cancer: The present invention relates to the anti-cancer activity of IL-19 polypeptide molecules. IL-19 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-19 for decreasing proliferation of cervical cancer cells, treating cervical cancer, amongst other uses disclosed. IL-19 polypeptides can be administered alone,... Agent: Zymogenetics, Inc. Intellectual Property Department

20070269409 - Adenoviral vector vaccine: Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L... Agent: Drinker Biddle & Reath LLP

20070269410 - Chimeric adenoviral vectors: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.... Agent: Townsend And Townsend And Crew, LLP

20070269411 - Porous silicon materials and devices: Provided are materials and devices comprising physiologically acceptable silicon. The materials and devices can comprise a vector, including a viral vector.... Agent: Needle & Rosenberg, P.C.

20070269414 - Method for producing gene transferred denritic cells: The present invention provides a method for introducing a gene into a dendritic cell, which includes the step of contacting a minus-strand RNA virus with a dendritic cell. The present invention also provides a method for producing a gene transferred dendritic cell, which includes the step of contacting a minus-strand... Agent: Clark & Elbing LLP

20070269415 - Anti-allergic agent containing both ground lotus and/or extract and lactic acid bacterium: The present invention relates to an anti-allergic agent, an anti-allergic food additive and an anti-allergic food each containing both ground lotus and/or extract and a lactic acid bacterium. The anti-allergic agent, anti-allergic food additive and anti-allergic food each contain both ground lotus and/or extract and a lactic acid bacterium as... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20070269416 - Live bacteria product: A live bacteria product including dormant viable bacteria suspended in a liquid carrier. The carrier contains mineral oil and polymers and may also include an adsorbent. The product is stored and shipped in a plastic bag and is sprayed onto its target host or the like. The moisture and pH... Agent: Thomte Law Office, L.L.C.

20070269417 - Nicotine delivery systems: A delivery system for nicotine including nicotine encapsulated in a microcapsule system which releases the encapsulated nicotine on contact of the microencapsules with a nicotine solvent.... Agent: Jacobson Holman PLLC

20070269412 - Pluripotent cells: Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells... Agent: Karen S. Canady Canady & Lortz LLP

20070269413 - Transdiscal administration of high affinity anti-mmp inhibitors: The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070269418 - Hair growth inhibition: The invention relates to the use of a composition for the preparation of a hair growth inhibitor and furthermore to the use of a system for the preparation of a hair growth inhibitor. The invention also relates to a composition comprising at least one enzyme, a solvent, and a water... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070269422 - Serum albumin binding proteins with long half-lives: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that... Agent: Wolf Greenfield & Sacks, P.C.

20070269420 - Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases: The present invention is directed to compounds, compositions and methods for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus. Also within the scope of this invention are assay methods for identifying agents that modulate... Agent: Dann, Dorfman, Herrell & Skillman

20070269421 - Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp): The invention provides a human PGCP which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urologial diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular... Agent: Banner & Witcoff, Ltd.

20070269423 - Method of detecting the expression of ppn/mg61 and the use of it: The present invention is directed to methods for comparatively detecting the level of human Porcupine (PPN)/MG61, a family member of membrane-bound O-acyltransferases, which is the human homologue of the Drosophila polarity gene Porcupine (Porc), and use thereof.... Agent: Wang & Ho

20070269424 - Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of moraxella bovis infections: Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of Moraxella bovis infections Moraxella bovis cytotoxin and a gene encoding Moraxella bovis cytotoxin. Identification, isolation, cloning and identification of nucleotide sequence of the Moraxella bovis genes mbxA, mbxB, mbxC and mbxD, partial purification of the native cytotoxin,... Agent: Quine Intellectual Property Law Group, P.C.

20070269419 - Use of caspase-8 inhibitors for modulating hematopoiesis: A method of inhibiting hematopoiesis in a subject is provided. The method is effected by downregulating an expression or activity of caspase-8 in the subject thereby inhibiting hematopoiesis therein.... Agent: Marshall, Gerstein & Borun LLP

20070269425 - Anti-idiotype antibodies of the human monoclonal antibody sc-1, and their production and use: The invention features anti-idiotype antibodies of the human monoclonal antibody SC-1, as well as methods for producing and using the anti-idiotype antibodies.... Agent: Clark & Elbing LLP

20070269426 - Use of soluble gammadelta cell receptors for regulating t cell function: Disclosed is a method of using soluble γδ T cell receptors to regulate a γδ T cell-mediated immune response in a mammal.... Agent: Sheridan Ross PC

20070269430 - Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome: Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and... Agent: Wyeth Patent Law Group

20070269428 - Method for the treatment of multiple sclerosis by inhibiting il-17 activity: The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.... Agent: Woodcock Washburn LLP

20070269427 - Therapeutical use of anti-myelin associated glycoprotein (mag) antibodies: A method of promoting oligodendrocyte survival in a human suffering from, or at risk of developing, stroke or other neurological diseases utilizes anti-MAG antibodies or functional fragments of such antibodies.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070269429 - Treatment with anti-erbb2 antibodies: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor.... Agent: Genentech, Inc.

20070269431 - Protein involved in cancer: The present invention relates to new uses of FLJ20584 in the diagnosis, screening, treatment and prophylaxis of ovarian and lung cancer. The invention also provides compositions comprising FLJ20584, including vaccines, antibodies that are immunospecific for FLJ20584 and agents which interact with or modulate the expression or activity of FLJ20584 or... Agent: Klauber & Jackson

20070269435 - Artificial proteins with reduced immunogenicity: The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused... Agent: Olson & Hierl, Ltd.

20070269433 - Cell cycle progressional proteins: Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.... Agent: Edwards Angell Palmer & Dodge LLP

20070269432 - Method of diagnosing breast cancer: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene... Agent: Townsend And Townsend And Crew, LLP

20070269434 - Tat-041 and methods of assessing and treating cancer: Surprisingly, the present inventors have discovered that expression of TAT-041 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-041 is associated with abnormal development and growth, and may be useful as a... Agent: Clark & Elbing LLP

20070269438 - Antibodies to the human prolactin receptor: This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and... Agent: Fish & Richardson PC

20070269436 - Method of antibody production: The present invention relates to a method for the in vitro production of antibody in an antigen specific manner and, more particularly, to the in vitro production of human antibody in an antigen specific manner. The present invention further extends to the antibody produced therefrom and to the antibody producing... Agent: Seed Intellectual Property Law Group PLLC

20070269437 - Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp): The present invention relates to providing antibodies against human heparin-binding protein (hHBP) or against a homologue of hHBP, such as porcine heparin binding protein (pHBP) or human neutrophil elastase (hNEL), and using said antibodies for the manufacture of a medicament for treatment of Gram positive and/or Gram negative infections, sepsis,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070269439 - Interleukin 17 receptor-like protein: The present invention relates to a novel IL17RLP protein which is a member of the interleukin (IL)-17 receptor family. In particular, isolated nucleic acid molecules are provided encoding the human IL17RLP protein. IL17RLP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070269440 - Stimulators of osteoblastogenesis and applications of the same: Compositions that stimulate osteoblastogenesis and the activity of osteoblasts are disclosed. Methods of stimulating osteoblastogenesis and the activity of osteoblasts are disclosed. Methods of treating a mammal for a bone condition by stimulating osteoblastogenesis and the activity of osteoblasts are disclosed. According to the present invention, a composition comprising a... Agent: L. Joseph Underwood Williams & Anderson PLC

20070269441 - Immunoregulation in cancer, chronic inflammatory and autoimmune diseases: The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing... Agent: Young & Thompson

20070269442 - Chimeric monoclonal antibody recognizing inos: A chimeric therapeutic agent recognizing iNOS utilizing a human/mouse chimeric anti-hiNOS monoclonal antibody having mouse complimentarity-determining regions forming a binding site for iNOS.... Agent: Theodore J. Bielen Jr. Bielen, Lampe, & Thoeming

20070269443 - Therapeutic regimens for baff antagonists: Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorders are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round of administration.... Agent: Biogen Idec / Finnegan Henderson, LLP

20070269444 - Adjuvant therapy with the use of anti-glypican 3 antibody: The present invention provides an anti-cancer agent comprising anti-glypican 3 antibody wherein the anti-cancer agent is administered after a cancer treatment, Preferably, after a cancer treatment is after a treatment for liver cancer, and the treatment for liver cancer is in particular a resection of liver cancer cells. The anti-cancer... Agent: Fish & Richardson PC

20070269445 - Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (prrsv), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a prrsv and a method of de: The present invention provides a purified preparation containing a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), proteins at least 80% but less... Agent: Bingham Mccutchen LLP

20070269446 - Compositions and methods for the treatment of tumor of hematopoietic origin: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20070269447 - Cytotoxic agents comprising new maytansinoids: New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful... Agent: Sughrue Mion, PLLC

20070269448 - Transition state analog inhibitors of ricin a-chain: Improved transition state analog inhibitors of ricin toxin-A are provided. Methods of using those inhibitors to inhibit ricin toxin-A and to prevent the toxic effects of rich toxin-A in a mammal are also provided.... Agent: Amster, Rothstein & Ebenstein LLP

20070269450 - Biologically active peptides: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.... Agent: EagleIPLimited

20070269449 - Fc fusion proteins: The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain.... Agent: Nixon Peabody, LLP

20070269452 - Methods and compositions for the diagnosis and treatment of cancer: The present invention relates to compositions and methods useful for the diagnosis of lymphoma and particular types of metastatic tumors and for treating same. Specifically, this invention relates to methods for the differential diagnosis of B cell derived lymphoma subtypes and to the diagnosis of the metastatic potential of some... Agent: Winston & Strawn LLP Patent Department

20070269451 - Nucleic acid vaccination: A nucleic acid vaccine construct comprising an isolated polynucleotide which encodes a polypeptide comprising at least five consecutive amino acid residues from the VNTR monomer of Muc1 wherein one or more of said amino acids is a glycosylation site, characterised in that when said isolated polynucleotide is expressed in a... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070269453 - Highly expressed peptide of white spot syndrome virus in hosts and application thereof: The present invention relates to a WSSV peptide, which comprises a peptide sequence as set forth in SEQ ID NO: 1 and can be used as target peptide for WSD immunodetection in crustaceans. In addition, the present invention also provides a WSSV nucleotide sequence, which comprises a nucleotide sequence encoding... Agent: Morris Manning Martin LLP

20070269454 - Composition for external use: or a salt or ester thereof which is safe to the human body, and a koji mold or a processed koji. The composition for external use is excellent in skin permeability, containing an ascorbic acid derivative which is excellent in stability, utilized persistently in the living body, and strong in... Agent: Drinker Biddle & Reath (dc)

20070269455 - Cytokine-coated cells and methods of modulating an immune response to an antigen: The invention relates to a method of vaccinating a mammal to a selected antigen, comprising administering to a mammal a vaccine composition comprising a cytokine-coated cell, wherein the cytokine-coated cell comprises the selected antigen.... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070269456 - Dna-based plasmid formulations and vaccines and prophylactics containing the same: The invention is a general method for improving the performance of the DNA-based vaccines. The method utilizes a complex DNA-generated profile of antigens to extend the effects of DNA-based vaccines and to broaden the immune response. This broadened immune response in turn improves the protection of the recipient from divergent... Agent: Vinson & Elkins L.L.P.

20070269457 - Immunotherapeutic compositions and methods: A vaccine is described which provides protection against a broad spectrum of viral strains, including but not limited to influenza A strains such as H1N1, H3N2, and H5N1. Embodiments of the present invention offer a number of advantages over conventional vaccine, in that they are cheaper to synthesize, more stable,... Agent: Medlen & Carroll, LLP

20070269458 - Vaccines against japanese encephalitis virus and west nile virus: The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.... Agent: Clark & Elbing LLP

20070269459 - Mutant g genes of the trout viral haemorrhagic septicaemia virus (vhsv) and applications thereof: The invention relates to mutant G genes of viral haemorrhagic septicaemia virus (VHSV) in rainbow trout, which encode mutant G proteins of VHSV with defective or null binding to cells that can be infected by VHSV. Said mutant G genes of VHSV can be used, among other applications, to produce... Agent: Ostrolenk Faber Gerb & Soffen

20070269460 - Composition comprising the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors including the corresponding nucleic sequences and their therapeutic use: The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The... Agent: Buchanan, Ingersoll & Rooney PC

20070269461 - Recombinant vaccine against japanese encephalitis virus (jev) infection and a method thereof: The present invention relates to a novel recombinant adenovirus (RAdEs) vaccine against JEV infection; an effective and superior method of immunization to Japanese encephalitis virus (JEV) infection; also, a method of preparing the recombinant adenovirus (RAdEs) vaccine.... Agent: Ladas & Parry

20070269462 - Novel exoenzyme toxin of aeromonas salmonicida, and uses therefor: A novel protein toxin named Aeromonas salmonicida exoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of A. salmonicida. Also disclosed are diagnostic, preventative, and therapeutic techniques, including the preparation of traditional, recombinant, and improved... Agent: Sughrue Mion, PLLC

20070269463 - Botulinum toxin formulation for oral administration: Pharmaceutical compositions of a botulinum toxin for oral administration to a patient with a gastrointestinal disorder.... Agent: Allergan, Inc.

20070269464 - Epitope synchronization in antigen presenting cells: Disclosed herein are vaccines and methods for inducing an immune response against cancer cells and cells infected with intracellular parasites. Vaccines having housekeeping epitopes are disclosed. The housekeeping epitope is formed by housekeeping proteasomes in peripheral cells, but not by professional antigen presenting cells. A vaccine containing a housekeeping epitope... Agent: Knobbe Martens Olson & Bear LLP

20070269465 - Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine: It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpynrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase;... Agent: Berenbaum, Weinshienk & Eason, P.c

20070269469 - Hand-held depilatory and exfoliating device: A depilatory and skin exfoliating device comprising a central pad, an abrasive layer attached to one side of the pad, and a cleansing layer attached to the other side of the pad. By including both a depilatory device and a skin exfoliator, surface detritus and residue can be removed from... Agent: Akerman Senterfitt

20070269467 - Use of hydrolysis resistant organomodified silylated surfactants: Organomodified silylated surfactant compositions that exhibit resistance to hydrolysis over a wide pH range.... Agent: Momentive Performance Materials Inc.IPLegal

20070269468 - Fat compositions: Low-lauric, low-trans fat compositions useful for food and other applications.... Agent: Darby & Darby P.C.

20070269466 - Metal oxide particles useful as free radical scavengers in sunscreen and cosmetic compositions: A composition is described which comprises a component which is susceptible to free radical attack, said composition comprising, as a free radical scavenger, at least one particle having a size not exceeding 100 nm of an oxide of a rare earth or transition metal possessing adjacent oxidation states. The composition... Agent: Wolf Greenfield & Sacks, P.C.

20070269471 - Methods of tooth bleaching: The present invention relates to a tooth whitening strip of material having a shape adapted to fit a user's teeth. Each user has four front teeth, two canine teeth and additional back teeth, such as molars. Each tooth has a front side, a tip, and a back side. The strip... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070269470 - Oil base and external preparation containing same: [Solution means] The oil base of the present invention is an oil base containing an ester condensate obtained by a reaction between polyglycerol, 12-hydroxystearic acid, and hydrogenated dimer acid, the oil base having a three-dimensional network structure in which hydrogenated dimer acid is condensed with a hydroxyl group of each... Agent: Wolf Greenfield & Sacks, P.C.

20070269472 - Pest-control product: A pest-control product including a product body made of a resin containing at least either an insect-repelling agent or an insecticide. The product body can keep a plane spiral shape and change its shape to a three-dimensional helix. Even if the volume (or size) of the pest-control product is small,... Agent: Carr & Ferrell LLP

20070269473 - Microbial encapsulation: The present invention relates to a method of encapsulation and a composition comprising an encapsulate material.... Agent: Morrison & Foerster LLP

20070269476 - Engineered extracellular matrices control stem cell behavior: A composition for culturing stem cells is provided. The composition comprises an engineered purified collagen based matrix that has been formed under controlled conditions to have the desired microstructure and mechanical properties. The engineered purified collagen based matrix compositions of the present invention can be used alone or in combination... Agent: Barnes & Thornburg LLP

20070269477 - Heart treatment method: A method of treating heart disease. Antioxidant agents, such as estradiol, N-acetylcysteine and procyanidins, are administered intra-pericardially to inhibit coronary and myocardial inflammation. The antioxidant agents can be carried in a biodegradable material.... Agent: Tim L. Burgess

20070269474 - Osteochondral plug graft trimming device and method: A device for trimming an osteochondral plug graph to an implantable configuration, comprises a blade assembly terminating in a configured leading cutting blade and a plug graft housing comprising a substantially longitudinal holding sleeve having a bore and oriented complementarily to the longitudinal structure of the blade assembly to receive... Agent: Philip D Freedman PC Philip D Freedman

20070269475 - Osteochondral plug graft trimming device and method: A device for trimming an osteochondral plug graft to an implantable configuration, comprises a blade assembly terminating in a configured leading cutting blade and a plug graft housing comprising a substantially longitudinal holding sleeve having a bore and oriented complementarily to the longitudinal structure of the blade assembly to receive... Agent: Philip D Freedman PC Philip D Freedman

20070269480 - Medical devices having bioactive surfaces: According to an aspect of the present invention, medical devices are provided, which contain (a) a substrate and (b) a polymeric region disposed over the substrate which contains at least one block copolymer. The block copolymer, in turn, contains at least two polymer blocks which phase separate into two or... Agent: Mayer & Williams PC

20070269478 - Method of preparing acellularized, biocompatible, implantable material: c

20070269481 - Biomimetic scaffolds: The invention provides a composition comprising a nanofiber polymer in which the fibers of the nanofiber polymer are aligned, and a molecule is covalently attached, either directly or through a linker, to the nanofiber polymer. This molecule is capable of either covalently or non-covalently attaching to a member selected from... Agent: Morgan, Lewis & Bockius LLP (sf)

20070269482 - Implants for the treatment of dopamine associated states: Biodegradable implants comprising dopamine modulating compounds are described.... Agent: Lahive & Cockfield, LLP

20070269479 - Medical devices coated with drug carrier macromolecules: A medical device coated with carrier macromolecules, wherein the carrier macromolecules are conjugated with a therapeutic agent. The carrier macromolecules may be antibodies which bind the therapeutic agent at the antigen binding site or by covalent bonding. The carrier macromolecules may be tethered to the surface of or dispersed within... Agent: Kenyon & Kenyon LLP

20070269483 - Method and apparatus for installation of dental implant: An organ derived from genetic material is inserted in a patient's body. Genetic material is inserted at a selected site in the body to grow an organ.... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.

20070269484 - Drug-delivery stent formulations for restenosis and vulnerable plaque: Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.... Agent: Squire, Sanders & Dempsey LLP

20070269485 - Medical devices having polymeric regions based on vinyl ether block copolymers: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions, which in turn contain at least one block copolymer. The block copolymer includes (a) at least one high Tg (glass transition temperature) polymer block that contains at least... Agent: Mayer & Williams PC

20070269486 - Methods and devices for reducing tissue damage after ischemic injury: Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac procedure such as stent implantation. The anti-ischemia agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction... Agent: Intellectual Property Department Conor Medsystems, Inc.

20070269487 - Drug delivery methods, structures, and compositions for nasolacrimal system: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within... Agent: Townsend And Townsend And Crew, LLP

20070269488 - Hydrogel nanocompsites for ophthalmic applications: The present invention relates to reversible hydrogel systems. Particularly, the hydrogel of the present invention is made up of copolymers that can be a hydrogel when in an oxidized state and can be a solution when in a reduced state. A solution of the copolymer can be oxidized to form... Agent: Blank Rome LLP

20070269489 - Extracorporeal cell-based therapeutic device and delivery system: Extracorporeal cell-based therapeutic devices and delivery systems are disclosed which provide a method for therapeutic delivery of biologically active molecules produced by living cells in response to a dynamic physiologic environment. Exemplary designs are disclosed. In a first exemplary embodiment the device includes long hollow fibers in which a layer... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070269490 - Material for processed food for weight reduction diets and weight reduction dietary processed food using thereof: The purpose of the invention is to provide a material for weight reduction diet food and the processed food using the same, that is a natural food product obtained from the materials eaten in everyday life, and very safe to the human body. There is provided a material for processed... Agent: Pepper Hamilton LLP

20070269491 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070269494 - Compositions and methods for enhancing active agent absorption: Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.... Agent: Thorpe North & Western, LLP.

20070269493 - Delivery of active agents using a chocolate vehicle: This invention provides edible compositions comprising pharmaceutically or nutraceutically active agents in particulate form homogeneously dispersed in a fat matrix, such as chocolate or chocolate compound coating.... Agent: King & Spalding

20070269492 - New product and use and manufacture thereof: Coated oral dosage forms for the delivery of nicotine in any form to a subject by rapid intraoral delivery of nicotine comprising at least one core, nicotine in any form and/or a nicotine mimicking agent, at least one coating layer and optionally at least one or more other additives, wherein... Agent: Rosemary M. Miano Legal Division

20070269495 - Compositions and methods for enhancing mineral levels in animals with reduced environmental impact: A method of enhancing a mineral level in an animal with reduced environmental impact can comprise orally administering a metal amino acid chelate to an animal, wherein the amino acid to metal molar ratio of the metal amino acid chelate is from about 1:1 to 4:1. The metal can contribute... Agent: Thorpe North & Western, LLP.

20070269497 - Chemical stick with soluble stabilizer: The chemical stick with soluble stabilizer eliminates or greatly reduces the problem of fractured chemical treatment sticks in wells, where such sticks occasionally break into relatively short lengths and jam crosswise within the well pipe. The chemical stick includes one or more water soluble stabilizer elements that extend substantially the... Agent: Litman Law Offices, Ltd.

20070269496 - Patch for reducing exposure of skin to ultraviolet radiation: A patch for reducing exposure to ultraviolet (UV) radiation includes a first layer that is adhesive. The patch includes a second layer. The second layer includes a material adjacent to the first layer. At least one of the first and second layers is opaque to UV radiation.... Agent: Patent Administrator Katten Muchin Rosenman LLP

20070269499 - Materials and methods for wound treatment: The subject invention pertains to methods and compositions for wound treatment. The methods and compositions provide for promoting and accelerating wound healing; provide for inhibition of microbial infection; provide for a protective scab-like covering on a wound; and/or for arresting the flow of blood or body fluids from an open... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070269498 - New dressing material promoting recovery of skin wound: The present invention discloses a novel dressing material for promoting the proliferation of epithelial cells and the use of the same in the treatment of wound surface of skin. The dressing material uses silicon and/or calcium inorganic elements as biologically active substances being capable of initiatively inducing the proliferation of... Agent: Connolly Bove Lodge & Hutz, LLP

20070269500 - Compositions and methods for enhancing active agent absorption: Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.... Agent: Thorpe North & Western, LLP.

20070269503 - Combinations of hmg coa reductase inhibitors and negatively charged phospholipids and uses thereof: The present invention provides combinations of pharmaceutically active agents (i.e. statins and negatively charged phospholipids) for treating or preventing atherosclerosis or coronary artery disease (CAD) in mammals, and methods therefore. In particular, these combinations and methods find utility for achieving one or more of the following effects in a subject:... Agent: Smart & Biggar P.o. Box 2999, Station D

20070269504 - Amphoteric liposomes: Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes.... Agent: Brown, Rudnick, Berlack & Israels, LLP.

20070269501 - Immunotherapeutic agent for the combined treatment of tuberculosis in association with other drugs: This invention refers to an immunotherapeutic agent based on cell wall fragments from virulent Mycobacterium tuberculosis strains, to a method for obtaining this immunotherapeutic agent, to pharmaceutical formulations containing it and to its use for the preparation of a drug for the combined treatment of tuberculosis in association with other... Agent: Ratnerprestia

20070269502 - Stable liposome compositions comprising lipophilic amine containing pharmaceutical agents: Stable liposome composition for delivering a pharmaceutical agent, the composition comprising: (a) a suitable aqueous medium; (b) liposomes formed from a suitable phospholipid; (c) at least one pharmaceutical agent being at least partially encapsulated in the liposomes, and being selected from: (i) a lipophilic amine and a pharmaceutically acceptable acid,... Agent: Volpe And Koenig, P.C.

20070269505 - Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing... Agent: Duane Morris LLP Patent Department

20070269506 - Oral sustained release pharmaceutical composition: An oral sustained release pharmaceutical composition comprising a plurality of granules having diameters of not more than 1000 μm, wherein each of the granules comprise a nucleus granule comprised of beraprost sodium and a coating agent coating the nucleus granule, and wherein the coating agent is comprised of a first... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070269508 - Coenzyme q10 formulation and process methodology for soft gel capsules manufacturing: A formulation of Coenzyme Q10, beta-carotenes, Vitamin E, and medium chain triglycerides in rice bran oil and an optional thickener, such as bee's wax, is provided in a soft gel capsule so that a maximum of the Coenzyme Q10 is absorbed by the human body. Generally, about 60 mg of... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070269507 - Pharmaceutical composition: A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of... Agent: Bacon & Thomas, PLLC

20070269509 - Enteric coated pharmaceutical oral formulations comprising acid-labile active substances, and a method thereof: This invention relates to an oral pharmaceutical formulation formed by a direct coating of an enteric layer containing polyethylene glycol as a plasticizer on a core containing an acid-labile pantoprazole, and its manufacturing method. The enteric-coated oral pharmaceutical formulation of this invention, which combines directly a core containing an acid-labile... Agent: Sughrue Mion, PLLC

20070269510 - Solid unit dosage forms of 5-ht1 agonist: The present invention relates to pharmaceutical compositions of 5-HT1 agonist. More particularly, the present invention relates to uncoated tablets of sumatriptan succinate. The present invention also relates to a process for the preparation of uncoated tablets of sumatriptan succinate.... Agent: Jay R Akhave

20070269512 - Gastroretentive sustained release formulations: The present invention is directed to a gastroretentive sustained release formulation, processes for preparing said gastroretentive sustained release formulation and the use thereof.... Agent: Philip S. Johnson Johnson & Johnson

20070269513 - Liver selective drug therapy: A method of pharmaceutical therapy comprising administering a pharmaceutical complementary medicine or herbal product orally at a dose sufficient to provide a clinically effective level in the portal vein and less than that required to provide a clinically effective blood level in the peripheral circulation to thereby provide a dose-delivery... Agent: Bio Intellectual Property Services (bio Ips) LLC

20070269511 - Solid pharmaceutical compositions containing pregabalin: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.... Agent: Warner-lambert Company

20070269514 - Tablet composition with a prolonged release of tamsulosin: The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is... Agent: SynthonIPInc

20070269516 - Modified release formulations of a bupropion salt: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070269515 - Probiotic tablet formulations: A probiotic tablet comprising a probiotic micro-organism and other nutritionally active ingredients in two zones, a first zone comprising said probiotic micro-organism and prcicrably selenium, and a second zone comprising at least one said other active ingredient such as iron, other minerals and vitamin B6 kept separated from the probiotic... Agent: O'keefe, Egan, Peterman & Enders LLP

20070269518 - Light-curable bone growth material for treating dental bone defects: Improved compositions comprising a mixture of particulate bone growth material and polymeric carrier are provided. The particulate is preferably porous, resorbable, anorganic bone material. The polymeric carrier can be light-cured to form a cross-linked, biodegradable hydrogel. In one version, the bone growth material is a synthetic peptide bound to anorganic... Agent: Dentsply International Inc

20070269517 - Pharmaceutical formulations for the prolonged release of interferons and their therapeutic applications: The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of an interferon (IFN) (and one or more other possible active principles), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a... Agent: Patton Boggs LLP

20070269520 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070269521 - Tooth whitening strips: A tooth whitening product is provided. The tooth whitening product includes film formed from a water hydratable polymer and a plasticizer. The film has a first side and a second side and a tooth whitening agent applied as coating to one side of the film.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070269519 - Whitening products: This invention relates generally to films having barrier as well as controlled disintegration properties and, more particularly, to controlled water disintegrable films.... Agent: Philip S. Johnson Johnson & Johnson

20070269523 - Carriers comprising colloidal metal praticles for translocation into cerberal neurons: The present inventors intravenously administered laboratory animals with molecules in which peptides and colloidal metal particles had been bound, to discover that the molecules translocated to the brain, specifically into cerebral neurons. Since activity to translocate into cerebral neurons could not be observed when the metal colloids were not bound,... Agent: Foley And Lardner LLP Suite 500

20070269522 - Transdermal drug delivery device with translucent protective film: The present invention comprises a transdermal drug delivery device comprising a reservoir comprising a releasably stored dosage of a pharmaceutically active agent and a translucent film adjacent to at least a portion of the reservoir, wherein the translucent film comprises at least one inorganic ultraviolet-absorbing compound. The present invention also... Agent: 3m Innovative Properties Company

20070269524 - Use of idrocilamide for the preparation of a pharmaceutical composition of rosacea: The invention relates to the use of idrocilamide for the preparation of novel pharmaceutical compositions, more particularly dermatological compositions, which can be used to treat rosacea.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070269526 - Carotenoid composition and method for preparation thereof: This invention relates to a carotenoid composition comprising the carotenoid as particles of size smaller than 100 nanometers in an oil medium and a method of preparing the composition by milling the carotenoid in an oil medium and therapeutic compositions containing the carotenoid.... Agent: Nixon Peabody LLP - Patent Group

20070269525 - O/w gel compositions comprising wax: An oil in water gel composition including (a) from about 0.05% to about 5% by weight of at least one polymeric gel former selected from the group consisting of acrylic acid, acrylamide, homopolymers and copolymers of acrylic acid, homopolymers and copolymers of acrylamide, derivatives thereof, and mixtures thereof; (b) from... Agent: Cognis Corporation Patent Department

20070269527 - Therapeutic agents for low hdl-cholesterolemia: The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070269528 - Pharmaceutical formulation comprising ziconotide: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivicaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically... Agent: Howrey LLP

20070269529 - Method for treating plants and plant parts: Methods of using modified lecithin to delivery various benefits to plants and plant parts are disclosed. Modified lecithins, applied to growing plants, can cause improvements in fruit and plant firmness, size, color and stability, in economically important fruits and vegetables.... Agent: Quarles & Brady LLP

20070269530 - Disinfectant and method of making: A nontoxic environmentally friendly aqueous disinfectant is disclosed for specific use as prevention against contamination by potentially pathogenic bacteria and virus. The aqueous disinfectant is formulated by electrolytically generating silver ions in water in combination with a citric acid. The aqueous disinfectant may include a suitable alcohol and/or a detergent.... Agent: Needle & Rosenberg, P.C.

20070269532 - Natural oriental medicinal composition for the promotion of hair growth and method of preparing the same: Disclosed herein is a natural oriental medicinal composition for the promotion of hair growth. The oriental medicinal composition comprises a black bean extract, a tangerine extract, a potato extract, a pine needle extract and a quartzite powder. Since the oriental medicinal composition comprises crude drugs extracted from natural substances that... Agent: Frommer Lawrence & Haug

20070269531 - Non-steroid anti-inflammatory agents with vitamins, minerals, and dietary supplements for the prevention and treatment of primary, secondary and tertiary cancer: A composition and method for prevention or treatment of cancer The composition comprises a non-steroid anti-inflammatory agent and at least one of nutritional supplement and/or chemotherapeutic agent.... Agent: Wyeth Patent Law Group

20070269533 - Oral dieting composition comprising conjugated linoleic acid and caffeine: The invention relates to a dieting composition for oral administration, comprising a mixture of conjugated linoleic acid and caffeine as active ingredient and an acceptable support for oral administration.... Agent: Alston & Bird LLP

20070269534 - Methods of treating skin to enhance therapeutic treatment thereof: Excellent percutaneous absorption of drug or active agent is achieved by pre-treating skin with a cationic constituent prior to application of a drug or active agent.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070269535 - Antifungal agent comprising natural plant extracts: An antifungal agent for the prevention and treatment of the fungal diseases caused by the water mould Saprolegnia parasitica includes the natural product sweet flag extract or its essential oil as an active ingredient and, therefore, is eco-friendly and not harmful to fish. In addition to offering effective prevention and... Agent: The Rafferty Patent Law Firm

20070269536 - Compositions enriched in anthocyanins: This invention provides compositions enriched for anthocyanins and methods of preparation thereof from a crude plant extract. The method of preparation includes a novel column purification step using a brominated polystyrene resin.... Agent: Hogan & Hartson LLP

20070269537 - Skin condition improvement including acne, rosacea, and topical wounds by artemisia annua extract via iron siderophore trojan horse delivery system: This invention relates to certain extracts of Artemisia annua plant, both in their crude and refined forms, and certain refined forms of Artemisia annua plant extracts composed substantially of Artemisinin and its analogs, which are chemically classified as sesquiterpenes with an endo-peroxide group [FIG. 1]. These are suitable for compositions... Agent: Shyam K. Gupta Bioderm Research

20070269538 - Method for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs: The present invention relates to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs, more particularly, to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs in postmenopausal women comprising one or more of Platycodi Radix and Cynanchum... Agent: Ked & Associates, LLP

20070269539 - Ginkgo biloba extract as a treatment for therapeutic-induced neurotoxicity: The invention features methods for treating neurotoxicity associated with therapeutic agents, e.g., chemotherapeutic agents, and compositions and kits for use therein. The methods employ an extract of Ginkgo biloba to mitigate the neurotoxic effects of the therapeutic agents.... Agent: Clark & Elbing LLP

20070269540 - Fat metabolism improving agent: The present invention provides a fat metabolism improving agent comprising rose hips or an extract therefrom as an active ingredient. This fat metabolism improving agent is very safe and has a superior body weight reducing effect.... Agent: Amin, Turocy & Calvin, LLP

20070269541 - Method and compositions for relieving menopausal and perimenopausal symptoms: The present invention is directed to novel methods of treating and reducing perimenopausal and climacteric symptoms using compositions comprising proanthocyanidins. In one embodiment, the methods provide for perimenopausal and climacteric symptom reduction without the use of female hormones or hormone like substances.... Agent: Eric Sinn, Esq. Mintz, Levin, Cohn, Ferris,glovsky And Popeo, P.C.

20070269542 - Endophytic streptomycetes from higher plants with biological activity: The present invention relates to isolated strains of a Streptomyces spp. which are endophytes of dicotyledonous plants and to methods for selecting such strains. The present invention also relates to compounds having biological activity selected from the group consisting of munumbicin A, munumbicin B, munumbicin C and munumbicin D, kakadumycin... Agent: Klarquist Sparkman, LLP

20070269543 - Use of red nocardia rubric cell wall skeleton in the preparation of medicament for treating cervical precancerous lesion: The use of Red Nocardia Rubric Cell Wall Skeleton in the preparation of medicaments for treating cervical precancerous lesion is disclosed in the present application.... Agent: Edward W. Goebel, Jr. Macdonald, Illig, Jones & Britton LLP

20070264203 - Active particle-enhanced membrane and methods for making and using the same: The present disclosure relates to active particle-enhanced membrane and methods for making and using the same. In some embodiments, a breathable membrane includes a base material solution and active particles. The active particles incorporated in the membrane may improve or add various desirable properties to the membrane, such as for... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070264204 - Personal care compositions containing functionalized polymers: The disclosure provides a personal care composition and method for forming the composition wherein the SCC polymer has at least one functionality selected from the group consisting of silicone, hydroxyl and carboxy. Such functionalized SCC polymers can be employed in a wide range of personal care compositions including skin care,... Agent: Air Products And Chemicals, Inc. Patent Department

20070264210 - Method of enhancing penetration of water-soluble actives: A method of enhancing the delivery of water-soluble skin care actives into keratinous tissue, comprising the step of applying to the keratinous tissue a water-in-oil emulsion comprising an aqueous phase and a non-aqueous phase, wherein the aqueous phase comprises a water-soluble skin care active, and whereupon application of shear stress... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070264216 - Water resistant sunscreen formulas with sulfopolyesters and phosphate ester surfactants: A sunscreen composition for the absorption of solar radiation that includes the combination of a phosphate surfactant and a sulfopolyester. The sunscreen formulas of the present invention are stable oil-in-water emulsions and require less phosphate surfactant than formulas omitting sulfopolyester.... Agent: Brett L. Nelson Eastman Chemical Company

20070264222 - Enhanced protection against skin injury in humans: The present invention includes compositions and methods for treating skin conditions, and more particularly, a medicinal progression of anti-oxy-vitamins to treat one or more skin conditions in a patient selected from at least one of acne, skin discoloration, comedo presence, foci of inflammation, hyper-keratinosis, enlarged sebum vessels, pores enlargement, scars... Agent: Chalker Flores, LLP

20070264226 - Synergistically enhanced disinfecting solutions: Synergistically enhanced disinfecting solutions comprising sodium chlorite in the range of 10 about ppm to about 5000 ppm and myristamidopropyl dimethylamine in the range of about 0.05 ppm to about 500 ppm for. In addition, synergistically enhanced disinfecting solutions comprising myristamidopropyl dimethylamine in the range of 0.05 ppm to 500... Agent: Stetina Brunda Garred & Brucker

20070264191 - Materials and methods relating to the treatment of glioblastomas: The invention provides human glioma-specific peptides as delivery vehicles for therapeutic agents. The peptides may be complexed with a diagnostic or therapeutic agent.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070264193 - Diagnostics and treatments for tumors: Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided.... Agent: Genentech, Inc.

20070264192 - Method of evaluating performance of activation gas deactivating antigenic substance and apparatus for generating processed antigenic substance used as evaluation sample of the evaluating method: A method of evaluating performance of an activation gas deactivating an antigenic substance including the steps of causing the antigenic substance and the activation gas to react with each other, to obtain a processed antigenic substance, and causing an antibody against the antigenic substance with the processed antigenic substance to... Agent: Birch Stewart Kolasch & Birch

20070264197 - Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection reagents: Novel peptides and the quantitative methods for the determination thereof in body fluids of patients suffering from progredient chronic dementia, in relation to the concentration of said peptides in a control group. The peptides derive from a protein precursor having the corresponding gene, are processed in a specific manner, and... Agent: Sills Cummis Epstein & Gross P.C.

20070264195 - Modulation of activity of neurotrophins: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070264196 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20070264194 - Peptides that bind to atherosclerotic lesions: The present invention provides peptides that selectively bind to mammalian atherosclerotic lesions. The present invention also provides methods for in vivo identification of peptides capable of binding to biomolecules as well as methods for identifying the targets of such binding moieties. Methods to diagnose or treat pathologic conditions that involve... Agent: Schwegman, Lundberg & Woessner, P.A.

20070264198 - Tumor necrosis agent: The present invention relates to novel drugs (pharmaceuticals) such as tumor necrosis agents, uses of substances having tumor necrosis effect for production of tumor necrosis agents, methods of screening substances having tumor necrosis effect, and methods of treating or improving tumor(s), particularly methods of necrotizing tumor(s). The invention further provides... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070264199 - Magnetic nanoparticle composition and methods for using the same: The present invention is a magnetic nanoparticle composition with enhanced drug delivery characteristics. The magnetic nanoparticle composition is composed of a magnetic particle core surrounded by a fatty acid and surfactant corona. Methods for increasing the efficacy of therapeutic agents and facilitating diagnostic imaging are also provided.... Agent: Dann, Dorfman, Herrell & Skillman

20070264200 - Mouse mri for drug screening: This invention provides a method for determining the amount of blood in a volume of cerebral tissue (cerebral blood volume) in a mammalian subject comprising (a) acquiring a first magnetic resonance image of the volume of tissue in vivo; (b) administering intraperitoneally to the subject a gadolinium-containing contrast agent in... Agent: Cooper & Dunham, LLP

20070264201 - Contrast agents: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety containing hydroxyl groups allowing for the arrangement of three iodinated phenyl groups bound... Agent: Ge Healthcare, IncIPDepartment

20070264202 - Pharmaceutical composition comprising an isomer of betamimetic agent and an anti-cholinergic agent: A pharmaceutical composition in a dosage form suitable for inhalation comprises a therapeutically isomer of a betamimetic agent or a salt, solvate, ester, derivative, or polymorph thereof substantially free of the less therapeutically effective isomer(s) of said agent and optionally an anti-cholinergic agent or a salt, solvate, ester, derivative, isomer... Agent: Conley Rose, P.C.

20070264205 - Cosmetic compositions having carnitine creatinate and methods for using: There is a topical composition having carnitine creatinate and a cosmetically acceptable vehicle. There is also provided a method for improving the aesthetic appearance of skin. There is also provided a method for inhibiting the induced lipid synthesis in skin. There is also provided a method for inhibiting the formation... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070264206 - Mucosal formulation: A mucosal formulation for administration to mucosal membranes, such as in the mouth, nasal passage, stomach, vagina, etc., is disclosed. The mucosal formulation contains a lipid-pharmaceutical agent complex formed from phospholipids possessing a hydrophobic moiety that orients into a hydrophobic phase and a polar head moiety that orients towards the... Agent: Dority & Manning, P.A.

20070264208 - Cosmetic and/or pharmaceutical composition comprising at least one copolymer comprising at least one ionizable group, and cosmetic treatment process: Disclosed herein is a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one (co)polymer comprising a polymer backbone and at least one junction group linked to the polymer backbone and capable of establishing H bonds with at least one partner junction group, each pairing of a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070264209 - Soluble containers for self-tanning formulations: There is provided a water-soluble container having a self-tanning agent sealed therein, a method for using said water-soluble container to form a self-tanning formulation and self-tanning formulations obtained therefrom. Methods for using the self-tanning formulations are provided as well as kits which include more than one water-soluble container.... Agent: Millen, White, Zelano & Branigan, P.C.

20070264207 - Ultraviolet protective preparation and cosmetics containing the same: An ultraviolet protective preparation comprising an ester prepared from glycerol and/or a condensate thereof, a straight-chain saturated fatty acid having 2 to 28 carbon atoms, and an aliphatic saturated dibasic acid having 12 to 28 carbon atoms, an oil liquid or pasty at ordinary temperatures which consists of an ester... Agent: Sughrue Mion, PLLC

20070264211 - Composition comprising sodium silicate for use in the treatment of dry skin conditions: A composition contains sodium silicate and is used in the treatment of dry skin conditions, inter alia psoariasis, dermatitis and eczema. The composition is formulated into creams, ointments and sprays, each formulation being adapted to the intended skin application area.... Agent: Kinney & Lange, P.A.

20070264212 - Skin lightening method: A skin lightening composition for lightening the natural skin color of a user, and for treating disorders of hyperpigmentation. The active ingredient is methyl sulfonyl methane (MSM), a naturally occurring sulfur compound which may be safely administered topically or orally and which is highly effective for decreasing the ratio of... Agent: Connolly Bove Lodge & Hutz LLP

20070264213 - Azobenzene derivative, fluorescent particle and method of fabricating the same: In general formula (I), R1 denotes a hydrogen atom or the like; Ar1 and Ar2 each independently denote an arylene group optionally comprising a substituent R or an aromatic heterocycle optionally comprising a substituent R, wherein Ar1 and Ar2 which are bonded through an azo group comprise at least two... Agent: Birch Stewart Kolasch & Birch

20070264214 - Assortment of antiperspirants having two or more product performance characteristics: A line of consumer products having two or more product performance characteristics, said line comprising: (a) a first product comprising at least one antiperspirant and a first identifier; and (b) a second product comprising at least one antiperspirant that is different from said first product and wherein said second product... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070264215 - Assortment of antiperspirants having two or more product performance characteristics: An array of antiperspirant products including a first antiperspirant product sold under a first brand name, a second antiperspirant product also sold under the first brand name, wherein the second antiperspirant product is marketed as clinical strength or prescription strength and is substantially devoid of an antiperspirant active comprising aluminum... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070264217 - Photo-labile pro-fragrance conjugates: The present invention relates to photo-labile pro-fragrance conjugates comprising: a) a photo-labile unit which upon exposure to electromagnetic radiation is capable of releasing a pro-fragrance unit; and b) a pro-fragrance unit, which when so released is either i) a pro-fragrance compound capable of releasing a fragrance raw material; or ii)... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070264219 - Cosmetic method for soothing the reactions of discomfort of the scalp, using an oxyalkylenated sorbitan ester as a soothing agent: The present disclosure relates to a cosmetic method for soothing the reactions of discomfort of the scalp, wherein it comprises applying on the scalp a cosmetic composition comprising, in an aqueous or aqueous-alcoholic medium, at least one ester of fatty acid and sorbitan comprising from 1 to 20 oxyalkylene units... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070264220 - Hair care composition: ii) an oil dispersible structurant such that the dynamic viscosity of the structured oil phase at 35° C. prior to formation of the emulsion is at least 50,000 mPa·s at a shear rate of 0.5 s−1 and is less than 6,000 mPa·s at a shear rate of 500 s−1.... Agent: Unilever Intellectual Property Group

20070264218 - Reducing composition for permanent wave or straight permanent: The present invention relates to a hair reducing composition having the composition pH in a range of 8 to 10, containing (A) 0.039 to 0.39 mol/L of one or more keratin reducing substance not having a mercapto group selected from a sulfite, a hydrogen sulfite, or the like, (B) 0.007... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070264221 - Extract of a plant belonging to the genus plukenetia volubilis and its cosmetic use: The invention relates to a preparation containing an extract of a plant of the family Euphorbiaceae genus Plukenetia and cosmetic and pharmaceutical preparations containing the extract. The extract contains proteins which when applied to the skin can provide an anti-inflammatory effect, a skin tightening effect, an antiaging effect and a... Agent: Cognis Corporation Patent Department

20070264224 - Exfoliating and softening composition: A skin exfoliating and softening composition, comprising sodium polyacrylate powder at between 5% to 70% by weight dispersed in a solution of base oil. The composition comprises sodium polyacrylate powder mixed with any suitable base oil including food grade oils, synthetic oils, natural oils or mineral oils, with added fragrances,... Agent: Dennison, Schultz & Macdonald

20070264223 - Use of hydrophilic-rich alkylmethylsiloxane-dimethylsiloxane-polyoxyalkylene copolymers as emulsifiers for the preparation of cosmetic o/w emulsions of improved aesthetic properties and mildness: This invention relates to the use of hydrophilic-rich, rake-type alkylmethylsiloxane-dimethylsiloxane-polyoxyalkylene copolymers.... Agent: King & Partners, PLC

20070264225 - Hindered amine nitric oxide donating polymers for coating medical devices: Disclosed are hindered amine nitric oxide (NO) donating polymers for coating implantable medical devices. The polymers include sterically hindered secondary amines that do not react with monomer carbonyls or electrophilic alkenes, facilitating the synthesis of the NO donating polymers. The polymers are coated on implantable medical devices, providing anti-restenosis therapy... Agent: Medtronic Vascular, Inc.IPLegal Department

20070264227 - Synthetic matrix for controlled cell ingrowth and tissue regeneration: Biomaterials containing a three-dimensional polymeric network formed from the reaction of a composition containing at least a first synthetic precursor molecule having n nucleophilic groups and a second precursor molecule having m electrophilic groups wherein the sum of n+m is at least five and wherein the sum of the weights... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070264228 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070264229 - Peptides for treatment of autoimmune disease: Peptides are provided that both inhibit more strongly than synthetic amino acid polymers the binding of MBP85-99 to HLA-DR2 (DRA/DRB1*1501), and inhibit interleukin-2 production by two MBP85-99-specific HLA-DR2-restricted T cells. Peptide 15mers J5, J3, and J2 suppress MBP85-99-induced EAE in humanized mice and proteolipid protein 139-151-induced EAE in SJL/J mice.... Agent: Lawson & Weitzen, LLP

20070264230 - Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070264232 - Cell populations which co-express cd49c and cd90: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070264231 - Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail) by adenoviral-mediated gene transfer: The invention refers to tumor-homing cells expressing the tumor necrosis factor-related apoptosis inducing ligand (TRIAL), particularly to CD34+ and NK cells transduced with adenoviral vetors coding for TRIAL. The cells of the invention are useful for the intravenous treatment of tumors, particularly of lymphoma.... Agent: Birch Stewart Kolasch & Birch

20070264234 - Cytokine variant polypeptides: We describe modified cytokine ligand polypeptides comprising a modified amino acid sequence which is a modification of the native cytokine amino acid sequence of said ligand, wherein the native amino terminal and carboxyl terminal amino acid residues of the native polypeptide are linked, directly or indirectly, together, characterised in that... Agent: Klarquist Sparkman, LLP

20070264233 - Francisella strain for live vaccine: A strain of Francisella species wherein a gene which encodes an enzyme in the purine pathway has been inactivated, and which is able to produce a protective immune response in an animal, for use as a live prophylactic or therapeutic vaccine against infection by said Francisella species. Suitable genes for... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070264236 - Novel therapeutic fusion proteins: The present invention provides novel therapeutic molecules called Culling Fusion Proteins (CFPs) that allow the continuous removal of therapeutic targets from extracellular space by exploiting the endosome/lysosome intracellular degradation pathway, and the exocytotic pathway in a combined manner. The products of the invention, by appropriately utilizing the cellular endocytosis and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070264235 - Polypeptide having an improved cytosine deaminase activity: The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070264241 - Compounds for enhanced cancer therapy: The present invention relates to methods and compositions for enhanced cancer treatment based on nucleoside analogue prodrugs. In a preferred embodiment, the invention relates to enhanced suicide cancer therapy.... Agent: Birch Stewart Kolasch & Birch

20070264242 - Genetically modified cells expressing a tgf beta inhibitor, the cells being lung cancer cells: The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGFβ inhibitor effective to reduce expression of TGFβ, where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related... Agent: Knobbe Martens Olson & Bear LLP

20070264244 - Pigment epithelial cell of the eye, its production and use in therapy of an eye or cns disease: The present invention relates to a pigment epithelial cell of the eye containing vector DNA of an adenoviral vector with large DNA capacity, to the improved isolation and cultivation of these cells and to methods for production and the use in the therapy of an eye or nerve disease.... Agent: Clark & Elbing LLP

20070264243 - Reversibly immortalized hepatocytes and methods of use: Hepatocyte cells that are reversibly immortalized and grown in culture, which are functional and safe for use in transplantation, are disclosed. Also disclosed are methods for immortalizing primary hepatocytes, expanding the population of immortalized hepatocytes in culture, then reversing the immortalization to produce hepatocytes that are functional and safe for... Agent: Dann, Dorfman, Herrell & Skillman

20070264240 - Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation: A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM) and optionally comprising bone morphogenetic protein/s (BMP) and/or other active agents, particularly for use in the transplantation of mesenchymal progenitor cells into a joint and/or a cranio-facial maxillary bone, for restoring and/or enhancing... Agent: John P. White Cooper & Dunham LLP

20070264239 - Isolation of pericytes: In one embodiment, the invention provides a pericyte having a marker pattern comprising CD146+, CD34−, and CD45−, wherein said pericyte is substantially isolated from cells that are CD146− or CD31+ or CD34+ or CD45+ or CD56+ or NG2− or CD133−. The invention also provides populations of such pericytes. In another... Agent: Leydig Voit & Mayer, Ltd

20070264238 - Procedure to regenerate articular cartilage in human advanced osteoarthritis using autologous hematopoetic stem cell transplantation: A procedure for regenerating cartilage in a patient's joint damaged by Osteoarthritis by transplanting autologous hematopoetic stem cells extracted from a human, preferably the same human. The procedure begins by screening to ensure that the patient is a suitable candidate, then preparation of the patient for the stem cell transplantation... Agent: Ober|kaler

20070264237 - Use of il-18 binding protein in inflammations: The invention relates to the combined use of an IL-1 antagonist/inhibitor and IL-18 binding protein in inflammatory diseases.... Agent: Marshall, Gerstein & Borun LLP

20070264245 - Compositions and minimally invasive methods for treating incomplete tissue repair: Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to tissue such as disc material, a vertebral body, spinal cord, or spinal tendon is disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20070264246 - Enhanced medical treatments resulting from chemical identification of calcium influx factor, identity with the factor activating phospholipolysis and precipitating sudden death during myocardial infarction, and determination of similar activating mechanis: A method for treating a mammal comprises administering at least one of a gene, enzyme and pharmaceutical which modulates the concentration of iPLA2β through transcriptional and/or translational regulation or effectively modulate the inhibition of iPLA2β through calmodulin or derivatives thereof.... Agent: Patrick W. Rasche (15060) Armstrong Teasdale, LLP

20070264247 - Use of human lysozyme in preparation of medicine for treating acne: A new use of human lysozyme is disclosed, especially human lysozyme can be used in the treatment of acne. Human lysozyme can be used for preparing medicine for treating acne induced by staphylococcus aureus, staphylococcus epidermidis, propionibacterium, acarus and drug-resistant bacteria. The medicine can be prepared in the form of... Agent: Mi An C/o Eric Chan

20070264248 - Preparation for preventing or treating disorders caused by toxic constituents contained in fiber combustion smoke: Preventive or therapeutic agents for controlling various disorders induced by toxic substances in smoke produced by the combustion of fibers such as tobacco are disclosed. A polypeptide of the thioredoxin family (TRX) prevents toxic substances in smoke, produced by the combustion of fibers such as tobacco, from inducing inflammatory reactions... Agent: Brown & Michaels, PC 400 M & T Bank Building

20070264250 - Composition for skin-whitening and wrinkle-care: The present invention relates to an external composition for skin, comprising 2-o-a-glucopyranosyl-L-ascorbic acid and a-glucosidase, which hydrolyzes 2-o-a-glucopyranosyl-L-ascorbic acid into ascorbic acid and glucose. In the composition of the present invention, 2-o-a-glucopyranosyl-L-asocorbic acid and a-glucosidase are contained in a formula, or separated in different formulas, which are mixed just before... Agent: Graybeal, Jackson, Haley LLP

20070264249 - Gene-based lipid hydrolysis therapy for atherosclerosis and related diseases: The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or... Agent: Frost Brown Todd, LLC

20070264255 - Antibodies to tgf-beta: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments... Agent: Ropes & Gray LLP Patent Docketing 39/361

20070264251 - C1q related protein: This invention relates to the novel protein, termed INSP161, herein identified as a secreted protein, in particular, as a c1q domain containing protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070264254 - Cardiac muscle function and manipulation: This invention relates to polypeptides which affect myocardial cell differentiation and organisation of cardiac muscle contractile units, assay for identifying such polypeptides, and methods for improving cardiac function by the administration of such polypeptides to patients with heart disease. In one aspect, the invention provides a therapeutic composition comprising a... Agent: Jones Day

20070264256 - Genes of an otitis media isolate of nontypeable haemophilus influenzae: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.... Agent: Marshall, Gerstein & Borun LLP

20070264253 - Human anti-epidermal growth factor receptor antibody: A condenser coil for a refrigerated beverage and food service merchandiser includes a plurality of parallel fins be-tween adjacent tubes. In order to reduce the likelihood of fouling by the bridging of fibers therebetween, the spacing of the fins is maintained at a distance of 0.4 to 0.8 inches apart.... Agent: Kenyon & Kenyon LLP

20070264252 - Modulators of ms4a gene products: A method of identifying a substance suitable for use in the treatment of a leukocyte-associated inflammatory disease that modulates the activity of a polypeptide encoded by a human MS4A gene. The method involves combining a candidate substance with said polypeptide and measuring the effect of the candidate substance on the... Agent: Novartis Corporate Intellectual Property

20070264257 - Immunotherapy of autoimmune disorders: Compositions and methods for treating autoimmune diseases are described. In particular, the use of B cell depleting agents and cytotoxic drug/B cell depleting agent conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) in treating autoimmune diseases is... Agent: Hunton & Williams LLP Intellectual Property Department

20070264259 - Methods for treating kidney disorders: Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR agonist, e.g., a Flt1 agonist to a subject. The agonists are composed of compositions comprising VEGFR agonists, e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents... Agent: Genentech, Inc.

20070264258 - Sialoadhesin factor-2 antibodies: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070264260 - Treatment methods using anti-cd22 antibodies: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the... Agent: Jones Day

20070264261 - Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin like receptor like proteins: Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with... Agent: Nuvelo, Inc

20070264262 - Phenylaminoethanol derivates as beta 2 receptor agonists: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory... Agent: Pharmacia Corporation Global Patent Department

20070264263 - Compositions for inhibiting sema7a and vla-1 interaction and the methods of using the same: Disclosed are compositions and methods of treating a cytokine mediated diseases by inhibiting Sema7A and VLA-1 interaction.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070264264 - Method and composition for conferring immunity in mammals: A composition and method for immunization of mammals, containing antibodies from the eggs/egg yolks of chickens, or other suitable avian source, hyperimmunized against a selected pathogen(s) or immunogens, and a quantity of non-specific mammalian antibodies, such as those from commercial colostrum or serum products, which are combined to produce a... Agent: Hall, Vande Sande & Pequignot, LLP

20070264265 - Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments: The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as... Agent: Faegre & Benson LLP Patent Docketing

20070264266 - Cytotoxic agents comprising new maytansinoids: New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful... Agent: Sughrue Mion, PLLC

20070264267 - Compositions and methods for treatment of cancer: The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer... Agent: Genentech, Inc.

20070264272 - Assessment and reduction of risk of graft-versus-host disease: Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described.... Agent: Merchant & Gould PC

20070264269 - Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation: Cell-based compositions and methods of their use to inhibit an adverse immune response such as graft versus host disease or rejection of transplanted tissue in a transplant recipient that is histocompatibility mismatched to the transplant donor are disclosed. The compositions and methods utilize postpartum-derived cells, such as cells derived from... Agent: Woodcock Washburn LLP

20070264270 - Endometriosis markers: The present invention relates to methods for determining a risk or identifying a condition associated with the presence of endometriosis in a subject as well as testing a candidate compound for a therapeutic activity for the treatment of endometriosis and sorting patients based on the risk of having endometriosis. Specifically,... Agent: Pearl Cohen Zedek Latzer, LLP

20070264268 - Man2as as modifiers of the igfr pathway and methods of use: Human MIGFR genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of MIGFR are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070264271 - Potent immunostimulatory from microalgae: Immunostimulatory polysaccharides can be preferentially extracted from food-grade microalgae using an aqueous ethanol extraction procedure. The resulting preparations exhibit extremely potent immunostimulatory activity. The preferential extraction of these immunostimulatory polysaccharides is dependent on the concentration of ethanol used and the extraction temperature. The most efficient conditions are 50% ethanol concentration... Agent: Hunton & Williams/new York Intellectual Property Dept.

20070264273 - Sphingoid polyalklamine conjugates, isomers and uses thereof: The present application discloses methods for stimulating or enhancing an immune response of a subject to protect against an infection caused by an agent selected from Hepatitis B Virus (HBV), avian influenza virus, the bacterium Bacillus anthracis or the bacterium Streptococcus pneumoniae, the method comprising administering to said subject a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070264274 - Veto cells effective in preventing graft rejection and devoid of graft versus host potential: A method of transplanting a transplant derived from a donor into a recipient is disclosed. The method comprises the steps of (a) transplanting the transplant into the recipient; and (b) administering to the recipient a dose including non-alloreactive anti-third party cytotoxic T-lymphocytes (CTLs), wherein the non-alloreactive anti-third party CTLs are... Agent: Martin D. Moynihan Prtsi, Inc.

20070264277 - Compositions and methods of use for mgd-csf in disease treatment: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070264275 - Peptides derived from the protein mmp-2, and the use thereof in antitumoral immunotherapy: The invention relates to peptides forming epitopes T of the antigen MMP-2, presented by MHC class I. Said peptides can especially be used in antitumoral immunotherapy.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070264276 - Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases: The present invention relates to a stereochemically based “non-self” antigen vaccine for the prevention and/or treatment of Alzheimer's and other amyloid related diseases. The present invention provides a vaccine for the prevention and treatment of Alzheimer's and other amyloid related diseases, which overcomes the drawbacks associated with using naturally occurring... Agent: Clark & Elbing LLP

20070264279 - Compositions and methods comprising a mage-b antigen: The present invention provides MAGE-b peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.... Agent: Pearl Cohen Zedek Latzer, LLP

20070264278 - Polypeptides for inducing a protective immune response against staphylococcus aureus: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full-length S. aureus polypeptide. The full-length polypeptide is referred to herein as full-length penicillin-binding protein 4 (“PBP4”). A... Agent: Merck And Co., Inc

20070264280 - Compositions and methods for treating neurological diseases: The invention includes therapeutic compositions and methods useful in the treatment of neurodegenerative diseases, such as those characterized by accumulation of extracellular plaques. Such neurodegenerative diseases include Alzheimer's disease. The compositions of the invention include HSVAβ/TtxFC, which can be used to deliver effective therapeutic benefits to a patient without inducing... Agent: Fish & Richardson PC

20070264282 - Herpes virus strains for gene therapy: The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene... Agent: Fulbright & Jaworski, LLP

20070264281 - Vaccination vectors derived from lymphotropic human herpes viruses 6 and 7: A vector is presented comprising a DNA sequence derived from HHV-6 or HHV-7, said DNA sequence comprising an origin of replication, a cleavage and packaging signal and a promoter sequence which induces expression of at least one nucleic acid sequence product in a lymphocyte cell host, wherein administration of said... Agent: Nath & Associates

20070264283 - Vaccine: The present invention relates to methods and compositions useful in the treatment and prevention of human papilloma virus infections. In particular the invention relates to nucleic acid molecules encoding E1 and/or E2 and vectors suitable for DNA vaccine delivery, and pharmaceutical compositions containing them. Methods for manufacturing said molecules, vectors... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070264284 - Therapeutic, prophylactic and diagnostic agents for hepatitis b: The present invention provides regulation of expression of toll-like receptors by the hepatitis B (HBV) pre-core protein, or its extracellular expression product the hepatitis B E antigen (HbeAg). Compounds regulating such expression have use in the treatment and prophylaxis of HBV infection in animal. The invention also provides methods for... Agent: Knobbe Martens Olson & Bear LLP

20070264285 - Compositions comprising cationic microparticles and hcv b1e2 dna and methods of use thereof: Immunogenic HCV E1E2809 DNA compositions and methods of using the same are described. The compositions comprise HCV EIE2809 DNA adsorbed to cationic microparticles, such as poly(lactide-co-glycolide) (PLG) microparticles.... Agent: Novartis Vaccines And Diagnostics Inc.

20070264286 - Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase: The invention relates to a live recombinant Mycobacterium bovis-BCG strain comprising a nucleic acid capable of expression, the nucleic acid encoding at least one protein or polypeptide that exhibits alanine dehydrogenase activity, glutamine synthetase activity, or serine dehydratase activity.... Agent: Harness, Dickey & Pierce, P.L.C

20070264287 - Methods for increasing the immune response in an animal: A method for increasing natural killer cell activity in an animal by feeding the animal lipoic acid in amounts of from about 10 mg to about 1000 mg per day.... Agent: Colgate-palmolive Company

20070264289 - Compositions and methods of administering doxepin to mucosal tissue: Compositions and methods for pain relief involve delivery of doxepin to mucosal tissue. Vehicles for administering doxepin may be formulated for sustained release and/or site-specific application to maximize beneficial pain relief locally while minimizing significant adverse side effects.... Agent: Marsh, Fischmann & Breyfogle LLP

20070264288 - Method for dermatological treatment using chromophores: The present invention encompasses methods that use heat and/or electromagnetic radiation for dermatological treatment and more particularly to a method that uses heat and/or electromagnetic radiation in combination with chromophores for fractional wounding and, in particular, discontinuous fractional damage of skin tissue.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070264291 - Compositions and methods for preventing or reducing plaque and/or gingivitis using a bioactive glass containing dentefrice: Methods and compositions for the prevention and/or reduction of plaque, plaque build-up and/or gingivitis are provided. Bioactive glass compositions are provided which prevent or reduce plaque, plaque build-up and/or gingivitis through the use of low levels of small bioactive glass particles in amounts from about 0.25 to about 10% by... Agent: Hutchison Law Group PLLC

20070264293 - Encapsulated fluorescent whitening compositions and their use in personal care applications: Microcapsules of a fluorescent whitening agent in a transparent or translucent polymer formed from a mixture of hydrophobic and ionic monomers that are capable of forming a homopolymer of glass transition temperature in excess of 50° C., wherein the fluorescent whitening agent is not bonded to the surface of a... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070264290 - Pharmaceutical and/or cosmetic care product, such as a mask: A pharmaceutical and/or cosmetic care product, such as a mask, intended to be applied to an area of the human body to be treated. The product includes an absorbent support and a preparation for impregnating the support, the preparation containing at least one active principle for the pharmaceutical and/or cosmetic... Agent: Young & Thompson

20070264292 - Sun-block cosmetic: The invention is a sunscreen cosmetic containing (a) a specific hydrophobic zinc oxide powder, (b) decamethylcyclopentasiloxane, and (c) an alkyl trimethicone having 6 to 12 carbons. Hydrophobic powder that has the noticeable effects of low oil absorption and a low apparent specific volume is stably blended into a sunscreen cosmetic... Agent: Townsend & Banta C/o Portfolio Ip

20070264297 - Formulated tick and insect repellent compositions: The present invention pertains to the field of tick- or insect-repellent formulated compositions containing dihydronepetalactone, a nepetalactam, a dihydronepetalactam and/or their respective derivatives, and one or more additives to provide a useful and effective means of delivering the composition in the manner and to the location as desired by the... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070264296 - Biofilm extracellular polysachharide solvating system: The invention provides a solvating system for the removal of biofilms which solvates the extracellular polysaccharide matrix holding it to a surface. The aqueous solvating system comprises water, a metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix, which is gentle enough to be used directly... Agent: Dicke, Billig & Czaja

20070264294 - Insect control compositions: Disclosed herein are sprayable insect repellent compositions that provide improved skin feel through the incorporation of a powder ingredient. The powder is essentially permanently suspended in the composition by a thickener (e.g. carbomer thickener) so that no shaking to resuspend settled out powder is necessary immediately before the composition is... Agent: S.c. Johnson & Son, Inc.

20070264295 - Topical insect repellent composition and method of application: Stable, single phase, low VOC, topical insect repellent compositions containing a film-forming polymer, insect repellent, water miscible organic solvent, and water.... Agent: 3m Innovative Properties Company

20070264298 - Harvestwinner: Saponin 25.03% Inert ingredients 74.97% Ingredients' are all natural and non toxic to humans and animals. Ingredients are derived during the process of removing oil from tea seeds, this oil is used in many cooking applications and soap making worldwide. The waste from this process is formed into cakes and... Agent: Stephen W. Lee

20070264299 - Cyano anthranilamide insecticides: R7is H, F or Cl. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an N-oxide thereof or a suitable salt of the compound (e.g., as a composition described herein). This... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070264303 - Coating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent: The invention relates generally to an implantable medical device for delivering a therapeutic agent to the body tissue of a patient, and a method for making such a medical device. In particular, the invention pertains to an implantable medical device, such as an intravascular stent, having a coating comprising an... Agent: Jones Day

20070264301 - Immobilized biologically active entities having a high degree of biological activity following sterilization: The present invention is directed to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities.... Agent: Eric J Sheets W. L. Gore & Associates, Inc.

20070264302 - Immobilized biologically active entities having high biological activity following mechanical manipulation: The present invention is directed to immobilized biologically active entities that retain significant biological activity following mechanical manipulation of a substrate material to which the entities are immobilized.... Agent: Eric J Sheets W. L. Gore & Associates, Inc.

20070264304 - Provision of vascular grafts with an active principle: One or more substances of the group consisting of gentamicin palmitate, gentamicin myristate, gentamicin laurate, tobramycin palmitate, tobramycin myristate, tobramycin laurate, amikacin palmitate, amikacin myristate, amikacin laurate, vancomycin palmitate, vancomycin laurate, and vancomycin myristate are suitable for providing vascular grafts with an antithrombogenically active principle. The appropriate method for providing... Agent: Norris, Mclaughlin & Marcus, Pa

20070264306 - Scaffold engineering: The present invention relates to the use of matrices in cell recruitment and the to modified matrices comprising homing factors for in vivo recellularisation of implantable medical devices such as cardiac valves and vascular grafts.... Agent: Clark & Elbing LLP

20070264305 - Surface interactions to improve retention of medical devices: A method for improving the retention between the surfaces of medical devices. The method includes coating a surface of one medical device such as a stent with a coating that includes a functional group and coating a surface of another medical device such as a balloon with a coating that... Agent: Squire, Sanders & Dempsey L.L.P.

20070264300 - Therapeutic agent carrier and method of treating bone fractures: A therapeutic agent carrier for treating a defect in a bone is disclosed and can include a body that can be configured to approximate a portion of the bone. Further, the therapeutic agent carrier can include a plurality of grooves formed along the body. Each groove can correspond to an... Agent: Larson Newman Abel Polansky & White, LLP

20070264307 - Biodegradable modified caprolactone polymers for fabricating and coating medical devices: Disclosed herein are biodegradable modified caprolactone polymers for coating and forming medical devices. The properties of the polymers are fine tuned for optimal performance depending on the medical purpose. Moreover, the polymers are suitable for the controlled in situ release of drugs at the treatment site.... Agent: Medtronic Vascular, Inc.IPLegal Department

20070264308 - Immobilized biologically active entities having high biological activity following mechanical manipulation: The present invention relates to immobilized biologically active entities that retain significant biological activity following mechanical manipulation of a substrate material to which the entities are immobilized.... Agent: Gore Enterprise Holdings, Inc.

20070264309 - Method of treating atrophic vaginitis: This invention relates to a method and pharmaceutical composition useful in treating a condition responsive to hormone replacement therapy. Specifically, the invention is related to the long term treatment of symptoms associated with atrophic vaginitis. The composition contains effective amounts of an estrogen, a progesterone compound and a pharmaceutically accepted... Agent: Baker Botts L.L.P.

20070264310 - Solvating system and sealant for medical use in the middle or inner ear: Chronic Otitis Media with Effusion (COME), Recurrent Acute Otitis Media (RAOM), cholesteatoma, and other bacterial ear conditions may be treated by applying a solvating system containing greater than 0.2 wt. % surfactant to a bacterial biofilm in the middle or inner ear, disrupting the biofilm, and applying a protective layer... Agent: Iplm Group, P.A.

20070264314 - Process and formula for treating irritable bowel syndrome: A process for treating irritable bowel syndrome wherein sometime before a meal, a user ingests a pill or tablet that slows down the muscles of their lower intestine that serve to push waste out from the user's digestive tract. At the same time, the user takes a fiber pill with... Agent: Kelly Lowry & Kelley, LLP

20070264311 - Cysteine protease from ginger (zingiber) as a food improver and anti-inflammatory: The present invention relates generally to plant extracts and/or components isolated therefrom which exhibit desirable properties in relation to therapy and/or food technology. More particularly, the present invention relates to extracts and components isolated thereof from the plant genus Zingiber and in particular from the rhizome of the species Zingiber... Agent: The Mccallum Law Firm, P. C.

20070264313 - Methods and compositions relating to animal dietary acids: The present invention relates to an animal dietary composition including a dietary acid and further to methods of feeding an animal that include providing a dietary acid as part of the animal's diet, resulting in enhanced feed efficiency and weight gain. According to one embodiment, the present invention further relates... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070264312 - Rheologically modified edible oils: The invention is an improved form of a rheologically modified fluid which is capable of suspending various particulates including polysaccharides, hydrocolloids, and other food approved items, in a pumpable oil-based carrier fluid. The modified fluid can be thickened such that it can be used as a lubricant or a food... Agent: Jane Shershenovich

20070264315 - Paste usable as a dressing on the oral mucosae or the skin: e

20070264318 - Compositions for the treatment and prevention of eyelid swelling: The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070264317 - Imiquimod cream formulation: Novel compositions containing imiquimod which are suitable for use in the treatment of skin disorders are disclosed. The compositions comprise micronized imiquimod and pharmaceutically acceptable excipients.... Agent: Pearl Cohen Zedek Latzer, LLP

20070264316 - Patch activated in use: The patch activated in use comprises an absorber 11 containing a dry drug 10 and formed of a material capable of absorbing a liquid, a wall material 13 arranged around the absorber 11 and having an adhesive layer 12 on the lower surface thereof, a support 15 arranged on the... Agent: Townsend & Banta C/o Portfolio Ip

20070264319 - Transdermal antiemesis delivery system, method and composition therefor: A transdermal antiemesis system, preferably in the form of a drug-in-adhesive matrix patch, is disclosed comprising an effective antiemesis amount of a selective serotonin (5-HT3) receptor antagonist as an antiemetic incorporated in a skin adhesive composition containing at least one permeation enhancer and a water-insoluble pressure-sensitive adhesive. A preferred antiemetic... Agent: Olson & Hierl, Ltd.

20070264320 - Microfluidic device for forming monodisperse lipoplexes: A method for forming monodisperse lipoplex assemblies includes providing a microfluidic device having a main microfluidic channel coupled to first and second reactant inlet channels. The first inlet channel is used to deliver a cationic lipid to the main channel while the second channel is used to deliver a nucleic... Agent: VistaIPLaw Group LLP

20070264322 - Method for making liposomes conjugated with temperature-sensitive ligands: The present invention relates to a method of making a liposome composition. In particular, the invention relates to a method of making liposomes targeted to a specific cell receptor for delivery of a liposome-entrapped drug to the cell. In one embodiment, the process involves the incorporation of lipid-linkers to the... Agent: Philip S. Johnson Johnson & Johnson

20070264321 - Method of treating skin wounds with vectors encoding hepatocyte growth factor: The present invention relates to a therapeutic preventive agent that includes an angiogenic factor gene (such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), fibroblast growth f actor (FGF), and hypoxia inducible factor (HIF)) as its active ingredient, and the administration of such an agent into the targeted... Agent: Klarquist Sparkman, LLP

20070264323 - Controlled dose drug delivery system: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising a pharmaceutically active amphetamine salt covered with an immediate-release coating and a pharmaceutically active amphetamine salt covered with an enteric coating wherein the immediate release coating and the enteric coating provide for multiple pulsed dose delivery of... Agent: Darby & Darby P.C.

20070264325 - Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls... Agent: Davidson, Davidson & Kappel, LLC

20070264324 - Use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus (hiv): The use of vegetable anthraquinone derivatives and vegetable polysaccharides for treating human immunodeficiency virus(HIV); the anthraquinone derivatives and polysaccharides were obtained by CO2 supercritical extraction from plants, then the vegetable anthraquinone derivatives and vegetable polysaccharides alone or the mixture thereof were subject to test for inhibiting HIV virus, HIV virus... Agent: Zhanqiu Yang Hong Xiao Shouhui Zhu Xilang Peng

20070264326 - Anti-misuse oral microparticle medicinal formulation: The field of the present invention is that of solid microparticulate analgesic oral medicines. The invention is that of providing novel analgesic medicines which allow at the same time the prevention of misuse and of addiction to certain analgesics, and/or the control of variability in the plasma concentration and/or the... Agent: Patton Boggs LLP

20070264327 - Methods and compositions for deterring abuse of opioid containing dosage forms: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.... Agent: Morgan, Lewis & Bockius LLP

20070264329 - Calcium compositions: Compositions comprising calcium carbonate and processes for making such compositions are provided. The invention provides a granulation comprising about 95% to about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of a porosity increasing agent.... Agent: Harness, Dickey, & Pierce, P.l.c

20070264328 - Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets: Spherically-shaped pharmaceutical pellets are produced using a novel spheronization apparatus in a continuous melt spheronization process in which an active pharmaceutical agent is blended with various excipients, fed to an extruder, cut and subsequently fed to the novel spheronizer for continuously producing uniform, spherically-shaped pellets. The pellets may be further... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070264330 - Pharmaceutical formulations of pimavanserin: Disclosed herein are stable pharmaceutical formulations of pimavanserin, which is useful for treating conditions associated with serotonin receptors.... Agent: Knobbe Martens Olson & Bear LLP

20070264331 - Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin: This invention is directed to a pharmaceutical composition in the form of a tablet with improved stability, as well as the process for obtaining said composition. The tablet of the present invention comprises two active ingredients comprising two oral hypoglycemic agents: one phase with a sulphonylurea, such as immediate release... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070264332 - Sustained release pharmaceutical formulation: A sustained release pharmaceutical formulation is disclosed. The formulation comprises a water soluble medicament and a polymer mixture comprising a first component of about 80 weight percent polyvinylacetate combined with about 20 weight percent polyvinyl pyrrolidone; of the total weight of the first component, combined with a second component of... Agent: Robert Deberardine Abbott Laboratories

20070264333 - Method of treatment: The invention provides the use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from overactive bladder.... Agent: Novartis Corporate Intellectual Property

20070264336 - Hydrophilic/lipophilic polymeric matrix dosage formulation: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070264335 - Modified release tablets comprising tramadol: Tablets for once-daily administration comprising a core comprising tramadol or a salt thereof, and a coating applied to said core comprising at least one water-insoluble polymer and at least one enteric polymer.... Agent: Nixon & Vanderhye, PC

20070264334 - Pharmaceutical formulations: The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.... Agent: Robert Deberardine Abbott Laboratories

20070264337 - Compositions and methods for the induction and maintenance of quality sleep: Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The... Agent: Kenyon & Kenyon LLP

20070264339 - Base-stabilized polyorthoester formulations: A stabilized semi-solid delivery vehicle contains a polyorthoester and an excipient, and a pharmaceutical composition contains an active agent, optionally a stabilizing agent, and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of... Agent: Heller Ehrman LLP

20070264340 - Aromachemicals: s

20070264338 - Base-stabilized polyorthoester formulations: A stabilized semi-solid delivery vehicle contains a polyorthoester and an excipient, and a pharmaceutical composition contains an active agent, optionally a stabilizing agent, and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of... Agent: Heller Ehrman LLP

20070264341 - Process of preparing microspheres for sustained release having improved dispersibility and syringeability: Disclosed is a process of preparing sustained release microspheres, containing a biodegradable polymer as a carrier and a drug, using spray drying. The process comprises preparing a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent; spray drying the solution, suspension or emulsion; and suspending spray-dried... Agent: Medlen & Carroll, LLP Suite 350

20070264342 - Solvating system and sealant for medical use in the sinuses and nasal passages: Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.... Agent: Iplm Group, P.A.

20070264343 - Methods for making and using particulate pharmaceutical formulations for sustained release: Pharmaceutical formulations and methods are provided for the sustained delivery of a pharmaceutical agent to a patient by injection. The injectable formulation includes porous microparticles which comprise a pharmaceutical agent and a matrix material, wherein upon injection of the formulation a therapeutically or prophylactically effective amount of the pharmaceutical agent... Agent: Sutherland Asbill & Brennan LLP

20070264344 - Topically applicable anti-inflammatory o/w emulsions comprising pro-penetrating glycols: a

20070264346 - Multimicroparticulate pharmaceutical forms for oral administration: The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active... Agent: Patton Boggs LLP

20070264345 - Transdermal pharmaceutical composition: The invention relates to a liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, propylene-glycol, iso-propyl myristate and a hyaluronic acid salt or complex for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics. The invention also relates to transdermal pharmaceutical composition consists of an estrogen and a progestin component as well... Agent: K.f. Ross P.C.

20070264347 - Agent for treating or preventing diabetic neuropathy: An agent effective for treating or preventing a diabetic neuropathy, which is a diabetic complication, is provided. The agent comprises a spherical activated carbon as an effective ingredient.... Agent: Reed Smith LLP

20070264349 - Nano-structured compositions and methods of making and using the same: The present invention provides a new tri-phasic method for making nanoparticles of poorly soluble active pharmaceutical ingredients.... Agent: Foley And Lardner LLP Suite 500

20070264348 - Nanoparticulate fibrate formulations: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20070264350 - Water-insoluble medicine: A water-insoluble medicine in the form of particulates, having an average particle diameter of 50 to 200 nm; and a particulate complex of the water-insoluble medicine and a polymer electrolyte, having an average particle diameter of 50 to 250 nm.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20070264351 - Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070264352 - Biostimulate and tonic solution for massage (solution \"biplatvirs\"): The composition “BIPLATVIRS” is a dark brown liquid, intended for external use by sanative massage. The composition possesses tonic and biostimulant characteristics. The composition can be a solution which consists of a mixture in which bile from young, sound animals is combined with extract of the placenta, extract from the... Agent: Flaster/greenberg P.C. 8 Penn Center

20070264353 - Extracellular polysaccharide solvating system for treatment of bacterial ear conditions: Chronic otitis media and other bacterial ear conditions may be treated by applying a solvating system containing a metal ion sequestering agent and surfactant to a bacterial biofilm in the middle or inner ear. The solvating system disrupts the biofilm and aids in its removal.... Agent: Iplm Group, P.A.

20070264354 - Treatment of a wound with a vasodilator: A wound treatment administers a vasodilator by: (a) active transdermal treatment such as: by direct perfusion of the wound with the vasodilator, by an intradermal injection of the vasodilator about the wound and its surrounding skin area, by iontophoresis about the wound and its surrounding skin area with the vasodilator,... Agent: Lewis And Roca LLP

20070264355 - Binary compositions and methods for sterilization: The present invention relates to binary methods and compositions comprising hypohalite (preferably hypochlorite) and peroxide (preferably hydrogen peroxide) directed to the killing of pathogenic microbes such as parasites, bacteria, fungi, yeast, and prions, the oxidation of toxins, and the preparation of potable water. The binary methods and compositions extend the... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070264356 - Process for the preparation of a ready-to-use disinfectant: e

20070264357 - Dendrimer fluid purification system and method: A dendrimer complex comprising a dendrimer and an antimicrobial agent with the dendrimer complex placeable directly into a fluid to inhibit growth of microbes or rid the fluid of microbes. In a further embodiment of the invention the dendrimer complex is secured to a carrier, which is placed in a... Agent: Carl L. Johnson Jacobson And Johnson

20070264358 - Methods and compositions for treating mood disorder: The invention relates to compositions and methods for treating mood spectrum disorder. The compositions relate to novel combinations and formulations of pharmaceutical compounds for treatment of mood spectrum disorders. The methods provide for use of the compounds provided herein for the treatment of mood spectrum disorders in addition to the... Agent: Bingham Mccutchen LLP

20070264360 - Gall bladder and liver cleansing suppository: A composition containing any of the following alone or in combination: Glycine, taurine, phosphatidyl choline, Bupleurum and or Chanca Piedra in a suppository.... Agent: Spencer Feldman

20070264359 - Use of phyllanthus constituents for treating or preventing infections caused by hepatitis b-viruses: The disclosure relates to a method of inhibiting synthesis of viral DNA in a mammal infected with a hepatitis B virus. This method includes administering at least one Phyllanthus component or substance to a mammal infected with the hepatitis B virus. It also includes inhibiting hepatitis B viral DNA synthesis... Agent: Baker Botts LLP C/o Intellectual Property Department

20070264361 - Composition for suppressing cyclooxygenase and/or 5-lypoxygenase: The present invention relates to a composition for the prevention or treatment of physiological and pathological disorders mediated by cyclooxygenase (COX) and/or 5-lipoxygenase (5-LO) comprising Uncaria genus plant, in particular, Uncaria gambir, or its extract, and to a combined composition of said Uncaria genus plant extract and Scutellaria baicalensis extract... Agent: Birch Stewart Kolasch & Birch

20070264362 - Method and composition for treating ear inflammation caused by dry ear: A method of treating diseases and conditions associated with dry ear comprising topically applying to the ear canal of a subject that is suffering therefrom a liquid composition comprising an anti-irritant agent, a wound healing agent; and an anti-inflammatory agent dissolved in a polyhydroxy liquid solvent.... Agent: Walter A. Hackler, Ph.d. Patent Law Office

20070264363 - Molluscicidal and anti-barnacle compounds: The present invention relates to the use of one or more compounds as a molluscicidal and/or mollusc-repellant agent, wherein the one or more compounds are terpenes or oxygenated derivatives thereof. The present invention also relates to a molluscicidal and/or mollusc-repellant agent comprising one or more of the compounds of the... Agent: Banner & Witcoff, Ltd.

20070264364 - Cosmetic compositions having extracts of amomum melegueta and methods of treating skin: There is disclosed a topical composition and method for preventing and/or ameliorating the effects of aging on skin to improve the aesthetic appearance of skin and/or scalp. The invention utilizes the topical application of Amomum melegueta extract.... Agent: Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070264365 - Linseed extract for xerostomia treatment: The present invention provides a water-soluble or water-dispersible linseed extract for the treatment of xerostomia characterised in that the extract has an absorption of at least 1.2 g/m2, wherein the adsorption is measured by contacting an aqueous solution or dispersion of the extract with a silica substrate, rinsing the silica... Agent: Marshall, Gerstein & Borun LLP

20070264367 - Composition containing an extract of shisandrae fructus for preventing and treating metabolic bone diseases, oxidative stress-induced diseases and inflammatory diseases: e

20070264368 - Carbohydrase inhibitors derived from fagaceous plants and use thereof: The present invention provides a plant-derived carbohydrase inhibitor, wherein the inhibitor is effective for preventing or alleviating diabetes, or preventing obesity, and foods, drinks, and medicines containing the same. The present invention is accomplished by use of an α-amylase inhibitor or an α-glucosidase inhibitor as a carbohydrase inhibitor that is... Agent: Fitch, Even, Tabin & Flannery

20070264366 - Moringa crude extracts and their derived fractions with antifungal activities: The present invention provides a method of treating fungal infection by administering a pharmaceutical composition comprising an extract of the leaf of M. oleifera as the sole active component.... Agent: Cohen, Pontani, Lieberman & Pavane

20070264369 - Nematicides from juglandaceae and methods of use thereof: The invention provides compositions and methods for inhibiting nematode damage to plants. The compositions comprise acid extracts or alcohol extracts from jugloneproducing members of the Juglandaceae. The methods comprise applying the compositions of the invention to soil contacting roots of nematode-susceptible plants.... Agent: Townsend And Townsend And Crew, LLP

20070264370 - Composition and methods for the treatment of joint pain using angelica gigas nakai extract and powder as combined with glucosamine sulfate, or chondroitin sulfate and hcl, or msm, or aspirin, or celedrin, and as combinations thereof in powder, pill, capsu: The present invention relates to composition comprising dry powder of decursinol, decursin, and their related derivates isolated from the roots of Angelica gigas Nakai (Korean Angelica) plant and at least one of joint improvement agents such as glucosamine, chondroitin, or methylsulfonylmethane (MSM). The present invention is directed to methods, combinations,... Agent: Michael G. Jeffers

20070264371 - Product of coromandel and method for its use: The present invention relates to a product of coromandel (Asystasia gangetica) and its use as a food by-product and medical value. By extracting the leaves of the coromandel (an antidiabetic agent or lactic acid bacteria promoter) for use in foods and animal feeds and dried goods, the manufacturing of a... Agent: Kazuyuki Nieda Dts

20070264372 - Cosmetic or pharmaceutical product for external use based on papaya: A cosmetic or pharmaceutical product for external use comprising papaya among its components, characterized in that the papaya is fermented.... Agent: Modiano & Associati

20070264373 - Toxin induced sympathectomy: A selective and extended sympathetic nerve block is achieved by administration of a botulinum toxin at and/or around a targeted sympathetic ganglion. The toxin induced sympathetic block finds use for the treatment of sympathetically maintained pain. The toxin induced sympathetic block is also used to treat cardiovascular conditions of sympathetically... Agent: Bozicevic, Field & Francis LLP

20070258910 - Methods and devices for remineralization of hard tissues: Provided herein are methods to remineralize the demineralized areas of hard tissues. The disclosure provides for remineralizing methods and systems that utilize a jet stream laden with particles comprising at least calcium and phosphorus to remove demineralized zone and implant particles within the hard tissue to stimulate remineralization. Some aspects... Agent: Benjamin Aaron Adler Adler & Associates

20070258915 - Anti-microbial composition and method for making and using same: The present invention generally relates to anti-microbial formulations and methods of their use and production. The formulations of the present invention are effective as broad spectrum anti-bacterial agents with efficacy against both Gram-negative and Gram-positive bacteria, as anti-viral agents with efficacy against both enveloped and non-enveloped viruses, and as anti-fungal... Agent: Reed Smith, LLP Attn: Patent Records Department

20070258918 - High ds cationic polygalactomannan for hair conditioner products: A hair conditioner composition is provided with a) from about 1 to about 99 wt % of water, b) at least about 0.05 wt % of a cationic polymer wherein the cationic polymer has a mean average molecular weight (Mw) from about 2,000 to about 10,000,000 Dalton, and the cationic... Agent: Hercules Incorporated Hercules Plaza

20070258917 - Process for removing or lightening stains caused by skin coloring agents: A process for removing or lightening a stain from human skin caused by a sunless tanning product involving contacting the stain with a stain removing composition containing at least one skin-abrading metal oxide to form a clean or lightened skin surface.... Agent: L'oreal Usa/ Patent Department

20070258935 - Water dispersible films for delivery of active agents to the epidermis: A water-dissipatable film forming formulation includes a polymer having at least one water solubilizing or dissipating moiety; an active ingredient or agent; and at least one of a plasticizer or a humectant. The present invention also includes a method for delivering an active agent to the epidermis of a subject.... Agent: Tammye L. Taylor Eastman Chemical Company

20070258940 - Hydrophilic fouling-release coatings and uses thereof: The present invention provides a process for obtaining a non-toxic coating suitable for preventing attachment of fouling organisms on marine structures which involves applying onto a substrate a coating composition and curing the coating composition to yield a water-insoluble hydrophilic coating wherein the coating composition includes at least one cellulose... Agent: Tammye L. Taylor Eastman Chemical Company

20070258941 - Methods and compositions for remediation of disc herniation by modifying structure: A therapeutic method and compositions are provided that involve injection of a cation solution into extracellular matrix of a tissue. In the preferred embodiment, a percutaneous (performed through the skin) injection of a polylysine solution into the nucleus of a herniated disc is provided, to reduce intradiscal pressure.... Agent: Sonia K. Guterman

20070258952 - Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna: The present invention includes compositions and methods for the knockdown of one or more genes to a target cell in need of gene therapy by using an siRNA transgene that is integrated into a replication-competent, oncolytic adenovirus.... Agent: Chalker Flores, LLP

20070258887 - Compounds and amyloid probes thereof for therapeutic and imaging uses: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070258885 - Device for concentrating technetium-99m pertechnetate and method thereof: A device for concentrating 99mTc pertechnetate and a method thereof are disclosed. The device includes a concentration device, a control device and a central processing unit. The concentration device is for concentrating 99mTc pertechnetate, the control device connects with each members of the concentration device, and the central processing unit... Agent: Rosenberg, Klein & Lee

20070258886 - Methods for assessing cell labeling: The disclosure relates to methods for labeling cells ex vivo with agents that can be detected by MRI or PET techniques, or other techniques that permit non-invasive imaging of living organisms. The labeled cells can be re-administered to the patient and the movements of the labeled cells can be tracked... Agent: Ropes & Gray LLP Patent Docketing 39/41

20070258888 - Contrast agent for medical imaging techniques and usage thereof: A contrast agent for medical imaging techniques is described, comprising particles consisting of at least a core, the core comprising at least an oxide, mixed oxide, or hydroxide of specific elements. The particles optionally comprise shells containing or consisting of precious metal, radioactive isotopes, bio-compatibility agents, and/or antibodies. The applied... Agent: Philips Intellectual Property & Standards

20070258889 - Novel nanoparticles and use thereof: The present invention is directed to novel compositions and methods utilizing delivery agents or nanoparticles that include protein cages with modified and/or unmodified subunits and various agents, such as therapeutic and/or imaging agents located on the interior and/or exterior surface of the protein cages.... Agent: Dorsey & Whitney LLP

20070258890 - Anthracycline derivatives: The present invention relates to new anthracycline derivatives and their use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step... Agent: Dinsmore & Shohl, LLP

20070258892 - Composition, comprising l-serine, l-isoleucine, folic acid and trace elements, for treating psoriasis: Biological medical means for treating psoriasis are disclosed. The invention relates to the use of L-serine (Ser) and L-isoleucine (Ile) for the manufacture of a pharmaceutical composition for treating or preventing psoriasis. The invention further relates to a pharmaceutical composition comprising said amino acids as active ingredients. Preferably the composition... Agent: Ladas & Parry

20070258891 - Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds: The present invention relates to new anti-cancer compounds and in particular to new compounds for use in nuclide activation therapy, such as neutron capture therapy. Specifically this invention provides a conjugate having the general formula P-(L-NAT)n wherein P represents an N-hydroxypropylmethacrylamide-methacrylate copolymer having a molecular weight of 5-6,000 kDa; NAT... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070258893 - Compositions and methods for imaging expression of cell surface receptors: The present disclosure provides imaging agents and methods for imaging surface cell receptors, particularly CXCR4 receptors and biological conditions associated with the expression of CXCR4 receptors, including, but not limited to, cancer and metastasis. In embodiments, the present disclosure provides radiolabeled CXCR4 peptide antagonists detectable in vivo or in vitro... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070258897 - Antibodies against bacterial antigens and their use in the generation of immune responses against apoptotic cells: The present invention provides a method of enhancing an immune response to apoptotic cells, the method comprising administration of a specific binding member which specifically binds to a microbial antigen. Also provided are pharmaceutical compositions comprising such antibodies and assays to identify specific binding members capable of enhancing an immune... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070258900 - Blood flow assessment of clostridial toxin applications: The present specification relates to methods for assessing the physiological activity of a target site being evaluated for potential administration of a Clostridial toxin, methods for administering a Clostridial toxin to a particular target site, methods for assessing the effect of an administration of a Clostridial toxin in a mammal,... Agent: Allergan, Inc.

20070258896 - Contrast agents in medical imaging: A method of imaging a living body. The method includes administering a contrast agent to the body, sensing signals of a first modality, which does not use ionizing radiation, from the body, responsive to the contrast agent in the body and acquiring one or more images of at least a... Agent: Wolf, Block, Schorr & Solis-cohen LLP

20070258899 - Diagnostic and therapeutic agents: Tumor targeting units are disclosed which have a peptide sequence Cy—Y—G-F—X—W-G-Z-Cyy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having... Agent: Buchanan, Ingersoll & Rooney PC

20070258895 - Estrogen receptors and methods of use: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID N0:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity... Agent: Mueting, Raasch & Gebhardt, P.A.

20070258898 - Markers for addiction: Correlations between polymorphisms and addiction are provided. Methods of diagnosing, prognosing, and treating addiction are provided. Systems and kits for diagnosis, prognosis and treatment of addiction are provided. Methods of identifying addiction modulators are also described.... Agent: Quine Intellectual Property Law Group, P.C.

20070258894 - System and method for real-time diagnosis, treatment, and therapeutic drug monitoring: Systems and methods for diagnosing and/or treating diseases as well as monitoring disease treatment. For diagnosis, the present invention uses nanoparticle-based assemblies, which comprise a nanoparticle; a surrogate marker; and a means for detecting a specific chemical entity. In certain embodiments, nanoparticle-based assemblies include a payload for simultaneous diagnosis and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070258901 - Capsules containing transiently transfected cells, method for preparing same and uses thereof: The invention concerns a capsule containing cells that are transiently transfected with a gene of interest and entrapped within a biocompatible polymer membrane, a method of preparing those capsules, a method for in vivo assessing an activity of the protein secreted by the gene of interest, which comprises administering to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070258902 - Method for assessing atherosclerosis: A non-invasive method for the diagnosis of atherosclerosis is provided. In one example, the method includes assaying the expression of FOS, DUSP1, or both FOS and DUSP1 in monocytes or a cell fraction thereof, or in plasma, serum or blood from the subject, wherein an increase the expression of FOS,... Agent: Klarquist Sparkman, LLP

20070258903 - Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers: Methods and compositions for the sustained release of treatment agents to treat an occluded blood vessel and affected tissue and/or organs are disclosed. Porous or non-porous bioabsorbable glass, metal or ceramic bead, rod or fiber particles can be loaded with a treatment agent, and optionally an image-enhancing agent, and coated... Agent: Blakely Sokoloff Taylor & Zafman

20070258908 - Detection and imaging of target tissue: Methods for high resolution imaging of a suspected target tissue are encompassed by the invention. Such methods include administering low resolution and high resolution contrast agents specific to targeted cells or tissues. The contrast agents are allowed to bind to the target cells or accumulate in a target tissue. A... Agent: Morrison & Foerster LLP

20070258907 - Polymer-coated paramagnetic particles: The present invention relates to novel compositions of polymer-coated paramagnetic particles, defined as paramagnetic particles non-covalently coated with polymeric materials, which optionally possess targeting ligands, therapeutic agents, or carrier ligands. By selecting from a variety of linker groups and targeting ligands the coated paramagnetic particles are suitable for a wide... Agent: Ropes & Gray LLP Patent Docketing 39/41

20070258905 - Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents: The present invention relates to a new class of paramagnetic ion-based contrast agents of molecular weight lower than 3.5 kDa that show a pharmacokinetic profile analogous to that of the commonly used T1-general extravascular agents and that are further characterized by a higher relaxivity.... Agent: Bracco Research Usa Inc.

20070258904 - Optical imaging contrast agents: The invention provides contrast agents for optical imaging of oesophageal cancer and Barrett's oesophagus in patients. The contrast agents may be used in diagnosis of oesophageal cancer and Barrett's oesophagus, for follow up of progress in disease development, for follow up of treatment of oesophageal cancer and Barrett's oesophagus and... Agent: Ge Healthcare, Inc.

20070258906 - Methods and devices for detection and therapy of atheromatous plaque: The present invention relates to devices for detection and therapy of active atheromatous plaque and/or thin-capped fibro-atheroma (“vulnerable plaque”), using selectively targeted fluorescent, radiolabeled, or fluorescent and radiolabeled compositions. The present invention further relates to methods and devices for detection and therapy of active atheromatous plaques and/or vulnerable plaques, using... Agent: Edwards Angell Palmer & Dodge LLP

20070258909 - Method for the analysis of 1,1,1,2-tetrafluoroethane: Method for the analysis of the content of organic impurities in 1,1,1,2-tetrafluoroethane, in which (a) the 1,1,1,2-tetrafluoroethane is subjected to a gas chromatography operation and; (b) an operation is carried out in which the organic impurities are detected by mass spectrometry and wherein said method is carried out using the... Agent: Connolly Bove Lodge & Hutz, LLP

20070258911 - Method of producing high alcohol content foaming compositions with silicone-based surfactants: This invention relates to a method of producing and dispensing a foam using a “high lower alcohol content”(>40% v/v of a C1-4 alcohol) liquid composition. The liquid compositions comprise an alcohol, C1-4(>40% v/v), a silicone-based surfactant of at least 0.001% by weight to prepare a foamable composition, 0-10% w/w of... Agent: Ralph A. Dowell Of Dowell & Dowell P.C.

20070258913 - Composition for inhibiting or preventing the formation of a biofilm: Compounds for inhibiting and/or preventing the formation of a biofilm are disclosed. The compounds are an anthraquinone and/or a naphtoquinone, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, or mixtures thereof, and/or at least one plant extract including the compound or active fraction thereof. Compositions containing the compounds such... Agent: Knobbe Martens Olson & Bear LLP

20070258914 - Metalloproteinase inhibotory agent: The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent of casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The invention also relates to the manufacture of an active agent, in which a food grade bacteria of the genus Lactobacillus helveticus is... Agent: Bell, Boyd & Lloyd LLP

20070258912 - Use of fluorescent whitening agents as antimicrobials: Use of fluorescent whitening agents for whitening and the antimicrobial treatment of surfaces, and preservation of cosmetics, household products, personal care products, textiles, paper and starting materials of paper, plastics and disinfectants.... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070258916 - Oral compositions for treating tooth hypersensitivity: Oral Compositions for Treating Tooth Hypersensitivity Disclosed herein are oral compositions for decreasing tooth hypersensitivity. In one aspect, the compositions induce remineralization of dentine using bioactive glass, thereby reducing tooth sensitivity.... Agent: Klarquist Sparkman, LLP

20070258920 - Process for obtaining polyphenol extracts from cocoa beans, the resulting extracts and uses thereof: The invention concerns a polyphenolic cocoa extract and methods of use. The cocoa extract comprises 15 to 66% of at least one polyphenol, 0 to 11% of at least one lipid and 5 to 20% of at least one xanthine. The cocoa extract is suitable for use as in cosmetic... Agent: Hoxie & Associates LLC

20070258919 - Topical acne vulgaris medication with a sunscreen: Increased compliance in the use of topical sunscreens is obtained by combining a topical sunscreen agent in a formulation containing an antibacterial medication such as azelaic acid or an antibiotic.... Agent: Howard Eisenberg, Esq.

20070258921 - Process for depigmenting the skin: Process for depigmenting and/or whitening human skin by the application of at least one compound of formula (I):... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070258923 - Cosmetic compositions containing block copolymers, tackifiers and modified silicones: A cosmetic composition containing at least one block copolymer having a hard segment and a soft segment, at least one tackifier component, at least one solvent, or solvent mixture, optionally, at least one modified silicone, and optionally, at least one colorant, and wherein the at least one hard segment has... Agent: L'oreal Usa/ Patent Department

20070258922 - Novel silica- or silicate-based pigments for wrinkle-hiding cosmetic applications: Unique pigments that exhibit excellent light diffusion when applied to a person's skin within an appropriate medium as well as acceptable feel during such application are provided. To be most efficacious for this application, such pigments should meet specific criteria being a proper particle size, having irregular structure (i.e. not... Agent: J M Huber Corporation

20070258925 - Cosmetic compositions containing block copolymers, tackifiers and a selective solvent for hard blocks: A cosmetic composition containing at least one block copolymer having at least one hard segment and at least one soft segment, at least one tackifier component, at least one solvent capable of solubilizing the at least one hard segment, and optionally, at least one colorant, and wherein the at least... Agent: L'oreal Usa/ Patent Department

20070258924 - Cosmetic compositions containing block copolymers, tackifiers and a selective solvent for soft blocks: A cosmetic composition containing at least one block copolymer having at least one hard segment and at least one soft segment, at least one tackifier component, at least one solvent capable of solubilizing the soft segment, and optionally, at least one colorant, and wherein the at least one hard segment... Agent: L'oreal Usa/ Patent Department

20070258926 - Composition containing retinoic acid nanoparticles coated with inorganic salt of polyvalent metal: A composition contains nanoparticles of retinoic acid as an active ingredient. The nanoparticles have reduced irritancy of retinoic acid and are suitable for subcutaneous or intravenous administration, as well as for use in sustained-release preparation. The high skin permeability of the nanoparticles makes the composition suitable for use in pharmaceutical... Agent: Ostrager Chong Flaherty & Broitman PC

20070258927 - Inverse emulsions as thickeners for cosmetics: c

20070258932 - Cosmetic compositions containing block copolymers, tackifiers and a solvent mixture: A cosmetic composition containing at least one block copolymer having at least one hard segment and at least one soft segment, at least one tackifier component, a solvent mixture, and optionally, at least one colorant, and wherein the at least one hard segment has a Tg value of 50° C.... Agent: L'oreal Usa/ Patent Department

20070258934 - Cosmetic compositions containing block copolymers, tackifiers and gelling agents: A cosmetic composition containing at least one block copolymer having a hard segment and a soft segment, at least one tackifier component, at least one solvent, at least one gelling agent, and optionally, at least one colorant, and wherein the at least one hard segment has a Tg value of... Agent: L'oreal Usa/ Patent Department

20070258933 - Cosmetic compositions containing block copolymers, tackifiers and shine enhancing agents: A cosmetic composition containing at least one block copolymer having a hard segment and a soft segment, at least one tackifier component, at least one solvent, or solvent mixture, at least one shine enhancing agent, and optionally, at least one colorant, and wherein the at least one hard segment has... Agent: L'oreal Usa/ Patent Department

20070258936 - Composition for washing keratin materials and cosmetic treatment process using said composition: The present disclosure relates to cosmetic compositions for washing keratin materials, comprising of a microemulsion comprising: water, at least one oxyethylenated sorbitan ester, at least one oil chosen from fatty esters and amino silicones, with the proviso that said fatty esters are not oxyethylenated sorbitan esters, at least one anionic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070258928 - Agent for coloring keratin fibers: The present invention has for an object agents for dyeing keratin fibers, characterized in that they contain at least one thiazoliumazo dye of general formula (I)... Agent: Michael J. Striker

20070258929 - Cationic dyes and dyestuff for keratin fibres containing said compounds: e

20070258931 - Cosmetic compositions comprising an oxyethylene sorbitol ester and a cyclodextrain, processes and uses: The present disclosure relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, at least one oxyethylenated C8 to C14 fatty acid ester of sorbitan comprising from 2 to 10 oxyethylene units, and at least one cyclodextrin or derivative thereof. The present disclosure also relates to a process... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070258930 - Water-in-oil emulsion for the treatment of keratin fibers, comprising a cyanoacrylate monomer: The present disclosure relates to a water-in-oil emulsion comprising an aqueous phase, at least one surfactant and at least one monomer polymerization inhibitor and an oily phase comprising at least one cyanoacrylate monomer. The water-in-oil emulsion of the present disclosure facilitates the application of cyanoacrylate monomers to keratin fibers.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070258937 - Deodorizing device: The present invention is directed to a deodorizing device and a method for forming the deodorizing device. The deodorizing device comprises a deodorizing composition and an adhesive, such as a hotmelt adhesive, adhered between two nonwoven gas porous sheets. The deodorizing composition includes deodorizing particles such as sodium bicarbonate and... Agent: Church & Dwight Co., Inc.

20070258939 - Drug delivery from embolic agents: A pharmaceutical composition for embolisation of blood vessels, especially for benign tumours, comprises a polymeric embolic agent and, associated with the polymer in a releasable form, a local anaesthetic agent. The polymer is preferably in particulate form, such as in the form of microspheres. A suitable polymer is a crosslinked... Agent: Sughrue Mion, PLLC

20070258938 - Compositions comprising biomembrane sealing agent for treatment of pain or inflammation, and methods of use: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal... Agent: Fox Rothschild, LLP

20070258942 - C-nitroso compounds and use thereof: A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is... Agent: Bacon & Thomas, PLLC

20070258943 - Genetically engineered cells for therapeutic applications: An isolated mesenchymal stem cell, multipotent adult progenitor cell, or other stem cells is genetically modified to express at least one of CXCR4, SDF-1, or a variant thereof.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20070258945 - G-gsf therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction: The present invention relates to methods of using Granulocyte Colony Stimulating Factor (G-CSF) polypeptide in conjunction with reperfusion therapy in the treatment of acute myocardial infarction or other ischemic events. This treatment can be used alone or in combination with other well-known methods of treatment.... Agent: Marshall, Gerstein & Borun LLP

20070258944 - Multiple cytokine protein complexes: The invention relates to protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety such as a region of an immunoglobulin. Methods of using the protein complexes and fusion proteins are also disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20070258946 - Combination therapy for treating hepatitis c virus infection: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in... Agent: Thelen Reid Brown Raysman & Steiner LLP

20070258947 - Depeptidized inhibitors of hepatitis c virus ns3 protease: The present invention discloses novel depeptidized compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070258949 - Human cdna clones comprising polynucleotides encoding polypeptides and methods of their use: The invention provides novel polynucleotides, related polypeptides related nucleic acid and polypeptide compositions corresponding to novel human cDNA clones, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070258948 - Tissue modeling in embryonic stem (es) cell system: Provided are embryonic stem (ES) cell-derived tissue modeling systems. In particular, systems for the de novo generation of tissue by parallel drug selection of cell types constituting the tissue of interest in one culture of differentiating ES cells is described as well as the use of such systems in transplantation... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070258950 - Methods and compositions for recovering or improving visual function: There are disclosed methods and compositions for recovering or improving visual function in a mammal, by means of adeno-associated viral vectors suitable for gene delivery to mammalian retina.... Agent: Arent Fox LLP

20070258951 - Methods of treating cardiac disorders: The invention feature methods and compositions for treating ischemic aand reperfusuin related injury such as cardiac disorders.... Agent: Ivor R. Elrifi, Ph.d. Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20070258961 - Cholesterol efflux and uses thereof: In a first aspect of the present invention, there is provided a method of modulating cholesterol efflux in a cell, said method comprising modulating expression and/or activity of sterol 27-hydroxylase (CYP27) and/or caveolin-1 in the cell. Applicants have found that cholesterol can be removed by cholesterol efflux which is regulated... Agent: Michael L Goldman Nixon Peabody

20070258962 - Expression vectors comprising the mcmv ie2 promoter: The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein expression vector does not contain any complete gene of the mCMV.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070258963 - Mesenchymal stem cells expressing tnf-alpha receptors: Mesenchymal stem cells which express TNF-{acute over (α)} receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.... Agent: Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein

20070258954 - Directed evolution of enzymes and antibodies: The invention relates to methods of selecting proteins, out of large libraries, having desirable characteristics. Exemplified are methods of expressing enzymes and antibodies on the surface of host cells and selecting for desired activities. These methods have the advantage of speed and ease of operation when compared with current methods.... Agent: Fulbright & Jaworski L.L.P.

20070258953 - Lactic acid utilising bacteria and their therapeutic use: There is provided a method of isolating novel lactic acid utilizing bacteria from human faeces, as well as novel strains so obtained. The use of the novel lactic acid utilising bacteria in therapy, including prophylactic therapy, is described and is of particular relevance for lactic-acidosis, short bowel syndrome and inflammatory... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070258955 - Lactobacillus acidophillus nucleic acid sequences encoding cell surface protein homologues and uses therefore: Cell wall, cell surface and secreted protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, cell wall, cell surface and secreted fusion proteins, antigenic peptides, and anti-cell wall, cell surface and secreted antibodies are encompassed. The invention also provides recombinant... Agent: Alston & Bird LLP

20070258965 - Method to improve lactococcus preservation: Lactococcus lactis strains with improved preservation characteristics, and improved acid and bile salt tolerance are disclosed. More specifically, a L. lactis strain having a heterologous trehalose-6-phosphate synthase gene and/or a trehalose-6-phosphate phosphatase gene, results in an accumulation of trehalose in the cytoplasm and/or in the cytoplasmic membrane. A L. lactis... Agent: Knobbe Martens Olson & Bear LLP

20070258964 - Selenium-enriched biomass, method for preparing thereof and probiotic and nutraceutical products including said biomass: The invention relates to a selenium-enriched biomass containing live microorganisms selected from the group consisting of Lactobacillus reuteri, Lactobacillus ferintoshensis, Lactobacillus buchneri/parabuchneri and combinations thereof, a method of preparation of the said selenium-enriched biomass, as well as food preparations, nutraceutical products and food supplements containing the said biomass. Moreover, new... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070258959 - Cd4+cd25- t cells and tr1-like regulatory t cells: The invention provides CD4+CD25− T cells and Tr1-like regulatory T cells (i.e., contact-independent Type 1-like regulatory T cells), processes for their production and their use for regulatory purposes.... Agent: Norris, Mclaughlin & Marcus, Pa

20070258958 - Interactive wound cover: The present invention relates to an interactive wound cover wherein a cultured monolayer of keratinocytes is delivered using a biopolymer. The present invention describes the composition, method of preparation and its properties relating to safety, and efficacy. The wound cover of the present invention is useful in the treatment of... Agent: Foley And Lardner LLP Suite 500

20070258957 - Method for obtaining and storing multipotent stem cells: The invention provides an isolated tissue comprising a source of millions of postnatal stem cells expressing embryonic stem cell markers, and a method of storing or banking such isolated tissue to provide stems cells for later therapeutic use for the donor or for allogeneic transplant with donor permission.... Agent: Maginot, Moore & Beck, LLP Chase Tower

20070258956 - Methods and apparatus for promoting hair growth using adipose cell based therapies: Methods and compositions for use in the treatment of androgenetic alopecia and other forms of hair loss by inducing and expediting the growth of hair in the scalp of a patient. Methods comprise the steps of isolating adipose-derived cells and hair follicles from the patient and implanting the combined cells... Agent: Harness, Dickey & Pierce, P.L.C

20070258960 - Stabilized products, process and devices for preparing same: Disclosed is a multi-compartment medical device useful in the storage, processing and extended shelf life of perishable products, especially pharmaceutical, food and biological products. Particular biological materials processed according to the present methods are human blood and blood products (RBCs). Also disclosed are processes for preserving food, pharmaceutical and biological... Agent: Denise L. Mayfield

20070258967 - Purification method of reduced coenzyme q10: The present invention provides reduced coenzyme Q10 with a low reduced coenzyme Q10 analog content, which is useful as a food, nutritional product, nutritional supplement, animal drug, drink, feed, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like, and a production method of the reduced coenzyme Q10. The present... Agent: Leydig Voit & Mayer, Ltd

20070258966 - Stabilization method of reduced coenzyme q10: The present invention provides a method for stabilizing reduced coenzyme Q10, which is useful as a food, nutritional product, nutritional supplement, animal drug, drink, feed, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like. The present invention also provides a method of producing a reduced coenzyme Q10-containing composition which... Agent: Leydig Voit & Mayer, Ltd

20070258968 - Use of specifically engineered enzymes to enhance the efficacy of prodrugs: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070258969 - Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers: Disclosed herein are compositions comprising a drug linked to a multivalent ligand polysaccharide and the use of this composition in the prevention and treatment of cancer. In one aspect, the polysaccharide is obtained by physical and chemical treatment of naturally occurring polymers or semi synthetic polymers which are bridged specifically... Agent: Greenberg Traurig, LLP

20070258970 - Methods for inhibiting hiv and other viral infections by modulating ceramide metabolism: The present invention provides methods of preventing infection by retroviruses and methods of treatment of patients suffering from or susceptible to a viral infection. More particularly, the present invention provides methods of preventing viral infection and methods of treating retroviral infections which comprise the administration of at least one compound... Agent: Edwards Angell Palmer & Dodge LLP

20070258971 - Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject.... Agent: Licata & Tyrrell P.C.

20070258976 - Combination therapy for diseases involving angiogenesis: A composition useful for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis comprises at least two therapeutic agents selected from the group consisting of compounds that interact with and inhibit a downstream activity of extracellular VEGF, compounds that interact with at least a VEGF receptor and render it... Agent: Bausch & Lomb Incorporated

20070258972 - Combination of a histone deacetylase inhibitor with a death receptor ligand: The invention relates to a method of preventing or treating proliferative diseases such as cancer in a mammal, particularly a human, with a combination of pharmaceutical agents which comprises: (a) an HDAI; and (b) a death receptor ligand. The invention further relates to pharmaceutical compositions comprising: (a) an HDAI; (b)... Agent: Novartis Corporate Intellectual Property

20070258975 - Crystallization of antibody or fragment thereof: The present disclosure concerns methods of crystallization and/or concentration of antibody or antibody fragments. The methods comprise contacting an antibody or antibody fragment with a solution comprising a salt of a divalent cation. Crystals and/or protein gels of antibody or antibody fragments are useful in compositions and formulations.... Agent: Merchant & Gould PC

20070258974 - Diagnostics and therapeutics for diseases associated with puromycin sensitive aminopeptidase npepps (npepps): The invention provides a human NPEPPS which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular... Agent: Banner & Witcoff, Ltd.

20070258973 - Diagnostics and therapeutics for diseases associated with tripeptidyl-peptidase 2(tpp2): The invention provides a human TPP2 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, gastroenterological diseases, cancer, inflammation, hematological diseases, respiratory diseases, muscle-skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention... Agent: Banner & Witcoff, Ltd.

20070258977 - Methods of treating cancer by administering antibodies to cd200: Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing... Agent: Bereskin And Parr

20070258978 - Immunogenic recombinant antibody: The invention refers to an immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a mammalian glycosylation.... Agent: Birch Stewart Kolasch & Birch

20070258979 - Chimeric and humanised monoclonal antibodies against interleukin-13: The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070258980 - Vascular endothelial cell growth factor antagonists and uses thereof: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.... Agent: Merchant & Gould PC

20070258981 - Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease: The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”).... Agent: Jones Day

20070258982 - Methods of using antibodies against human il-22: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.... Agent: Wyeth/finnegan Henderson, LLP

20070258983 - Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing: Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interaction among pro-inflammatory or anti-inflammatory stimulators or mediators occur, or during events that do induce... Agent: Ryan Kromholz & Manion, S.c.

20070258984 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20070258985 - Human mini-antibody cytotoxic for tumor cells which express the erb-b2 receptor: The invention refers to a fully human miniantibody (scFv), called Erbicin, specific for the receptor ErbB2, with a pharmacological, in particular antitumour, activity. It has been obtained from a larger fagmidic library (Griffin 1.) (19) of human synthetic scFv by panning (affinity selection on antigen) carried out on live cells... Agent: Morgan, Lewis & Bockius LLP (sf)

20070258986 - Targeted delivery system for bioactive agents: In accordance with the present invention, compounds, compositions and methods are provided that allow for the administration of a bioactive agent to an organism, including a human or an animal. The present invention can be used to treat or prevent a disease and/or disorder with a bioactive agent, or can... Agent: Edwards Angell Palmer & Dodge LLP

20070258987 - Recombinant anti-cd30 antibodies and uses thereof: The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the... Agent: Seattle Genetics, Inc.

20070258988 - Identification and characterization of multiple splice variants of the mu opioid receptor gene: The present invention encompasses novel splice variant forms of the mu-opioid receptor-1 (MOR-1) and the polynucleotide sequences encoding the MOR-1 splice variants. The invention further encompasses methods of screening for compositions regulating the MOR-1 splice variant activities and the development of therapeutic modalities directed to regulating activity. Regulation of the... Agent: Edwards Angell Palmer & Dodge LLP

20070258991 - Immunogenic agent therapy using plasmapheresis: Lowering the level of antibody or complement in the blood of a subject by plasmapheresis or exchange transfusion prior to administering an immunogenic therapeutic agent containing a foreign epitope reduces the immune response of the subject to the therapeutic agent.... Agent: Lewis J. Kreisler

20070258989 - Immunomodulatory pharmaceutical composition and a process for preparation thereof: The present invention provides a novel pharmaceutical composition consisting of a combination of three coumarinolignoids of formula 1, 2 and 3 isolated from the seeds of the plant Cleome viscose along with a pharmaceutically acceptable carrier useful as a immunomodulator. The invention also describes the ability of the compounds to... Agent: Edwards Angell Palmer & Dodge LLP

20070258990 - Means and methods for detecting and/or staging follicular lymphoma cells: The invention provides a method for detecting and/or staging a malignant functional cell comprising measuring an expression profile of said malignant cell and a non-malignant cell. Preferably, said non malignant cell and said malignant cell are capable of interacting. In one aspect the invention provides reporter genes whose expression patterns... Agent: Trask Britt

20070258992 - Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides: The present invention provides BoNT/A peptide compositions, tolerogizing compositions, vaccine compositions and antibody compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of preventing or reducing immunoresistance to botulinum toxin therapy in an individual, methods of vaccinating an individual against botulinum toxin, methods... Agent: Allergan, Inc.

20070258993 - Dna-carrier conjugate: A cell-specific delivery method of genetic material for the purposes of providing polynucleotide- or oligonucleotide-based genetic vaccines or a means for gene therapy. The delivery method involves the use of a compound comprising a conjugate of a polynucleotide or oligonucleotide molecule, a carrier comprising at least one aldehyde group and,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070258994 - Immunomodulatory formulations and methods for use thereof: The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.... Agent: Morrison & Foerster LLP

20070258996 - Antimicrobial compositions: An antimicrobial composition, including a synergistic combination of three or more potentiating agents as an active ingredient. Each of the three or more potentiating agents may be selected from the following types of compounds: sequestering agents, carbohydrates, terpenes, terpenoids, peptides, alkaloids, plant-derived oils, dyes and stains, sulfonates, phenols, esters, fatty... Agent: Sughrue Mion, PLLC

20070258995 - Herbal formulation for treatment of depression and other related disorders and method of preparing the same: A herbal formulation used for treatment of depression and other related disorders comprises the following ingredients, namely Os Draconis, Concha Ostreae, Fructus Tritici Aestivi, Bulbus Lilii, Radix Rehmanniae, Caulis Polygoni Multiflori, Fructus Jujubae, Flos Albiziae, Radix Et. Rhizoma Glycyrrhizae Praeparata Cum Melle, Sclerotium Poriae Circum Radicem Pini, Caulis Bambusae in... Agent: EagleIPLimited

20070258997 - Rescue of mumps virus from cdna: This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and,... Agent: Wyeth Patent Law Group

20070258999 - Sars virus nucleotide and amino acid sequences and uses thereof: The invention provides, in part, the genomic sequence of a putative coronavirus, the SARS virus, and provides novel nucleic acid and amino acid sequences that may be used, for example, for the diagnosis, prophylaxis, or therapy of a variety of SARS virus related disorders.... Agent: Ronald I. Eisenstein

20070259002 - Botulinum toxin therapy of heart rhythm disorders: The instant invention relates to the use of a pre-synaptic neuromuscular blocking substance for preparing a medicament intended to treat or prevent heart fibrillation disorders. Preferably, the pre-synaptic neuromuscular blocking substance will be a botulinum toxin. Preferably also, the heart fibrillation disorder to be treated or prevented will be atrial... Agent: Jacobson Holman PLLC

20070259003 - Clostridial toxin derivatives and methods for treating pain: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting... Agent: Allergan, Inc.

20070259001 - Cosmetic use of botulinum toxin for the treatment of eyebrow and forehead ptosis, and unwanted eyebrow expression: A method of temporarily elevating the eyebrow position and softening undesirable glabellar muscle activity to affect a more desirable appearance. In a broad aspect the invention comprises injecting small quantities of botulinum toxin (BTX) dissolved in microdroplets of injectable saline carrier to treat the septal and orbital orbicularis oculi muscles,... Agent: Lawrence N. Ginsberg

20070259000 - Methods for alleviating testicular pain: Method for alleviating testicular pain in a patient in need thereof. The method can comprise the step of locally administering a neurotoxin (e.g., a botulinum toxin) to at least one anatomical site selected from the group consisting of a testicle and a tissue associated with the testicle of the patient.... Agent: Stephen Donovan Allergan, Inc.

20070259004 - Expression vector for bacillus species: The present invention is related to the use of the gsiB promoter as an inducible promoter in an expression system, whereby the promoter can be induced by a measure selected from the group comprising decrease in pH, increase in temperature, addition of alcohol, preferably ethanol, exhaustion of nutrients and oxygen... Agent: Proskauer Rose LLP

20070259005 - Method of treating cancer: Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical composition made from ‘Mycobacterium w’ (Mw) is found to be useful in the management of cancer. We have now found that the same therapeutic agent is useful in management of cancer. The use of Mycobacterium... Agent: Morrison & Foerster LLP

20070259006 - Shed antigen vaccine with dendritic cells adjuvant: The invention provides a method for producing a composition for use as a vaccine for treatment or prevention of cancer, comprising collecting antigens released or shed by the type of tumor cell against which it is desired to prepare the vaccine; preparing mammalian dendritic cells in a culture from a... Agent: Cooper & Dunham, LLP

20070259007 - Lactoferrin: an adjuvant for vaccines: The method of the present invention provides a novel use of Lactoferrin as an adjuvant composition suitable to be used in vaccines. More specifically, the present invention is directed to the use of Lactoferrin to augment a vaccine efficacy by generation of T lymphocytes and B lymphocytes response and subsequent... Agent: Kurt S. Myers

20070259009 - Aqueous pharmaceutical preparation comprising roflumilast: An aqueous pharmaceutical preparation for administration of a slightly soluble PDE4 inhibitor is described.... Agent: Nath & Associates PLLC

20070259010 - Dosage forms and methods of use thereof: Pharmaceutical dosage forms with external or internal features to complicate counterfeiting and support authentication are described. External features include surface texture, surface markings defined by patterns of physical or chemical markers, or complex interlocking shapes. Internal features also include physical or chemical markers in two or three-dimensional patterns observable after... Agent: Innovar, LLC

20070259008 - Polymalic acid-based multi-functional drug delivery system: A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and... Agent: Davis Wright Tremaine LLP

20070259012 - Clear cosmetic compositions and methods of use: A solid, substantially clear cosmetic composition having a refractive index of between 1.4-1.6 comprising a partially crystalline polyolefin homopolymer or copolymer wax and a solvent system, wherein the refractive index of the solvent system is matched with the refractive index of the wax. Also contemplated are methods of making the... Agent: The Estee Lauder Cos, Inc

20070259011 - Oral care products: An oral care product comprising a strip and one or more oral care compositions. The oral care composition comprises an oral care active and when applied to the teeth the oral care product delivers one or more oral care benefits.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070259013 - Pharmaceutical compositions comprising silica microspheres: The present invention relates to a topical composition which includes a bioactive drug formulated with silica in the form of microspheres, or drugs in a combination with the silica microspheres in an oily suspension, gel or emulsion. The topical compositions of the invention provide sustained release of a bioactive drug... Agent: Pearl Cohen Zedek Latzer, LLP

20070259014 - Compositions for and methods for treating hiv: Pharmaceutical composition comprising compounds and/or compositions useful to inhibit HIV replication are disclosed. Methods of treating individuals infected with HIV are disclosed. Methods of preventing HIV infection in high risk individuals are disclosed.... Agent: Cozen O'connor, P.C.

20070259015 - Enhancer: The Enhancer is a mixture of 0.28 grams of Better Bait, which is a combination of sodium thiosulfate, acroflavine, metromersol sodium, and methylene blue, used to remove chlorine from water and 2.4 ounces of 46% nitrogen urea fertilizer, and Water, which, when added to Insecticides activates the ingredients of the... Agent: Robert Edward Throneberry

20070259016 - Method of treating crops with submicron chlorothalonil: A chlorothalonil slurry product having greater than 90% by weight of the chlorothalonil present in discrete particles having a diameter less than 1 micron, more preferably less than 0.3 microns, is useful at reduced application rates, compared to prior art chlorothalonil formulations, to control a variety of diseases such as... Agent: Morgan Lewis & Bockius LLP

20070259018 - Implant depots to deliver growth factors to treat avascular necrosis: The present invention relates to the design and composition of a depot implant for optimal delivery of growth factors to treat bone avascular necrosis, in that such depot implant is constructed to be in a cylinder (rod) or sphere shape and have a natural or synthetic polymer scaffold with or... Agent: Fox Rothschild, LLP

20070259017 - Medical device having coating with zeolite drug reservoirs: A medical device having a drug-eluting coating that includes a pharmaceutical compound or, more generally, a therapeutic material housed within pores of a zeolite carrier. The zeolite carrier has an open porous structure with reservoirs for holding the therapeutic material. The therapeutic material loaded zeolites may be suspended or dispersed... Agent: Medtronic Vascular, Inc.IPLegal Department

20070259019 - Implant depots to deliver growth factors to treat osteoporotic bone: The present invention relates to the design and composition of a depot implant for optimal delivery of growth factors to treat osteoporotic bone, in that such depot implant is constructed to be in a cylinder (rod) or sphere shape and have a natural or synthetic polymer scaffold with or without... Agent: Fox Rothschild, LLP

20070259020 - Methods and compositions for the treatment of open and closed wound spinal cord injuries: Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070259021 - Compositions, methods, and kits for treating dry eye: The present invention is related to a method for treating dry eye, the method comprising administering to a lacrimal punctum a gelatinous or film forming composition. The present invention is also related to ophthalmic compositions, and kits for treating dry eye, the kit comprising (a) the ophthalmic compositions of the... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070259023 - Insulin compensated nutrition: A product and method of producing a product and a system are taught usefully in providing nutrition whose glucose content is compensated for by embedded insulin containing capsules. The invention includes techniques to protect the insulin in some environments and which release the insulin in other environments to form nutrient... Agent: Josh Hogan

20070259022 - Composition comprising statin: Composition comprising at least 0.001 mg/g statin wherein the composition is a particulate comprising a matrix material in an amount of 10-70 wt % and fatty matter dispersed in the matrix material, wherein the amount of fatty matter and statin together is 30-90 wt % and wherein the matrix material... Agent: Unilever Intellectual Property Group

20070259024 - Composition and method for prevention or treatment of stomatitis: A composition and a method effective in preventing or treating stomatitis are presented. The composition contains glutathione or a pharmaceutically acceptable salt thereof and/or orotic acid or a derivative thereof or a pharmaceutically acceptable salt thereof is provided.... Agent: Darby & Darby P.C.

20070259025 - Absorbent antiviral structure: An absorbent device including an absorbent portion, an impermeable membrane that is coupled to the absorbent portion and an attachment member operably coupled to the absorbent portion. The attachment member is adapted to couple the absorbent device to a human appendage such as a forearm, wrist or upper arm. The... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20070259026 - Vasodialating dressing for use with intravenous catheters: The present invention is drawn to adhesive dressings and associated systems and methods for use in reducing the occurrence of phlebitis and extending the lifespan of intravenous catheters. The adhesive dressings can include a backing layer, and a nitroglycerin-containing composition supported at least in part by the backing layer. The... Agent: Thorpe North & Western, LLP.

20070259027 - Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070259028 - Percutaneous absorption preparations of antidementia drugs: Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070259029 - Water-dispersible patch containing an active agent for dermal delivery: A dermal patch having comprising at least two layers wherein at least one layer is a polymer matrix system having an active agent admixed therein. At least one of the layers includes a water-dispersible or water-dissipatable polymer. The dermal patch has an elongation factor of at least 50%.... Agent: Tammye L. Taylor Eastman Chemical Company

20070259031 - Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics: A method of therapeutic treatment of CNS disorders using local convection enhanced delivery.... Agent: John P. O'banion O'banion & Ritchey LLP

20070259032 - Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury: A method for protection of tissues subject to ischemic and/or reperfusion damage is provided. The method includes administering to the tissue a composition comprising nanodevices. The nanodevices can take the form of, for example, polymeric nanoparticles or lipidic nanoparticles. The nanodevices also find use in methods for reducing ischemic injury... Agent: Perkins Coie LLP

20070259030 - Methods, systems and reagents for tendon and ligament therapy: A method for the use and delivery of tissue inhibitors of matrix metalloproteinase (TIMPs) to control the activity of the matrix metalloproteinase (MMPs) in the extracellular matrix (ECM) in order to treat and prevent extracellular matrix degradation in an injured tendon or ligament is presented. Accelerated breakdown of the extracellular... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070259033 - Controlled release formulations exhibiting an ascending rate of release: A sustained release dosage form is comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides an ascending rate of release of the pharmaceutically active agent for at least about 4... Agent: Philip S. Johnson Johnson & Johnson

20070259034 - Highly absorbable coenzyme q10 composition and method of producing same: The present invention provides an essentially crystal-free, highly bioavailable and absorbable coenzyme Q10 (CoQ10) composition including CoQ10, a solvent, and a carrier oil for supplementing nutrition and for use as an antioxidant. The present invention further provides method of increasing the absorption and bioavailability levels of coenzyme Q10 in the... Agent: Amin Hallihan, LLC

20070259035 - Colored liquid-filled soft capsules and method of manufacture thereof: The present invention relates to a coated liquid-filled soft capsule containing a colored shell and method for making same. The shell material contains a colorant incorporated in the material in an amount sufficient to provide a visual contrast between the capsule shell and any liquid fill that escapes from the... Agent: Hoffmann & Baron, LLP

20070259036 - Lactic acid polymer and process for producing the same: A process for producing a lactic acid polymer of 15,000 to 50,000 in weight-average molecular weight, the content of polymeric materials having not more than about 5,000 in weight-average molecular weight therein being not more than about 5% by weight, characterized by hydrolyzing a high molecular weight lactic acid polymer,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070259037 - Method and composition for treatment of inflammatory conditions: Methods of treating inflammation of the gastrointestinal tract and/or systemic or local inflammation by administering a steroid anti-inflammatory or a non-steroid anti-inflammatory drug in conjunction with polyunsaturated fatty acids or their derivatives and optionally also a pharmacologically active antioxidant and compositions for practicing these methods are described.... Agent: Nixon & Vanderhye P.C.

20070259039 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20070259040 - Novel triptan formulations and methods for making them: Rapidly disintegrating oral triptan formulations having superior palatability and methods of making such are provided herein. A rapidly disintegrating oral triptan composition can comprise a triptan compound, a resin, a lubricant, a disintegrant, and a compressible material, where the triptan is admixed with the resin forming a taste-masked triptan composition,... Agent: Thorpe North & Western, LLP.

20070259038 - Solid medicament dosage form consumption aid: A flavored, lubricating solution is applied to a solid medicament by spray, dipping, or otherwise coating the medicament. This liquid coating masks the often objectionable taste of the medicament while lubricating it, and thus significantly improving the ability to swallow the medicament. The improvement to the swallowing process is dramatically... Agent: Liner Yankelevitz Sunshine And Regenstreif

20070259041 - Solid dosage formulations: f

20070259042 - Cyclopropanated aromachemicals: R6 has at least 10 carbon atoms and is an aliphatic group or an aromatic group. Mixtures of these compounds, methods for their preparation, their use as perfume materials for application to a variety of substrates and their use in flavouring and in articles of manufacture is also provided.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070259044 - Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal... Agent: Fox Rothschild, LLP

20070259043 - Halide-free glucosamine-therapeutic drug salt compositions: A salt of a glucosamine base having a purity of at least about 99 wt. % and a maximum halide content of about 0.01 wt. %, and a therapeutic drug having at least one acid functionality, e.g., a carbonyl moiety, a carboxyl moiety, a sulfoxide moiety, etc. Preferably, the salt... Agent: Law Offices Of Jack Matalon

20070259045 - Alcohol resistant dosage forms: Disclosed in certain embodiments is a controlled release dosage form comprising a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material; wherein less than 25% of the opioid salt is released after 1 hour of in-vitro dissolution of the dosage form in 900 ml... Agent: Darby & Darby P.C.

20070259046 - Process for removal of solvents from bead polymers: Process for removal of organic solvents from bead polymers, where the bead polymers are subjected to distillation of the organic solvent with addition of a water-soluble carboxylic acid.... Agent: Lanxess Corporation

20070259047 - Protein sustained-release microparticle preparation for injection and process for producing the same: To provide protein drug sustained-release microparticle preparations for injection that in the production thereof, minimize the use of organic solvents and avoid the simultaneous use of an organic solvent immiscible with water and an aqueous solution and that with respect to the obtained product, simultaneously have in vivo disappearing and... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20070259048 - Pharmaceutical composition containing an active ingredient and a micronised carrier/diluent: The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoteral or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose.... Agent: Fish & Richardson P.C.

20070259049 - Process for preparing lansoprazole: The invention relates to a process for preparing lansoprazole. It is also directed to lansoprazole having a specific surface area and a pharmaceutical composition comprising lansoprazole.... Agent: Cohen, Pontani, Lieberman & Pavane

20070259050 - Combined cosmetic or therapeutic preparation: A combined cosmetic or therapeutic preparation having a carrier system comprising membrane-forming lipids and at least two active ingredients which are selected from at least two of the groups (a) anti-coagulants, (b) vasoprotective agents and (c) microcirculation-promoting substances. The invention also includes the method for making the preparation from its... Agent: Michael L. Dunn

20070259051 - Method of treating a condition associated with phosphorylation of task-1: This invention provides methods and compositions for treating a condition associated with phosphorylation of TASK-1 in a subject comprising administering to the subject an amount of an agent effective to overcome the phosphorylation dependent loss of TASK-1 function so as to thereby treat the condition. In a specific embodiment of... Agent: Kenyon & Kenyon LLP

20070259052 - Assay for lanthanum hydroxycarbonate: An assay for analytically determining the amount of an impurity in a solid sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.... Agent: Darby & Darby P.C.

20070259053 - Inhibition of nephrotoxicity induced by trasylol® and like agents: Increased positive charge of compounds or agents leads to increased glomerular filtration, increased binding by positively charged agents by the cells of the proximal tubules and decreased digestion of the reabsorbed materials. The present invention concerns the use of non-toxic positively charged materials to saturate binding sites on the proximal... Agent: William M. Selenke

20070259054 - Oral rehydration compositions: An oral rehydration mixture (ORM) may include from 47 to 75 wt % of a glucose containing saccharide, from 6 to 13 wt % sodium chloride, from 6.5 to 19 wt % potassium chloride, from 2 to 5 wt % sodium citrate, from 10 to 16 wt % citric acid,... Agent: Evan Law Group LLC

20070259055 - Method of deactivating dust mite allergens: A method is provided for deactivating a Der-p and/or Der-f allergen which comprises volatilizing into a space to be treated a deactivating amount of a volatile oil selected from cajeput oil (tea tree oil) or an oil comprising one or more terpene hydrocarbons.... Agent: Fish & Richardson PC

20070259056 - Anti-tumour terpene compounds: The present invention relates to the use of a terpene compound in the treatment or prophylaxis of cancer. The present invention also relates to a pharmaceutical composition comprising the terpene compound and a pharmaceutically acceptable excipient, carrier, adjuvant or vehicle.... Agent: Banner & Witcoff, Ltd.

20070259057 - Wrinkle reduction agent, lipolysis accelerator, composition for external use on skin, and food or beverage composition: e

20070259060 - Formulations and methods for treating breast cancer with morinda citrifolia and methylsulfonymethane: The present invention advances prior art techniques, formulations, and methods for treating mammary breast cancer during its initial phases, as well as for preventing mammary breast cancer, by providing a safe, nutraceutical formulation comprising Morinda citrifolia, methylsulfonylmethane (MSM), and other ingredients.... Agent: Michael F. Krieger Kirton And Mcconkie

20070259059 - Kiwi extract: The invention describes the preparation, isolation and use of an extract of kiwi fruit for the treatment of a disease or condition related with, caused by or mediated by activity of human pancreatic lipase and/or human fatty acid synthase.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070259058 - Morinda herbal extracts and compositions thereof: The present invention provides herbal extracts, and methods of making them, utilizing a Morinda solution as an extraction medium. It has been found herein that herbal extraction procedures that use Morinda solutions as a solvent produce an effective herbal extract product with enhanced and synergistic properties.... Agent: Millen, White, Zelano & Branigan, P.C.

20070259061 - Seeds of the genus lecythis as nutritional selenium carrier: extracting seeds of selenium containing plants with an apolar organic solvent yielding an extract wherein the selenium containing plants are selected from the group consisting of Lecythis ollaria Loeffling, Lecythis minor Jacquin, Lecythis usitata Miers, and Lecythis tuyrana Pittier, collecting the extract and substantially removing the apolar organic solvent yielding... Agent: Jacobson Holman PLLC

20070259062 - Composition containing an extract of rubi fructus for preventing and treaing anxiety, depression and dementia and improving memory: Disclosed is a composition containing an extract of Rubi Fructus for preventing and treating anxiety, depression and dementia and improving memory. The composition can be used as drugs and dietary supplements which induce prophylactic and therapeutic effects on anxiety, depression and dementia as well as memory-improving effect in the modems... Agent: Stetina Brunda Garred & Brucker

20070253897 - Radioactive material sequestration: A radioactive material sequestration system may include a radionuclide containment composition dispenser and a sorption based media container. The radionuclide containment composition dispenser may be configured for holding a radionuclide containment composition and be capable of dispensing the radionuclide containment composition to remove radionuclides from a radioactive material. The radionuclide... Agent: George Mason University Office Of Technology Transfer, Msn 5g5

20070253915 - Methods for coating dental devices with dry-to-the-touch saliva soluble flavors: Methods for imparting a dry-to-the-touch, saliva soluble, coating containing high levels of flavors and active ingredients to disposable, one-handed, dental devices comprising imparting tumbling motion to said devices and simultaneously coating said tumbling devices with multiple coatings of the dry-to-the-touch-coatings, wherein said multiple coatings comprise from between about 0.25 and... Agent: Banner & Witcoff, Ltd.

20070253916 - Oral care composition with silicone composite: A composite comprising a silicone compound sorbed onto a porous cross-linked polymer. This composition can be included in an oral care composition and inhibit bacterial adhesion on an oral surface.... Agent: Colgate-palmolive Company

20070253917 - Method for brightening teeth: A method for brightening teeth in which (a) a bleaching agent is applied to the surface of the tooth or teeth to be bleached, (b) the bleaching agent is left to act on the tooth for a period of 3 to 30 minutes, (c) the bleaching agent is removed from... Agent: Buchanan, Ingersoll & Rooney PC

20070253919 - Oral compositions comprising siloxane polymers: Oral compositions are provided that comprise an active ingredient comprising a siloxane polymer having at least one hydrophilic region. The oral care composition comprises a siloxane polymer having a phosphorus-containing moiety. A source of fluoride ions and/or other oral care actives can be included in the oral care composition. Methods... Agent: Colgate-palmolive Company

20070253941 - Coenzyme q10, lactoferrin and angiogenin compositions and uses thereof: Methods of enhancing the bio-availability of coenzyme Q10, and methods of supporting the cardiovascular system to accommodate the increase in cellular energy synthesis as a result of the bio-availability of coenzyme Q10 are described. Compositions which include coenzyme Q10, lactoferrin and/or angiogenin are described for use in the related methods,... Agent: Knobbe Martens Olson & Bear LLP

20070253896 - 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors: The invention relates in general to 7,9-dihydro-purin-8-one and related compounds that show broad utility, e.g., in inhibiting heat shock protein 90 (HSP90) to thereby treat or prevent HSP90-mediated diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20070253898 - Polymer based radionuclide containing particulate material: The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.... Agent: Merchant & Gould PC

20070253899 - Dual function polymer micelles: The invention relates to micelles that are elaborated with functionality useful for imaging and/or selectively targeting tissue, e.g., in the delivery of hydrophobic agents.... Agent: Christopher B. Jacobs - Case Renner, Otto, Boisselle & Sklar, LLP

20070253900 - Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer: A novel gene 098P4B6 (also designated STEAP-2) and its encoded protein, and variants thereof, are described wherein 98P4B6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table 1. Consequently, 98P4B6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Heller Ehrman LLP

20070253901 - Atherosclerosis genes and related reagents and methods of use thereof: The invention provides genes (DEA genes) that are differentially expressed in atherosclerotic lesions and polypeptides encoded by these genes. The invention provides compositions comprising a targeting agent conjugated to a functional moiety, wherein the targeting agent selectively binds to a polypeptide encoded by one a DEA gene. The functional moiety... Agent: Agilent Technologies, Inc Attn: Michael Beck, Esq.

20070253902 - Treatment for inflammatory bowel disease: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.... Agent: Fish & Richardson

20070253905 - Abeta42 lowering agents: The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ42 lowering agent to a mammal under conditions in which levels of Aβ42 are selectively reduced, levels of Aβ38 are increased, and levels of Aβ40 are unchanged. The invention provides methods and... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070253906 - Abeta42 lowering agents: The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ42 lowering agent to a mammal under conditions in which levels of Aβ42 are selectively reduced, levels of Aβ38 are increased, and levels of Aβ40 are unchanged. The invention provides methods and... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070253903 - Method for (two-step) dosing and dosage finding: The invention relates to a method for dosing specific doses and timed dosage profiles of medicaments (in animals and humans) as well as agrochemicals (for the treatment of plants).... Agent: Norris, Mclaughlin & Marcus, Pa

20070253904 - Methods of treating diabetes: The invention provides methods of screening for compounds that increase levels or activity of Aryl hydrocarbon Nuclear Receptor Translocator (ARNT) and/or Hypoxia Inducible Factor 1α (HIF1α), for the treatment and prevention of diabetes-related disorders, including type 1 and type 2 diabetes mellitus, impaired glucose tolerance, insulin resistance and beta cell... Agent: Fish & Richardson PC

20070253907 - Non human transgenic animal as model of neurodegenerative diseases and for the early diagnosis thereof: A non human transgenic animal able to express ubiquitarily an anti-NGF neutralizing antibody wherein said anti-body is composed by an endogenous VH chain and by an exogenous VK chain; uses as an animal model to identify compounds with therapeutic activity, in particular for neurodegenerative pathologies. Method for the early prognosis... Agent: Juneau Partners

20070253910 - Cellular labeling and quantification for nuclear magnetic resonance techniques: The disclosure provides, in part, a method for quantifying cell numbers in vivo. The disclosure comprises a method of quantifying labeled cells by nuclear magnetic resonance techniques and a computer method for the same.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070253908 - Fluorescent light tomography: Described herein are systems and methods for obtaining a three-dimensional (3D) representation of the distribution of fluorescent probes inside a sample, such as a mammal. Using a) fluorescent light emission data from one or more images, b) a surface representation of the mammal, and c) computer-implemented photon propagation models, the... Agent: Beyer Weaver LLP

20070253909 - Aqueous antiseptic solution and compatible cationic dye for staining skin: Aqueous antiseptic solutions and compatible dyes for staining skin and methods for making and using such solutions are provided. More specifically, in one embodiment, the present invention relates to an aqueous antiseptic solution comprising an aqueous solution of chlorhexidine or a salt thereof and a cationic dye in an amount... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department

20070253911 - Foamable compositions, kits and methods for hyperhidrosis: The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070253912 - Process for the preparation of micronised collagen, and its therapeutic applications: Non-denatured type I native collagen extracted from animal tendons is purified and brought into the form of a stable, sterile and meterable powder having a particle size of not more than 20 microns. The powdered collagen so obtained has favourable characteristics of distribution and is particularly efficacious in the more... Agent: Dykas, Shaver & Nipper, LLP

20070253913 - Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation: Pharmaceutical aerosol formulations of dihydroergotamine, or pharmaceutically acceptable salts thereof, to administer dry powders and propellant suspensions via pulmonary aerosol or nasal spray inhalation. Such formulations may be used for the treatment of various disease states and conditions, including, but not limited to, migraine headaches. The dihydroergotamine particles are produced... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20070253914 - Method of exfoliation: Method of exfoliating mammalian skin comprising the step of using a foam applicator to apply a personal care composition to delicate mammalian skin, wherein the foam applicator comprises a material selected from the group consisting of polyester, polyurethane, polyether, polyethylene, polystyrene, cross-linked polyethylene, and mixtures thereof, and has a porosity... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070253918 - Stable tooth whitening gel: Stable tooth bleaching gels with a high concentration of peroxide are disclosed. The present invention also provides a method for treating one or more teeth. The method includes steps of applying a therapeutically effective amount of a tooth bleaching gel with a high concentration of peroxide to one or more... Agent: Crowell & Moring LLP Intellectual Property Group

20070253920 - Array of swim care articles and method for providing same to shopper and retailer: An array of swim care articles includes a disposable swim pant and a sunscreen preparation. A method of promoting the sale of the array of swim care articles to a shopper includes combining the articles into in a common container, wherein the disposable swim pant and the sunscreen preparation are... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20070253921 - Composition comprising at least one cyanoacrylate monomer, at least one glucide compound and at least one liquid organic solvent, and cosmetic treatment processes using it: The present disclosure relates to a cosmetic composition comprising at least one cyanoacrylate monomer, at least one glucide compound and at least one liquid organic solvent. The present disclosure also relates to a process for treating for and caring for keratinous fibers that comprises applying to the fibers the disclosed... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070253922 - Anhydrous antiperspirant/deodorant stick compositions: An anhydrous antiperspirant/deodorant stick composition containing the following ingredients (A), (B), (C) and (D): (A) from 15 to 30 wt % of a higher alcohol having from 12 to carbon atoms, (B) a polypropylene glycol having an average molecular weight from 400 to 2,000, (C) a volatile cosmetic oil, and... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070253924 - Administration of 4-aminopiperidine compounds for inducing and/or stimulating the growth of keratin fibers and/or preventing loss thereof:

20070253923 - Personal care composition: A personal care composition comprising a cationically modified cellulose ether, wherein the cellulose ether comprises from 0.5 to 4 moles of an ether substituent per mole of anhydroglucose repeat unit and the cellulose ether is further substituted with a cationic substituent of the formula (I) wherein R1, R2 and R3... Agent: The Dow Chemical Company

20070253925 - Silicon-based tocopherol derivatives: Silicon-based tocopherol derivatives are provided, as well as methods for making the same, in which the derivatives have a tocopherol molecule having a silicon-based group. The derivatives are useful in cosmetic compositions, have antioxidant properties, enhance solubility and compatibility in cosmetic formulations having silicon-based materials within the compositions.... Agent: Flaster/greenberg P.C. 8 Penn Center

20070253926 - Packaged cleaning composition concentrate and method and system for forming a cleaning composition: A packaged cleaning composition concentrate includes a container for holding a cleaning composition concentrate, and a cleaning composition concentrate. The cleaning composition concentrate has a solids content of at least about 1 wt. % based on the weight of the cleaning composition concentrate. The cleaning composition concentrate includes a surfactant... Agent: Kagan Binder, PLLC

20070253927 - Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator: The present disclosure relates to novel compositions for the cosmetic treatment of keratinous fibers, such as the hair, comprising, in a cosmetically acceptable medium, at least one dielectrophile monomer and at least one radical initiator. The disclosure also relates to processes for the treatment of keratinous fibers comprising the composition.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070253929 - Derivatives of growth hormone and related proteins, and methods of use thereof: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in... Agent: Sheridan Ross PC

20070253928 - Pharmaceutical removal of neuronal extensions from a degenerating disc: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070253930 - Pharmaceutical removal of vascular and/or neuronal extensions form a degenerating disc: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070253931 - Use of mesenchymal stem cells for treating genetic diseases and disorders: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.... Agent: Raymond J. Lillie, Eq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20070253932 - Recombinant adenoviral vectors and methods of use: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also... Agent: Townsend And Townsend And Crew, LLP

20070253933 - Carotene synthase gene and uses therefor: Described herein is a novel three domain gene from Schizochytrium, denoted carotene synthase, that encodes a protein with three different enzymatic activities: phytoene dehydrogenase (PD), phytoene synthase (PS), and lycopene cyclase (LC). Also described is the isolated gene encoding the carotene synthase, homologues thereof, the enzyme encoded by such gene,... Agent: Sheridan Ross PC

20070253934 - New strain of lactic acid bacterium and edible compositions, drugs and veterinary products containing it: Describes a new strain of Streptococcus thermophilus ssp. salivarius (deposited on 4 Dec. 2001 at the DSMZ—Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany, with accession No. DSM 14667) and edible compositions, drugs and veterinary products containing it. The use of the said strain is particularly effective in the... Agent: Nixon & Vanderhye, PC

20070253935 - Surface expression method of peptides p5 and anal3 using the gene encoding poly-gamma-glutamate synthetase: The present invention relates to a method for expressing each of peptide antibiotics P5 3 and Anal3 35 having amphiphilicity and showing antibacterial, antifungal and anticancer activities 61, 63, 65, 67, 69, 71, on the microbial surface, using a vector containing outer membrane protein genes (pgsBCA) that are derived from... Agent: Moore & Van Allen PLLC

20070253936 - Self-complementary parvoviral vectors, and methods for making and using the same: The teachings herein are generally directed to a method of enhancing the genetic stability of parvovirus vectors. The stability of conventional ss or dsAAV vector constructs can be enhanced, for example, to obtain a concurrent increase in vector titer and purity, as well as an improvement in vector safety, due... Agent: Perkins Coie LLP

20070253939 - Cell delivery system: Baldness or hair loss has been treated using pharmaceutical drugs and/or hair transplant surgery. The present invention relates to an improved method for treating baldness. In one aspect, there is provided a method for inducing hair follicle formation in a dermal layer lying beneath an outer skin surface, comprising delivering... Agent: Clark & Elbing LLP

20070253938 - Methods and compositions for repairing cartilage: Disclosed is a method for inducing repair of a joint tissue in a mammal includes the steps of removing a sample of synovial membrane from a joint of the mammal, isolating type B synoviocytes from the membrane to yield a suspension of enriched type B synoviocytes, and introducing the suspension... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070253937 - Novel multipotent stem cells and use thereof: Disclosed is an isolated bone marrow stem cell (BMSC) having undetectable or low levels of selected cell markers including those typical of endothelial, neuronal and smooth muscle cells. Also disclosed are grafts and pharmaceutical products that include such cells. Methods of making the BMSCs are also provided. The invention has... Agent: Edwards Angell Palmer & Dodge LLP

20070253940 - Composition comprising platelet-rich plasma: The present invention provides a platelet-rich plasma with high activities in an easy and economical manner. The platelet-rich plasma is obtained by aggregating and precipitating erythrocytes from collected whole blood selectively and facilitatively without employing centrifugation. For example, the plasma is obtained by the addition of a polymer having a... Agent: Jhk Law